Fused azazine derivatives used to treat inflammatory diseases
By designing compounds with specific structures to inhibit the cGAS-STING pathway, the problem of inhibiting the cyclic GMP-AMP synthase pathway in existing technologies has been solved, enabling effective treatment and prevention of autoinflammatory and autoimmune diseases.
Patent Information
- Application Number
- CN202580027298.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2024-09-04
- Filing Date
- 2025-04-09
- Publication Date
- 2026-11-17
AI Technical Summary
Existing technologies are insufficient to effectively inhibit the cyclic GMP-AMP synthase (cGAS) pathway, leading to the activation of various autoinflammatory and autoimmune diseases, and there is a lack of effective small molecule inhibitors.
Provide a compound of formula (I) or its tautomer or pharmaceutically acceptable salt for inhibiting the cGAS-STING pathway, by designing compounds with specific structures to target cGAS and block the production of inflammatory cytokines.
It effectively inhibits the cGAS-STING pathway, reduces the expression of inflammatory cytokines, alleviates the symptoms of autoimmune and inflammatory diseases, and provides a means of treatment and prevention.
Smart Images

Figure CN123125210A_ABST
Abstract
Description
Technical Field
[0001] This invention relates to compounds, compositions containing them, and their use in the treatment of various disorders, particularly autoimmune diseases, autoinflammatory diseases, or immune-mediated diseases, such as systemic lupus erythematosus (SLE), cutaneous lupus erythematosus (CLE), lupus nephritis, Sjogren's syndrome, dermatomyositis, scleroderma, amyotrophic lateral sclerosis (ALS), Parkinson's disease (PD) and Alzheimer's disease (AD), acute kidney injury, chronic kidney disease, diabetic nephropathy or injury, APOL1 nephropathy, focal segmental glomerulosclerosis, membranous nephropathy, idiopathic pulmonary fibrosis, interstitial lung disease, myocardial infarction, stroke, cardiac hypertrophy / heart failure, non-alcoholic steatohepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD), especially systemic lupus erythematosus, cutaneous lupus erythematosus, and lupus nephritis. Background Technology
[0002] Circular GMP-AMP synthase (cGAS) is a DNA sensor in the cytosol that mediates the production of type I interferons and inflammatory cytokines in response to dsDNA (Sun et al., Science, 33(6121) 786-791, 2013; Cai et al., Mol Cell, 54(2) 289-296, 2014). In the absence of DNA, cGAS exists in an autorepressed state. Binding to DNA induces a conformational change at the active site, which catalyzes the synthesis of circular GMP-AMP (cGAMP) from ATP and GTP (Zhang et al., CellRep, 6(3) 421-430, 2014; Gao et al., Cell, 153(5) 1094-1107, 2013; Civril et al., Nature, 498(7454) 332-337, 2013). The generated cGAMP acts as a second messenger that binds to and activates the interferon gene stimulator (STING). Activated STING recruits TANK-binding kinase 1 (TBK1), which phosphorylates STING and subsequently phosphorylates the transcription factor IFN regulator 3 (IRF3). Phosphorylated IRF3 dimers and translocates to the nucleus, where it works in conjunction with nuclear factor kB (NF-κB) (also a transcription factor activated by STING) to initiate the expression of type I IFN and inflammatory cytokines (Ablasser and Chen, Science, 363(6431) eaat8657, 2019).
[0003] Although the cGAS-STING pathway has evolved into a major defense mechanism for detecting microbial infections, activation of cGAS through one's own DNA has been associated with a variety of monogenic diseases (AGS, FCL, RVCL) and multifactorial autoimmune / inflammatory diseases.
[0004] Therapeutic targeting of the cGAS-STING pathway with small-molecule cGAS inhibitors can be beneficial in a wide range of autoinflammatory, autoimmune, and immune-mediated diseases. Therefore, there is a need for novel chemical compounds capable of inhibiting the cGAS pathway. Summary of the Invention
[0005] In a first aspect, the present invention provides a compound of formula (I) or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or a tautomer thereof.
[0006] (I)
[0007] in
[0008] R 1 It is either hydrogen or a prodrug portion; R 2 Selected from hydrogen, halogen, cyano, nitro, C 1-3 Alkyl, halogenated (C 1-3 )alkyl, halogenated (C 1-3 )alkoxy, -S(O)R 7 -SO2R 7 -C(O)NR 7 R 8 -NR 7 C(O)R 8 and -CO2R 7 C 1-3 Alkyl, halogenated (C 1-3 )alkyl and halogen (C 1-3 Alkoxy groups may be optionally substituted with hydroxyl groups or -NR. 7 R 8 Or C 3-4 cycloalkyl; R 3 C is an optional replacement. 1-3 Alkyl, -C(O)R 8 Or a 5- or 6-membered heteroaryl group in the prodrug portion; Ring A is a 5- or 6-membered heteroaryl or a 5- to 7-membered heterocyclic alkyl ring, wherein the heteroaryl or heterocyclic alkyl ring contains 1, 2 or 3 heteroatoms independently selected from N, O and S; p is 0, 1, 2 or 3; Each X is independently selected from oxidized and LY; Each L is independently selected from the key, -(CR) a R b ) n -、-O-、-(CR a R b ) n O-、-O(CR a R b ) n -、-(CR a R b ) n O(CR a R b ) m -, -SO2-, -SO2(CR) a R b ) n -, -C(O)O-, -OC(O)-, -C(O)O(CR a R b ) n -、-(CR a R b ) n C(O)O-、-C(O)NH(CR a R b ) n -、-NR a C(O)(CR a R b ) n -or-NH(CR) a R b ) n - where each n or m is independently selected from 1, 2 or 3; Each R a and R b Independently selected from hydrogen, halogen, or C 1-4 alkyl; Each Y group is independently selected from hydrogen, halogen, hydroxyl, cyano, C 1-4 Alkyl, C 1-4 Alkoxy, C 3-7 cycloalkyl, C 5-7 Cycloalkenyl, C 2-4 alkenyl, C 2-6 alkynyl, thioyl (C 1-4 )alkyl, hydroxyl (C 1-6 )alkyl, cyano (C 1-4 )alkyl, halogenated (C 1-4 )alkyl, halogenated (C 2-4 alkenyl, hydroxyl (C) 2-6 ) ynyl group, -NR 9 R 10 -C(O)NR 9 R10 -C(O)SR 10 -CO2R 10 -C(O)R 10 -CHCHC(O)OR 10 -OSO2R 10 -S(O)R 10 -N(R) 10 SO2R 10 -P(O)(Ph)OR 10 -P(O)(OR) 10 )2、-P(S)(Ph)OR 10 phenyl, 5- or 6-membered heteroaryl, and 3- to 7-membered heterocyclic alkyl rings, wherein the heteroaryl or heterocyclic alkyl ring comprises 1, 2, or 3 heteroatoms independently selected from N, O, and S, wherein the C 3-7 cycloalkyl, C 5-7 The cycloalkenyl, phenyl, heteroaryl, and heterocyclic alkyl groups may be optionally substituted with one, two, or three independent substituents selected from the following: halogen, amino, hydroxyl, -C(O)R 10 Oxygen, C 1-4 Alkyl, C 1-4 Alkoxy, halogenated (C 1-4 )alkyl and hydroxyl (C 1-4 alkyl; or Two X substituents, together with the carbon atoms they are attached to, form a ring selected from the following: phenyl, C... 5-8 cycloalkyl, C 5-8 Cycloalkenyl, 5- to 8-membered heteroaryl, or 5- to 8-membered heterocyclic alkyl ring, wherein the heteroaryl or heterocyclic alkyl ring comprises one or two heteroatoms independently selected from N, O, and S, wherein the phenyl, C 5-8 cycloalkyl, C 5-8 The cycloalkenyl, 5- to 8-membered heteroaryl, or 5- to 8-membered heterocyclic alkyl ring is optionally substituted by one, two, or three independent substituents selected from the following: halogen, C 1-4 Alkyl, oxo, -C(O)R 10 -SO2R 10 -C 1-3 Alkylene-NR 9 R 10 and -C 1-3 Alkylene-OR 10 ; R 7 and R 8 Independently selected from hydrogen and C 1-3 alkyl; R 9 Independently selected from hydrogen, hydroxyl, C 1-4 Alkyl, -C(O)C 1-4 Alkyl and halogenated (C1-4 )alkyl; and R 10 Independently selected from hydrogen and C 1-6 Alkyl; or Where R 9 and R 10 Together with the nitrogen atoms attached to them, they form a 5- to 8-membered heterocyclic alkyl ring comprising one or two heteroatoms independently selected from N, O, and S, wherein the heterocyclic alkyl ring is optionally substituted by one, two, or three substituents independently selected from: halogen, amino, hydroxyl, -C(O)R 10 Oxygen, C 1-4 Alkyl, C 1-4 Alkoxy, halogenated (C 1-4 )alkyl and hydroxyl (C 1-4 )alkyl; The condition is that the compound of formula (I) is not a compound of formula (II).
[0009] (II)
[0010] Where R 1 R 2 R 3 X and p are as defined by equation (I).
[0011] In a second aspect, the present invention provides pharmaceutical compositions comprising the compounds of the present invention and pharmaceutically acceptable excipients.
[0012] In a third aspect, the present invention provides a method for treating autoimmune diseases, autoinflammatory diseases, or immune-mediated diseases in persons in need, comprising administering to said persons a therapeutically effective amount of the compound of the present invention disclosed herein.
[0013] In a fourth aspect, the present invention provides compounds of the present invention as disclosed herein for therapeutic purposes.
[0014] In a fifth aspect, the present invention provides the use of the compounds disclosed herein in the preparation of medicaments for treating autoimmune diseases, autoinflammatory diseases, or immune-mediated diseases. Invention Details
[0016] definition
[0017] As used in this article, the term halogen refers to a chlorine, fluorine, bromine, or iodine substituent.
[0018] As used in this article, the term cyano refers to the group -CN.
[0019] As used in this article, the term nitro refers to the group -NO2.
[0020] As used in this article, the term hydroxyl refers to the -OH group.
[0021] As used in this article, the term amino refers to the group -NH2.
[0022] As used herein, the term “oxo” refers to the oxygen moiety of a double bond; for example, if it is directly attached to a carbon atom, it forms a carbonyl moiety (C = O).
[0023] As used in this article, “Ph” refers to the phenyl group.
[0024] As used herein, the term "prodrug" refers to a compound that readily undergoes chemical changes under physiological conditions to provide a pharmacologically active parent compound. The term "prodrug moiety" refers to the chemical portion of a prodrug that is released under physiological conditions to form an active parent compound.
[0025] As used herein, the term "alkyl" refers to a saturated straight-chain or branched hydrocarbon group having a specified number of carbon atoms. For example, the term "C 1-6 "Alkyl" refers to an alkyl group having 1 to 6 carbon atoms. Exemplary groups include, but are not limited to, methyl, ethyl, propyl (n-propyl and isopropyl), butyl (n-butyl, sec-butyl, isobutyl, and tert-butyl), pentyl, and hexyl. The term "C"... 1-4 "Alkyl" refers to an alkyl group having 1 to 4 carbon atoms.
[0026] As used herein, the term "cycloalkyl" refers to a non-aromatic saturated monocyclic hydrocarbon ring containing a specified number of carbon atoms. For example, "C 3-7 "Cycloalkyl" refers to a cycloalkyl group containing 3 to 7 carbon atoms. Exemplary groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, or cyclooctyl.
[0027] As used herein, the term "cycloalkenyl" refers to a non-aromatic, unsaturated, monocyclic hydrocarbon ring containing a specific number of carbon atoms and at least one double bond. For example, "C 5-7 "Cycloalkenyl" refers to a cycloalkyl group containing 5 to 7 carbon atoms. Exemplary groups include cyclopentenyl, cyclohexenyl, and cycloheptenyl.
[0028] As used herein, the term "alkylene" refers to a divalent group (C1 or C6) derived from a straight-chain or branched saturated hydrocarbon group, for example, of 1 to 6 carbon atoms. 1-6 Alkyl groups. Exemplary groups include, but are not limited to, -CH2- (methylene), -CH2CH2- (ethylene), -CH2CH2CH2- (propylene), and -CH2CH(CH3)2- (isobutylene).
[0029] As used in this article, the term "C" 2-4"Alkenyl" refers to a straight-chain or branched hydrocarbon group containing a specified number of carbon atoms and at least one double bond. For example, "C 2-4 "Alkenyl" has 2 to 4 carbon atoms. Exemplary groups include, but are not limited to, vinyl and propenyl groups.
[0030] As used herein, the term "alkynyl" refers to a straight-chain or branched hydrocarbon group containing a specific number of carbon atoms and at least one triple bond. For example, "C 2-4 The "alkynyl" group has 2 to 6 carbon atoms. Exemplary groups include, but are not limited to, ethynyl and propynyl.
[0031] As used herein, the term "alkoxy" refers to an -O-alkyl group, that is, an alkyl group linked by an oxygen atom, where "alkyl" is defined as above. For example, the term "C 1-4 "Alkoxy" refers to an alkoxy group having 1 to 4 carbon atoms. Exemplary groups include, but are not limited to, methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, sec-butoxy, isobutoxy, and tert-butoxy.
[0032] As used in this article, the term "halogenated (C)" 1-4 "alkyl" is intended to represent a group having one or more halogen atoms (which may be the same or different) at one or more carbon atoms of an alkyl moiety containing 1 to 4 carbon atoms, said alkyl moiety being a straight-chain or branched carbon group. Exemplary groups include, but are not limited to, -CF3 (trifluoromethyl), -CF2H (difluoromethyl), -CCl3 (trichloromethyl), -CF2Cl (chlorodifluoromethyl), 1,1-difluoroethyl, 2,2,2-trifluoroethyl, and hexafluoroisopropyl. Thus, the term halogenated (C) 1-2 Alkyl groups are groups that have one or more halogen atoms (which may be the same or different) at one or more carbon atoms in an alkyl moiety containing one or two carbon atoms.
[0033] As used in this article, the term "halogenated (C)" 1-4 "Alkoxy" refers to a straight-chain or branched hydrocarbon group having at least one and at most four carbon atoms, with one or more halogen atoms (which may be the same or different) attached to one or more carbon atoms, the hydrocarbon group being connected by oxygen atoms. Exemplary groups include, but are not limited to, -OCHF2 (difluoromethoxy), -OCF3 (trifluoromethoxy), and -OCH(CF3)2 (hexafluoroisopropoxy).
[0034] As used in this article, the term "thio-(C)" 1-4 )alkyl(thio(C) 1-4 "alkyl" refers to an -S-alkyl group, that is, an alkyl group linked by a sulfur atom, where "alkyl" is defined as above. For example, the term "C" 1-4"Thioalkyl" refers to a thioalkyl group having 1 to 4 carbon atoms. Exemplary groups include, but are not limited to, thiomethyl, thioethyl, thiopropyl, and thioisopropyl.
[0035] As used in this article, the term "hydroxyl (C)" 1-6 "alkyl" is intended to represent a group having one or more hydroxyl groups at one or more carbon atoms of an alkyl moiety containing 1 to 6 carbon atoms, wherein the alkyl moiety is a straight-chain or branched carbon group. Exemplary groups include, but are not limited to, hydroxymethyl (-CH2OH), 2-hydroxyethyl (-CH2CH2OH), 2-hydroxybutanol (-CH2C(OH)CH2CH3), and hydroxy-isopropyl.
[0036] As used in this article, the term "cyano (C)" 1-4 "alkyl" is intended to represent a group having one or more cyano groups at one or more carbon atoms of an alkyl moiety containing 1 to 4 carbon atoms, wherein the alkyl group is a straight-chain or branched carbon group.
[0037] As used in this article, the term "halogenated (C)" 2-4 "Alkenyl" refers to a straight-chain or branched hydrocarbon group having at least two and at most four carbon atoms and at least one double bond, with one or more halogen atoms (which may be the same or different) attached to one or more carbon atoms. Exemplary groups include, but are not limited to, -CH=CHF, -CH=CF2 and -CF=CF2.
[0038] As used in this article, the term "hydroxyl (C)" 2-4 "Alkyne" refers to a straight-chain or branched hydrocarbon group having at least two to at most four carbon atoms and at least one triple bond, with one or more hydroxyl atoms attached to one or more carbon atoms. Exemplary groups include, but are not limited to, -CH≡C-OH, -CH2C≡C-OH, and -C≡C-CH2OH.
[0039] As used herein, the term "heteroaryl" refers to a group or portion containing an aromatic monovalent monocyclic group, comprising a specific number of ring atoms, including at least one carbon atom and at least one heteroatom independently selected from nitrogen, oxygen, and sulfur.
[0040] As used herein, the term "5- or 6-membered heteroaryl" refers to a group or portion comprising an aromatic monovalent monocyclic group containing 5 or 6 ring atoms, including at least one carbon atom and at least one heteroatom independently selected from nitrogen, oxygen, and sulfur. The selected 5-membered heteroaryl group contains one nitrogen, oxygen, or sulfur ring heteroatom and optionally contains 1, 2, or 3 additional nitrogen ring atoms. The selected 6-membered heteroaryl group contains 1, 2, or 3 nitrogen ring heteroatoms. Exemplary groups include, but are not limited to, furanyl, thiopheneyl, pyrroleyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, oxazolyl, thiazolyl, isoxazolyl, isothiazolyl, oxadiazolyl, thiazolyl, pyridinyl, pyrazinyl, pyrimidinyl, and triazinyl.
[0041] As used herein, the term "5-membered nitrogen-containing heteroaryl" refers to a group or portion comprising an aromatic monovalent monocyclic group containing five ring atoms, including at least one carbon atom, at least one nitrogen atom, and optionally at least one other heteroatom independently selected from nitrogen, oxygen, and sulfur. Exemplary groups include, but are not limited to, pyrroleyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, oxazolyl, thiazolyl, isoxazolyl, isothiazolyl, oxadiazolyl, and thiadiazolyl.
[0042] As used herein, the term "hybrid aryl" refers to a group or portion comprising an aromatic divalent monocyclic or bicyclic group containing 5 to 10 ring atoms, including at least one heteroatom independently selected from nitrogen, oxygen, and sulfur. For example, the term "hybrid aryl" refers to a group or portion comprising an aromatic divalent monocyclic or bicyclic group containing 5 to 10 ring atoms, including one or two heteroatoms independently selected from nitrogen, oxygen, and sulfur.
[0043] As used herein, the term "heterocyclic alkyl" refers to a saturated or unsaturated monocyclic or bicyclic group containing a specified number of atoms and including at least one heteroatom independently selected from nitrogen, oxygen, and sulfur (the other atoms being carbon). For example, the term "5- to 7-membered heterocyclic alkyl" refers to a heterocyclic alkyl group having 5 to 7 atoms. Bicyclic heterocyclic alkyl groups can be bridged, fused, or spirobicyclic groups. For the avoidance of doubt, heterocyclic alkyl groups are not aromatic.
[0044] As used herein, the term “3-to-7-membered heterocyclic alkyl” refers to a saturated or unsaturated 3-to-7-membered monocyclic ring that must contain one or two non-carbon atoms selected from nitrogen, oxygen, and sulfur. Exemplary groups include, but are not limited to, oxetane, oxetane, azirne, pyrrolyl, pyrazolyl, pyrazolinyl, imidazolinyl, imidazolinyl, oxazolinyl, thiazolinyl, piperidinyl, piperazinyl, tetrahydrofuranyl, dihydrofuranyl, 1,3-dioxetane, tetrahydro-2H-pyranyl, dihydropyranyl, morpholinyl, morpholinyl-3-one, 1,3-dioxane, 1,4-dioxane, 1,3-oxetane, 1,3-oxetane, 1,3-oxetane, 1,3-dithiazolinyl, 1,4-oxetane, 1,4-dithiazolinyl, piperidinyl-2-one, pyrimidinyl-2,4(1 H ,3 H )-Diketone, thiomorpholino, thiomorpholino 1,1-dioxide, tetrahydropyridinyl, pyrrolidinyl-2-one and 2-oxa-5-azabicyclo[2.2.1]heptyl.
[0045] As used herein, the term "5-to-7-membered heterocyclic alkyl" refers to a saturated or unsaturated 5-to-7-membered monocyclic ring that must contain one or two non-carbon atoms selected from nitrogen, oxygen, and sulfur. Exemplary groups include, but are not limited to, pyrrolidinyl, pyrazolylyl, pyrazolinyl, imidazoalkyl, imidazolinyl, oxazolinyl, thiazolinyl, piperidinyl, piperazinyl, tetrahydrofuranyl, dihydrofuranyl, 1,3-dioxacyclopentyl, tetrahydro-2H-pyranyl, dihydropyranyl, morpholinyl, morpholinyl-3-one, 1,3-dioxylyl, 1,4-dioxylyl, 1,3-oxathionyl, 1,3-oxathiylyl, 1,3-dithiylyl, 1,4-oxathiylyl, 1,4-dithiylyl, piperidinyl-2-one, pyrimidinyl-2,4(1 H ,3 H )-Diketone, Thiomolinyl, Thiomolinyl 1,1-dioxide, Azacyclic heptyl, Tetrahydroazacyclic hepttrienyl, Dihydrooxazinyl, Tetrahydropyrazinyl, Oxazoxycyclic heptyl, Dihydrooxozylated hepttrienyl, Tetrahydropyridyl, Oxazolidinyl, 2,3-dihydropyrroleyl, Tetrahydropyridyl, Dihydropyridyl, Dihydropyrroleyl and 5 H -Pyrroleyl.
[0046] As used herein, the term "bicyclic" may refer to a bridging, fused, or spirobicyclic group.
[0047] To avoid any doubt, all dual-ring systems can be connected to any suitable location on either ring.
[0048] As used herein, the term "optionally substituted" means that the group may be unsubstituted or substituted with one or more substituents as defined herein. The term "substituted" with respect to a group means that a hydrogen atom bonded to a member atom within the group is replaced by one of the defined substituents. Where a group may be chosen from multiple substituents, the selected groups may be the same or different.
[0049] The term "independent selection" means that when more than one substituent is selected from a large number of possible substituents, those substituents can be the same or different. Therefore, each substituent is selected from the entire enumerated set of possible substituents.
[0050] As used herein, the term "pharmaceutically acceptable salt" refers to a salt that retains the desired biological activity of the subject compound and exhibits minimal undesirable toxicological effects. Such pharmaceutically acceptable salts may be prepared in situ during the final isolation and purification of the compound, or by reacting the purified compound, in its free acid or free base form, with a suitable base or acid, respectively.
[0051] The term “treatment” refers to improving or stabilizing a specified condition, reducing or eliminating the symptoms of a condition, slowing or eliminating the progression of a condition, and preventing or delaying the recurrence of a condition in a patient or subject who has previously been ill.
[0052] The term "prevention" refers to avoiding the disease in subjects who do not have the disease.
[0053] The term "compound of the present invention" refers to a compound of formula (I) or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or a tautomer thereof.
[0054] The term "therapeutic effective amount" refers to the amount of the compound of the present invention that will elicit the desired biological response in a human body. This amount can vary depending on the compound, the disease and its severity, and the age and weight of the subject to be treated.
[0055] The compound with reference formula (I) includes any one of reference formulas (IA), (IAA), (IB), (IBB), (IC), (ICC), (ID), (IE), (IEE), (IF), (IH), (IHH), (IJ), or (IJJ).
[0056] Invention Statement
[0057] In a first aspect, the present invention provides a compound of formula (I) or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or a tautomer thereof.
[0058] (I)
[0059] in
[0060] R 1 It is either hydrogen or a prodrug portion; R 2 Selected from hydrogen, halogen, cyano, nitro, C 1-3 Alkyl, halogenated (C 1-3 )alkyl, halogenated (C 1-3 )alkoxy, -S(O)R 7 -SO2R 7 -C(O)NR 7 R 8 -NR 7 C(O)R 8 and -CO2R 7 C 1-3 Alkyl, halogenated (C 1-3 )alkyl and halogen (C 1-3 Alkoxy groups may be optionally substituted with hydroxyl groups or -NR. 7 R 8 Or C 3-4 cycloalkyl; R 3 C is an optional replacement. 1-3 Alkyl, -C(O)R 8 Or a 5- or 6-membered heteroaryl group in the prodrug portion; Ring A is a 5- or 6-membered heteroaryl or a 5- to 7-membered heterocyclic alkyl ring, wherein the heteroaryl or heterocyclic alkyl ring contains 1, 2 or 3 heteroatoms independently selected from N, O and S; p is 0, 1, 2 or 3; Each X is independently selected from oxidized and LY; Each L is independently selected from the key, -(CR) a R b ) n -、-O-、-(CR a R b ) n O-、-O(CR a R b ) n -、-(CR a R b ) n O(CR a R b ) m -, -SO2-, -SO2(CR) a R b ) n -, -C(O)O-, -OC(O)-, -C(O)O(CR a R b ) n -、-(CR a R b) n C(O)O-、-C(O)NH(CR a R b ) n -、-NR a C(O)(CR a R b ) n -or-NH(CR) a R b ) n - where each n or m is independently selected from 1, 2 or 3; Each R a and R b Independently selected from hydrogen, halogen, or C 1-4 alkyl; Each Y group is independently selected from hydrogen, halogen, hydroxyl, cyano, C 1-4 Alkyl, C 1-4 Alkoxy, C 3-7 cycloalkyl, C 5-7 Cycloalkenyl, C 2-4 alkenyl, C 2-6 alkynyl, thioyl (C 1-4 )alkyl, hydroxyl (C 1-6 )alkyl, cyano (C 1-4 )alkyl, halogenated (C 1-4 )alkyl, halogenated (C 2-4 alkenyl, hydroxyl (C) 2-6 ) ynyl group, -NR 9 R 10 -C(O)NR 9 R 10 -C(O)SR 10 -CO2R 10 -C(O)R 10 -CHCHC(O)OR 10 -OSO2R 10 -S(O)R 10 -N(R) 10 SO2R 10 -P(O)(Ph)OR 10 -P(O)(OR) 10 )2、-P(S)(Ph)OR 10 phenyl, 5- or 6-membered heteroaryl, and 3- to 7-membered heterocyclic alkyl rings, wherein the heteroaryl or heterocyclic alkyl ring comprises 1, 2, or 3 heteroatoms independently selected from N, O, and S, wherein the C 3-7 cycloalkyl, C 5-7 The cycloalkenyl, phenyl, heteroaryl, and heterocyclic alkyl groups may be optionally substituted with one, two, or three independent substituents selected from the following: halogen, amino, hydroxyl, -C(O)R10 Oxygen, C 1-4 Alkyl, C 1-4 Alkoxy, halogenated (C 1-4 )alkyl and hydroxyl (C 1-4 alkyl; or Two X substituents, together with the carbon atoms they are attached to, form a ring selected from the following: phenyl, C... 5-8 cycloalkyl, C 5-8 Cycloalkenyl, 5- to 8-membered heteroaryl, or 5- to 8-membered heterocyclic alkyl ring, wherein the heteroaryl or heterocyclic alkyl ring comprises one or two heteroatoms independently selected from N, O, and S, wherein the phenyl, C 5-8 cycloalkyl, C 5-8 The cycloalkenyl, 5- to 8-membered heteroaryl, or 5- to 8-membered heterocyclic alkyl ring is optionally substituted by one, two, or three independent substituents selected from the following: halogen, C 1-4 Alkyl, oxo, -C(O)R 10 -SO2R 10 -C 1-3 Alkylene-NR 9 R 10 and -C 1-3 Alkylene-OR 10 ; R 7 and R 8 Independently selected from hydrogen and C 1-3 alkyl; R 9 Independently selected from hydrogen, hydroxyl, C 1-4 Alkyl, -C(O)C 1-4 Alkyl and halogenated (C 1-4 )alkyl; and R 10 Independently selected from hydrogen and C 1-6 Alkyl; or Where R 9 and R 10 Together with the nitrogen atoms attached to them, they form a 5- to 8-membered heterocyclic alkyl ring comprising one or two heteroatoms independently selected from N, O, and S, wherein the heterocyclic alkyl ring is optionally substituted by one, two, or three substituents independently selected from: halogen, amino, hydroxyl, -C(O)R 10 Oxygen, C 1-4 Alkyl, C 1-4 Alkoxy, halogenated (C 1-4 )alkyl and hydroxyl (C 1-4 )alkyl; The condition is that the compound of formula (I) is not a compound of formula (II).
[0061] (II)
[0062] Where R 1 R 2 R 3 X and p are as defined by equation (I).
[0063] In one alternative aspect, the present invention provides a compound of formula (I) or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or its tautomer thereof.
[0064] (I)
[0065] in
[0066] R 1 It is either hydrogen or a prodrug portion; R 2 Selected from hydrogen, halogen, cyano, nitro, C 1-3 Alkyl, halogenated (C 1-3 )alkyl, halogenated (C 1-3 )alkoxy, -S(O)R 7 -SO2R 7 -C(O)NR 7 R 8 -NR 7 C(O)R 8 and -CO2R 7 C 1-3 Alkyl, halogenated (C 1-3 )alkyl and halogen (C 1-3 Alkoxy groups may be optionally substituted with hydroxyl groups or -NR. 7 R 8 Or C 3-4 cycloalkyl; R 3 C is an optional replacement. 1-3 Alkyl, -C(O)R 8 Or a 5- or 6-membered heteroaryl group in the prodrug portion; Ring A is a 5- or 6-membered heteroaryl or a 5- to 7-membered heterocyclic alkyl ring, wherein the heteroaryl or heterocyclic alkyl ring contains 1, 2 or 3 heteroatoms independently selected from N, O and S; p is 0, 1, 2 or 3; Each X is independently selected from oxidized and LY; Each L is independently selected from the key, -(CR) a R b ) n -、-O-、-(CR a R b ) n O-、-O(CR a R b )n -、-(CR a R b ) n O(CR a R b ) m -, -SO2-, -SO2(CR) a R b ) n -, -C(O)O-, -OC(O)-, -C(O)O(CR a R b ) n -、-(CR a R b ) n C(O)O-、-C(O)NH(CR a R b ) n -、-NR a C(O)(CR a R b ) n -or-NH(CR) a R b ) n - where each n or m is independently selected from 1, 2 or 3; Each R a and R b Independently selected from hydrogen, halogen, or C 1-4 alkyl; Each Y group is independently selected from hydrogen, halogen, hydroxyl, cyano, C 1-4 Alkyl, C 1-4 Alkoxy, C 3-7 cycloalkyl, C 5-7 Cycloalkenyl, C 2 --4 alkenyl, C 2-6 alkynyl, thioyl (C 1-4 )alkyl, hydroxyl (C 1-6 )alkyl, cyano (C 1-4 )alkyl, halogenated (C 1-4 )alkyl, halogenated (C 2-4 alkenyl, hydroxyl (C) 2-6 ) ynyl group, -NR 9 R 10 -C(O)NR 9 R 10 -C(O)SR 10 -CO2R 10 -C(O)R 10 -CHCHC(O)OR 10 -OSO2R 10 -S(O)R 10 -N(R)10 SO2R 10 -P(O)(Ph)OR 10 -P(O)(OR) 10 )2、-P(S)(Ph)OR 10 phenyl, 5- or 6-membered heteroaryl, and 3- to 7-membered heterocyclic alkyl rings, wherein the heteroaryl or heterocyclic alkyl ring comprises 1, 2, or 3 heteroatoms independently selected from N, O, and S, wherein the C 3-7 cycloalkyl, C 5-7 The cycloalkenyl, phenyl, heteroaryl, and heterocyclic alkyl groups may be optionally substituted with one, two, or three independent substituents selected from the following: halogen, amino, hydroxyl, -C(O)R 10 Oxygen, C 1-4 Alkyl, C 1-4 Alkoxy, halogenated (C 1-4 )alkyl and hydroxyl (C 1-4 alkyl; or Two X substituents, together with the carbon atoms they are attached to, form a ring selected from the following: phenyl, C... 5-8 cycloalkyl, C 5-8 Cycloalkenyl, 5- to 8-membered heteroaryl, or 5- to 8-membered heterocyclic alkyl ring, wherein the heteroaryl or heterocyclic alkyl ring comprises one or two heteroatoms independently selected from N, O, and S, wherein the phenyl, C 5-8 cycloalkyl, C 5-8 The cycloalkenyl, 5- to 8-membered heteroaryl, or 5- to 8-membered heterocyclic alkyl ring is optionally substituted by one, two, or three independent substituents selected from the following: halogen, C 1-4 Alkyl, oxo, -C(O)R 10 -SO2R 10 -C 1-3 Alkylene-NR 9 R 10 and -C 1-3 Alkylene-OR 10 ; R 7 and R 8 Independently selected from hydrogen and C 1-3 alkyl; R 9 Independently selected from hydrogen, hydroxyl, C 1-4 Alkyl, -C(O)C 1-4 Alkyl and halogenated (C 1-4 )alkyl; and R 10 Independently selected from hydrogen and C 1-6 Alkyl; or Where R 9 and R 10Together with the nitrogen atoms attached to them, they form a 5- to 8-membered heterocyclic alkyl ring comprising one or two heteroatoms independently selected from N, O, and S, wherein the heterocyclic alkyl ring is optionally substituted by one, two, or three substituents independently selected from: halogen, amino, hydroxyl, -C(O)R 10 Oxygen, C 1-4 Alkyl, C 1-4 Alkoxy, halogenated (C 1-4 )alkyl and hydroxyl (C 1-4 )alkyl; Where ring A is not...
[0067] Where X and p are defined as in equation (I).
[0068] In one alternative aspect, the present invention provides a compound of formula (I) or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or its tautomer thereof.
[0069] (I)
[0070] in
[0071] R 1 It is either hydrogen or a prodrug portion; R 2 Selected from hydrogen, halogen, cyano, nitro, C 1-3 Alkyl, halogenated (C 1-3 )alkyl, halogenated (C 1-3 )alkoxy, -S(O)R 7 -SO2R 7 -C(O)NR 7 R 8 -NR 7 C(O)R 8 and -CO2R 7 C 1-3 Alkyl, halogenated (C 1-3 )alkyl and halogen (C 1-3 Alkoxy groups may be optionally substituted with hydroxyl groups or -NR. 7 R 8 Or C 3-4 cycloalkyl; R 3 C is an optional replacement. 1-3 Alkyl, -C(O)R 8 Or a 5- or 6-membered heteroaryl group in the prodrug portion; Ring A is a 5- or 6-membered heteroaryl or a 5- to 7-membered heterocyclic alkyl ring, wherein the heteroaryl or heterocyclic alkyl ring contains 1, 2 or 3 heteroatoms independently selected from N, O and S; p is 0, 1, 2 or 3; Each X is independently selected from oxidized and LY; Each L is independently selected from the key, -(CR) a R b ) n -、-O-、-(CR a R b ) n O-、-O(CR a R b ) n -、-(CR a R b ) n O(CR a R b ) m -, -SO2-, -SO2(CR) a R b ) n -, -C(O)O-, -OC(O)-, -C(O)O(CR a R b ) n -、-(CR a R b ) n C(O)O-、-C(O)NH(CR a R b ) n -、-NR a C(O)(CR a R b ) n -or-NH(CR) a R b ) n - where each n or m is independently selected from 1, 2 or 3; Each R a and R b Independently selected from hydrogen, halogen, or C 1-4 alkyl; Each Y group is independently selected from hydrogen, halogen, hydroxyl, cyano, C 1-4 Alkyl, C 1-4 Alkoxy, C 3-7 cycloalkyl, C 5-7 Cycloalkenyl, C 2-4 alkenyl, C 2-6 alkynyl, thioyl (C 1-4 )alkyl, hydroxyl (C 1-6 )alkyl, cyano (C 1-4 )alkyl, halogenated (C 1-4 )alkyl, halogenated (C 2-4 alkenyl, hydroxyl (C) 2-6 ) ynyl group, -NR9 R 10 -C(O)NR 9 R 10 -C(O)SR 10 -CO2R 10 -C(O)R 10 -CHCHC(O)OR 10 -OSO2R 10 -S(O)R 10 -N(R) 10 SO2R 10 -P(O)(Ph)OR 10 -P(O)(OR) 10 )2、-P(S)(Ph)OR 10 phenyl, 5- or 6-membered heteroaryl, and 3- to 7-membered heterocyclic alkyl rings, wherein the heteroaryl or heterocyclic alkyl ring comprises 1, 2, or 3 heteroatoms independently selected from N, O, and S, wherein the C 3-7 cycloalkyl, C 5-7 The cycloalkenyl, phenyl, heteroaryl, and heterocyclic alkyl groups may be optionally substituted with one, two, or three independent substituents selected from the following: halogen, amino, hydroxyl, -C(O)R 10 Oxygen, C 1-4 Alkyl, C 1-4 Alkoxy, halogenated (C 1-4 )alkyl and hydroxyl (C 1-4 alkyl; or Two X substituents, together with the carbon atoms they are attached to, form a ring selected from the following: phenyl, C... 5-8 cycloalkyl, C 5-8 Cycloalkenyl, 5- to 8-membered heteroaryl, or 5- to 8-membered heterocyclic alkyl ring, wherein the heteroaryl or heterocyclic alkyl ring comprises one or two heteroatoms independently selected from N, O, and S, wherein the phenyl, C 5-8 cycloalkyl, C 5-8 The cycloalkenyl, 5- to 8-membered heteroaryl, or 5- to 8-membered heterocyclic alkyl ring is optionally substituted by one, two, or three independent substituents selected from the following: halogen, C 1-4 Alkyl, oxo, -C(O)R 10 -SO2R 10 -C 1-3 Alkylene-NR 9 R 10 and -C 1-3 Alkylene-OR 10 ; R 7 and R 8 Independently selected from hydrogen and C 1-3 alkyl; R 9Independently selected from hydrogen, hydroxyl, C 1-4 Alkyl, -C(O)C 1-4 Alkyl and halogenated (C 1-4 )alkyl; and R 10 Independently selected from hydrogen and C 1-6 Alkyl; or Where R 9 and R 10 Together with the nitrogen atoms attached to them, they form a 5- to 8-membered heterocyclic alkyl ring comprising one or two heteroatoms independently selected from N, O, and S, wherein the heterocyclic alkyl ring is optionally substituted by one, two, or three substituents independently selected from: halogen, amino, hydroxyl, -C(O)R 10 Oxygen, C 1-4 Alkyl, C 1-4 Alkoxy, halogenated (C 1-4 )alkyl and hydroxyl (C 1-4 )alkyl; Ring A, which is bound to the adjacent imidazole ring, is not imidazole [1,2-]. a ]Pyrimidine group.
[0072] In one implementation, R 1 and R 3 Only one contains a prodrug portion. In one embodiment, the prodrug portion is located in R. 1 Instead of R 3 In another embodiment, the prodrug portion is located in R. 3 Not in R 1 In one implementation, R 1 It is the prodrug portion and R 3 C is an optional replacement. 1-3 Alkyl or -C(O)R 8 5-membered heteroaryl. In one embodiment, R 1 It is the prodrug portion and R 3 C is an optional replacement. 1-3 Alkyl or -C(O)R 8 5-membered nitrogen-containing heteroaryl group. In one embodiment, R 1 It is the prodrug portion and R 3 It is an imidazole group or a pyrazole group, wherein R 3 C can be arbitrarily replaced 1-3 Alkyl or -C(O)R 8 .
[0073] In one implementation, R 1 This is the prodrug portion.
[0074] In one embodiment, the prodrug portion is a phosphate ester, ester, or amino acid-type prodrug.
[0075] In one embodiment, the prodrug portion is a phosphate ester.
[0076] In one implementation, R 1 It is a phosphate prodrug.
[0077] In one implementation, each prodrug moiety is independently selected from -CH(R) c )OP(O)(OR d (OR) e ), -CH(R c )OC(O)-C 1-6 Alkylene-OP(O)(OR) d (OR) e ), -CH(R c )OC(O)-C 1-6 Alkylene-P(O)(OR) d (OR) e ), -CH(R c )OC(O)-C 1-6 Alkylene -CO2H, -CH(R) c )OC(O)R d -CH(R) c )OC(O)OR d -CH(R) c )OC(O)OC 1-6 Alkylene -CO2H, -CH(R) c )OC(O)-C 1-6 Alkylene-NR d R e -CH(R) c )OC(O)OC 1-6 Alkylene-NR d R e -C(O)R d -CH(R) c )OC(O)-C 1-6 alkylene-heterocyclic alkyl, -CH(R) c )OC(O)-C 1-6 alkylene-heterocyclic alkyl and -CR d R e -O-(C(O)-NR d -heteroaryl-CH2O-C(O)-CH2-NR d R e ; Where R c Independently selected from hydrogen and methyl; R d and R eEach is independently hydrogen or C 1-6 alkyl; Each heterocyclic alkyl group is 4- to 6-membered and contains one or two heteroatoms independently selected from N, O, and S; and Each heteroaryl group is 5- or 6-membered and contains one or two heteroatoms independently selected from N, O and S.
[0078] In one implementation, R c Independently selected from hydrogen, halogens and C 1-3 alkyl.
[0079] In one implementation, R c It is independently selected from hydrogen, fluorine, and methyl.
[0080] In one implementation, R c It is independently selected from hydrogen and methyl.
[0081] In one implementation, R c It is hydrogen.
[0082] In one implementation, each prodrug moiety is independently selected from -CH2O-P(O)(OR) d (OR) e -CH2O-C(O)-C 1-6 Alkylene-OP(O)(OR) d (OR) e -CH2O-C(O)-C 1-6 Alkylene-P(O)(OR) d (OR) e -CH2O-C(O)-C 1-6 Alkylenes -CO2H, -CH2O-C(O)R d -CH2O-C(O)OR d -CH2O-C(O)OC 1-6 Alkylene -CO2H, -CH2O-C(O)-C 1-6 Alkylene-NR d R e -CH2O-C(O)OC 1-6 Alkylene-NR d R e -C(O)R d -CH2O-C(O)-C 1-6 Alkylene-heterocyclic alkyl, -CH2O-C(O)-C 1-6 alkylene-heterocyclic alkyl and -CR d R e -O-(C(O)-NR d -heteroaryl-CH2O-C(O)-CH2-NRd R e ; Where R d and R e Each is independently hydrogen or C 1-6 alkyl; Each heterocyclic alkyl group is 4- to 6-membered and contains one or two heteroatoms independently selected from N, O, and S; and Each heteroaryl group is 5- or 6-membered and contains one or two heteroatoms independently selected from N, O and S.
[0083] In one implementation, each prodrug moiety is independently selected from -CH2O-P(O)(OR) d (OR) e -CH2O-C(O)-C 1-6 Alkylene-OP(O)(OR) d (OR) e -CH2O-C(O)-C 1-6 Alkylene-P(O)(OR) d (OR) e -CH2O-C(O)-C 1-6 Alkylenes -CO2H, -CH2O-C(O)R d -CH2O-C(O)OR d -CH2O-C(O)O- C 1-6 Alkylene -CO2H, -CH2O-C(O)-C 1-6 Alkylene-NR d R e -CH2O-C(O)OC 1-6 Alkylene-NR d R e and -C(O)R d .
[0084] In one implementation, each prodrug moiety is independently selected from -CH2O-P(O)(OR) d (OR) e -CH2O-C(O)-C 1-6 Alkylene-OP(O)(OR) d (OR) e -CH2O-C(O)-C 1-6 Alkylene-P(O)(OR) d (OR) e -CH2O-C(O)-C 1-6 Alkylene -CO2H, -CH2O-C(O)O- C 1-6 Alkylene -CO2H, -CH2O-C(O)-C 1-6Alkylene-NR d R e and -CH2O-C(O)OC 1-6 Alkylene-NR d R e .
[0085] In one implementation, each prodrug moiety is independently selected from -CH2O-P(O)(OR) d (OR) e -CH2O-C(O)-C 1-3 Alkylene-OP(O)(OR) d (OR) e -CH2O-C(O)-C 1-3 Alkylene-P(O)(OR) d (OR) e -CH2O-C(O)-C 1-3 Alkylenes -CO2H, -CH2O-C(O)R d -CH2O-C(O)OR d -CH2O-C(O)OC 1-3 Alkylene -CO2H, -CH2O-C(O)-C 1-3 Alkylene-NR d R e -CH2O-C(O)OC 1-3 Alkylene-NR d R e -C(O)R d -CH2O-C(O)-C 1-3 Alkylene-heterocyclic alkyl, -CH2O-C(O)-C 1-3 alkylene-heterocyclic alkyl and -CR d R e -O-(C(O)-NR d -heteroaryl-CH2O-C(O)-CH2-NR d R e ; Where R d and R e Each is independently hydrogen or C 1-6 alkyl; Each heterocyclic alkyl group is 4- to 6-membered and contains one or two heteroatoms independently selected from N, O, and S; and Each heteroaryl group is 5- or 6-membered and contains one or two heteroatoms independently selected from N, O and S.
[0086] In one implementation, each prodrug moiety is independently selected from -CH2O-P(O)(OR) d (OR)e -CH2O-C(O)-C 1-3 Alkylene-OP(O)(OR) d (OR) e -CH2O-C(O)-C 1-3 Alkylene-P(O)(OR) d (OR) e -CH2O-C(O)-C 1-3 Alkylenes -CO2H, -CH2O-C(O)R d -CH2O-C(O)OR d -CH2O-C(O)OC 1-3 Alkylene -CO2H, -CH2O-C(O)-C 1-3 Alkylene-NR d R e -CH2O-C(O)OC 1-3 Alkylene-NR d R e and -C(O)R d .
[0087] In one implementation, each prodrug moiety is independently selected from -CH2O-P(O)(OR) d (OR) e -CH2O-C(O)-C 1-3 Alkylene-OP(O)(OR) d (OR) e -CH2O-C(O)-C 1-3 Alkylene-P(O)(OR) d (OR) e -CH2O-C(O)-C 1-3 Alkylene -CO2H, -CH2O-C(O)O- C 1-3 Alkylene -CO2H, -CH2O-C(O)-C 1-3 Alkylene-NR d R e and -CH2O-C(O)OC 1-3 Alkylene-NR d R e .
[0088] In one implementation, each prodrug moiety is independently selected from -CH2O-C(O)-C 1-3 Alkylenes -CO2H, -CH2O-C(O)R d -, -CH2O-C(O)OR d -CH2O-C(O)-C 1-4 Alkylene-NRd R e and CH2O-P(O)(OR d (OR) e ).
[0089] In one implementation scheme, each prodrug portion is independently selected from... .
[0090] In one implementation scheme, each prodrug portion is independently selected from... .
[0091] In one implementation, each prodrug moiety is -CH2O-P(O)(OR d (OR) e ), where R d and R e As defined above.
[0092] In one implementation scheme, each prodrug portion is: .
[0093] In one implementation, R 1 for .
[0094] In one embodiment, the compound of formula (I) is a compound of formula (IA) or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or a tautomer thereof:
[0095] (IA)
[0096] Where R 2 R 3 X, p, and ring A are as defined herein with respect to formula (I), provided that the compound of formula IA is not a compound of formula (IIA).
[0097] (IIA)
[0098] Where R 2 R 3 X and p are as defined by equation (I).
[0099] In one implementation, R 1 It is hydrogen.
[0100] In one embodiment, the compound of formula (I) is a compound of formula (IAA) or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or a tautomer thereof:
[0101] (IAA)
[0102] Where R 2 R 3 X, p, and ring A are as defined herein with respect to formula (I), provided that a compound of formula IAA is not a compound of formula (IIAA).
[0103] (IIAA)
[0104] Where R 2 R 3 X and p are as defined by equation (I).
[0105] In one implementation, R 2 Selected from hydrogen, halogen, cyano, C 1-3 Alkyl, halogenated (C 1-3 )alkyl, halogenated (C 1-3 )alkoxy, -S(O)R 7 -C(O)NR 7 R 8 and CO2R 7 Among them, halogenated (C 1-3 Alkyl groups may be optionally substituted with hydroxyl groups or -NR. 7 R 8 Or cyclopropyl.
[0106] In one implementation, R 2 Selected from hydrogen, halogen, cyano, halogen (C 1-3 )alkyl, halogenated (C 1-3 )alkoxy, -S(O)R 7 -C(O)NR 7 R 8 and CO2R 7 Among them, halogenated (C 1-3 Alkyl groups may be optionally substituted with hydroxyl groups or -NR. 7 R 8 Or cyclopropyl.
[0107] In one implementation, R 2Selected from hydrogen, bromine, cyano, -C(O)NH2, -CF2CH2NH2, -CF2CH2CH2NH2, -CHFCH2NH2, -CF2CH2NHCH3, -CF2CH2OH, -CH2F, -CHF2, -CF3, -CF2CF3, -CF2CH3, -CF2CH(OH)CH3, -CF2CH(NH2)CH3, -CF2CHF2, -OCHF2, -S(O)CH3, -C(O)OCH2CH3, -CClF2, -CH3 and -CF2-cyclopropyl.
[0108] In one implementation, R 2 Selected from hydrogen, bromine, cyano, -C(O)NH2, -CF2CH2NH2, -CF2CH2CH2NH2, -CHFCH2NH2, -CF2CH2NHCH3, -CF2CH2OH, -CH2F, -CHF2, -CF3, -CF2CF3, -CF2CH3, -CF2CH(OH)CH3, -CF2CH(NH2)CH3, -CF2CHF2, -OCHF2, -S(O)CH3, -C(O)OCH2CH3, -CClF2 and -CF2-cyclopropyl.
[0109] In one implementation, R 2 Selected from hydrogen, bromine, cyano, -C(O)NH2, -CF2CH2NH 2、- CF2CH2OH, -CH2F, -CHF2, -CF3, -CF2CHF2, -OCHF2, -S(O)CH3, -C(O)OCH2CH3, -CClF2, -CH3 and -CF2-cyclopropane.
[0110] In one implementation, R 2 Selected from hydrogen, bromine, cyano, -C(O)NH2, -CF2CH2NH 2、- CF2CH2OH, -CH2F, -CHF2, -CF3, -CF2CHF2, -OCHF2, -S(O)CH3, -C(O)OCH2CH3, -CClF2 and -CF2-cyclopropane.
[0111] In one implementation, R 2 Selected from halogens, cyano groups, -C(O)NH2, halogenated (C 1-3 )alkoxy, halogen (C 1-3 Alkyl groups, -CF2CH2NH2, -CF2CH2OH and -S(O)CH3.
[0112] In one implementation, R 2Selected from bromine, cyano, -C(O)NH2, -CF2CH2NH2, -CF2CH2OH, -CH2F, -CHF2, -CF3, -CF2CF3, -CF2CH3, -CF2CHF2, -OCHF2 and -S(O)CH3.
[0113] In one implementation, R 2 Selected from hydrogen, halogens, C 1-3 Alkyl, halogenated (C 1-3 )alkyl and halogen (C 1-3 )alkoxy.
[0114] In one specific implementation plan, R 2 Selected from halogens and C 1-3 Alkyl group. In one embodiment, R 2 Selected from bromine, -CF3, and -CHF2. In one embodiment, R... 2 Selected from Br and -CF3.
[0115] In one implementation, R 2 It is -CF3.
[0116] In one embodiment, the compound of formula (I) is a compound of formula (IB) or formula (IBB) or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or a tautomer thereof: or
[0117] (IB) (IBB)
[0118] Where R 3 X, p, and ring A are as defined herein with respect to formula (I), provided that the compound of formula (IB) or (IBB) is not a compound of formula (IIB) or (IIBB). or
[0119] (IIB) (IIBB)
[0120] Where R 3 X and p are as defined by equation (I).
[0121] In one implementation, R 3 For optional substitution, -C(O)R 8 Or a 5- or 6-membered heteroaryl group in the prodrug portion.
[0122] In one implementation, R 3 It is a 5-membered heteroaryl group.
[0123] In one implementation, R3 C is an optional replacement. 1-3 Alkyl, -C(O)R 8 Or the 5-membered heteroaryl group of the prodrug. In one embodiment, R 3 For optional substitution, -C(O)R 8 Or the 5-membered heteroaryl group of the prodrug. In one embodiment, R 3 The 5-membered heteroaryl group is optionally substituted with the prodrug moiety.
[0124] In one implementation, R 3 It is a 5-membered nitrogen-containing heteroaryl group.
[0125] In one implementation, R 3 C is an optional replacement. 1-3 Alkyl, -C(O)R 8 Or the 5-membered nitrogen-containing heteroaryl group of the prodrug. In one embodiment, R 3 For optional substitution, -C(O)R 8 Or the 5-membered nitrogen-containing heteroaryl group of the prodrug. In one embodiment, R 3 The 5-membered nitrogen-containing heteroaryl group is optionally substituted with a prodrug moiety.
[0126] In one implementation, R 3 It is a 5-membered nitrogen-containing heteroaryl group, which optionally contains 1, 2, or 3 additional heteroatoms selected from N, O, and S, wherein the heteroaryl group is optionally substituted with C. 1-3 Alkyl, -C(O)R 8 Or the prodrug portion. In one implementation, R 3 It is a 5-membered nitrogen-containing heteroaryl group, which optionally contains 1, 2 or 3 additional heteroatoms selected from N, O and S, wherein the heteroaryl group is optionally substituted with -C(O)R 8 Or the prodrug portion. In one implementation, R 3 It is a 5-membered nitrogen-containing heteroaryl group, optionally comprising 1, 2, or 3 additional heteroatoms selected from N, O, and S, wherein the heteroaryl group is optionally substituted with a prodrug moiety. In one embodiment, R 3 It is an imidazole group or a pyrazole group, wherein R 3 C can be arbitrarily replaced 1-3 Alkyl, -C(O)R 8 Or the prodrug portion. In one implementation, R 3 It is an imidazole group or a pyrazole group, wherein R 3 The prodrug portion can be arbitrarily replaced.
[0127] In one implementation, R 3 It is imidazole or pyrazole. In one embodiment, R 3It is an imidazole group. To avoid any doubt, in one embodiment, R 3 It is an unsubstituted imidazole group.
[0128] In one implementation, R 3 The group is an imidazole or pyrazol group linked by carbon, i.e., a C-linked imidazole or a C-linked pyrazol group. In one embodiment, R 3 It is a C-linked imidazole group. In one embodiment, R 3 It is imidazole-4-yl or imidazole-5-yl. In one embodiment, R 3 It is imidazole-5-yl.
[0129] In one implementation, R 1 It is the prodrug portion and R 3 It is an imidazole group, especially a C-linked imidazole group.
[0130] In one implementation, R 1 For H and R 3 It replaces the prodrug portion.
[0131] In one specific implementation plan, R 1 for And R 3 It is an imidazole group, especially a C-linked imidazole group.
[0132] Or, R 1 It is hydrogen and R 3 It is an imidazole group, especially a C-linked imidazole group.
[0133] In one embodiment, the compound of formula (I) is a compound of formula (IC) or formula (ICC) or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or a tautomer thereof: or
[0134] (IC) (ICC)
[0135] Where X, p, and ring A are as defined herein with respect to formula (I), provided that the compound of formula (IC) or (ICC) is not a compound of formula (IIC) or (IICC). or
[0136] (IIC) (IICC)
[0137] Where X and p are defined as in equation (I).
[0138] In one implementation, ring A is selected from...
[0139] Each ring A is substituted with -X p As defined according to any of the embodiments disclosed herein.
[0140] To avoid any doubt, ring A is fused to the adjacent imidazole ring. For example, when ring A is... The compound of formula (I) is the same as the compound of formula (ID). .
[0141] (ID)
[0142] In one implementation, ring A is selected from...
[0143] To avoid any doubt, each depicted ring A is replaced with -X. p (As defined in any of the embodiments disclosed herein).
[0144] In one implementation, ring A is a 6-membered heteroaryl group.
[0145] In one implementation, ring A is selected from...
[0146] To avoid any doubt, each depicted ring A is replaced with -X. p (As defined in any of the embodiments disclosed herein).
[0147] In one embodiment, the compound of formula (I) is a compound of formula (ID) or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or a tautomer thereof:
[0148] (ID)
[0149] Where R 1 R 2 R 3 X and p are as defined in this paper with respect to equation (I).
[0150] In one embodiment, the compound of formula (I) is a compound of formula (ID) or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or a tautomer thereof:
[0151] (ID)
[0152] in
[0153] R 1 It is either hydrogen or a prodrug portion; R2 Selected from hydrogen, halogen, cyano, halogen (C 1-3 )alkyl, halogenated (C 1-3 )alkoxy, -S(O)R 7 -C(O)NR 7 R 8 and CO2R 7 Among them, halogenated (C 1-3 Alkyl groups may be optionally substituted with hydroxyl groups or -NR. 7 R 8 Or cyclopropyl; R 3 The 5-membered heteroaryl group with the prodrug moiety is optionally substituted; p is 0, 1, 2 or 3; Each X is LY; Each L represents a key, -(CR) a R b ) n -、-O-、-(CR a R b ) n O-、-O(CR a R b ) n -、-(CR a R b ) n O(CR a R b ) m -, -SO2-, -SO2(CR) a R b ) n -, -C(O)O-, -OC(O)-, -C(O)O(CR a R b ) n -、-C(O)NH(CR a R b ) n -or-NH(CR) a R b ) n - where each n is independently 1, 2 or 3; Each R a and R b Independently selected from hydrogen, halogen, or C 1-4 alkyl; Each Y group is independently selected from hydrogen, halogen, hydroxyl, cyano, C 1-4 Alkyl, C 1-4 Alkoxy, C 3-7 cycloalkyl, C 5-7 Cycloalkenyl, C 2-4 alkenyl, C 2-6alkynyl, hydroxyl (C 1-6 )alkyl, halogenated (C 1-4 )alkyl, hydroxyl (C 2-6 ) ynyl group, -NR 9 R 10 -C(O)NR 9 R 10 -CO2R 10 -COR 10 -OSO2R 10 phenyl, 5- or 6-membered heteroaryl, and 4- to 6-membered heterocyclic alkyl rings, wherein the heteroaryl or heterocyclic alkyl ring comprises 1, 2, or 3 heteroatoms independently selected from N, O, and S, wherein the C 3-7 cycloalkyl, C 5-7 The cycloalkenyl, heteroaryl, and heterocyclic alkyl groups may optionally be substituted by one or two independent substituents selected from the following: halogen, amino, C 1-4 Alkyl, C 1-4 Alkoxy and hydroxyl (C 1-4 )alkyl; Two substituents, together with the carbon atom to which they are attached, form a ring selected from the following: C 5-8 Cycloalkyl or a 5- to 8-membered heterocyclic alkyl ring comprising one or two heteroatoms independently selected from N, O, and S, wherein the C 5-8 The cycloalkyl or 5- to 8-membered heterocyclic alkyl ring is optionally substituted by one or two independent substituents selected from the following: oxo and C. 1-4 alkyl; R 7 and R 8 Independently selected from hydrogen and C 1-3 alkyl; R 9 Independently selected from hydrogen, hydroxyl and C 1-4 Alkyl; and R 10 Independently selected from hydrogen and C 1-6 Alkyl; or Where R 9 and R 10 Together with the nitrogen atoms attached to them, they form 5- or 6-membered heterocyclic alkyl rings, which contain one or two independent heteroatoms selected from N and O.
[0154] In one embodiment, the compound of formula (I) is a compound of formula (IE) or formula (IEE) or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or a tautomer thereof: or
[0155] (IE) (IEE)
[0156] Where R2 R 3 X and p are as defined in this paper with respect to equation (I).
[0157] In one embodiment, the compound of formula (I) is a compound of formula (IF) or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or a tautomer thereof:
[0158] (IF)
[0159] Where R 1 R 3 X and p are as defined in this paper with respect to equation (I).
[0160] In one embodiment, the compound of formula (I) is a compound of formula (IG) or formula (IGG) or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or a tautomer thereof: or
[0161] (IG) (IGG)
[0162] Where R 3 X and p are as defined in this paper with respect to equation (I).
[0163] In one embodiment, the compound of formula (I) is a compound of formula (IH) or formula (IHH) or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or a tautomer thereof: or
[0164] (IH) (IHH)
[0165] Where R 2 X and p are as defined in this paper with respect to equation (I).
[0166] In one embodiment, the compound of formula (I) is a compound of formula (IJ) or (IJJ) or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or a tautomer thereof: or
[0167] (IJ) (IJJ)
[0168] Where X and p are as defined in this paper with respect to equation (I).
[0169] In one alternative aspect, the present invention provides a compound of formula (III) or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or its tautomer thereof.
[0170] (III)
[0171] in
[0172] R 1 It is either hydrogen or a prodrug portion; R 2 Selected from hydrogen, halogen, cyano, nitro, C 1-3 Alkyl, halogenated (C 1-3 )alkyl, halogenated (C 1-3 )alkoxy, -S(O)R 7 -SO2R 7 -C(O)NR 7 R 8 -NR 7 C(O)R 8 and -CO2R 7 C 1-3 Alkyl, halogenated (C 1-3 )alkyl and halogen (C 1-3 Alkoxy groups may be optionally substituted with hydroxyl groups or -NR. 7 R 8 Or C 3-4 cycloalkyl; R 3 C is an optional replacement. 1-3 Alkyl, -C(O)R 8 Or a 5- or 6-membered heteroaryl group in the prodrug portion; Indicates a single bond or a double bond; q can be 0, 1, 2, or 3; X 1 X 2 X 3 and X 4 Independently selected from O, S, N, NR h CR i and CR h R i ; Each R h and R i Independently LY or R h and R i Together for oxygenation; Each L is independently selected from the key, -(CR) a R b ) n -、-O-、-(CR a R b ) n O-、-O(CR a Rb ) n -、-(CR a R b ) n O(CR a R b ) m -, -SO2-, -SO2(CR) a R b ) n -, -C(O)O-, -OC(O)-, -C(O)O(CR a R b ) n -、-(CR a R b ) n C(O)O-、-C(O)NH(CR a R b ) n -or-NH(CR) a R b ) n - where each n or m is independently 1, 2 or 3; Each R a and R b Independently selected from hydrogen, halogen, or C 1-4 alkyl; Each Y group is independently selected from hydrogen, halogen, hydroxyl, cyano, C 1-4 Alkyl, C 1-4 Alkoxy, C 3-7 cycloalkyl, C 5-7 Cycloalkenyl, C 2-4 alkenyl, C 2-6 alkynyl, thioyl (C 1-4 )alkyl, hydroxyl (C 1-6 )alkyl, cyano (C 1-4 )alkyl, halogenated (C 1-4 )alkyl, halogenated (C 2-4 alkenyl, hydroxyl (C) 2-6 ) ynyl group, -NR 9 R 10 -C(O)NR 9 R 10 -C(O)SR 10 -CO2R 10 -C(O)R 10 -CHCHC(O)OR 10 -OSO2R 10 -S(O)R 10 -N(R) 10 SO2R 10 -P(O)(Ph)OR 10-P(O)(OR) 10 )2、-P(S)(Ph)OR 10 phenyl, 5- or 6-membered heteroaryl, and 3- to 7-membered heterocyclic alkyl rings, wherein the heteroaryl or heterocyclic alkyl ring comprises 1, 2, or 3 heteroatoms independently selected from N, O, and S, wherein the C 3-7 cycloalkyl, C 5-7 The cycloalkenyl, phenyl, heteroaryl, and heterocyclic alkyl groups may be optionally substituted with one, two, or three independent substituents selected from the following: halogen, amino, hydroxyl, -C(O)R 10 Oxygen, C 1-4 Alkyl, C 1-4 Alkoxy, halogenated (C 1-4 )alkyl and hydroxyl (C 1-4 alkyl; or Two Rs h Or R i The atoms bonded to them together form rings selected from the following: phenyl, C 5-8 cycloalkyl, C 5-8 Cycloalkenyl, 5- to 8-membered heteroaryl, or 5- to 8-membered heterocyclic alkyl ring, wherein the heteroaryl or heterocyclic alkyl ring comprises one or two heteroatoms independently selected from N, O, and S, wherein the phenyl, C 5-8 cycloalkyl, C 5-8 The cycloalkenyl, 5- to 8-membered heteroaryl, or 5- to 8-membered heterocyclic alkyl ring is optionally substituted by one, two, or three independent substituents selected from the following: halogen, C 1-4 Alkyl, oxo, -C(O)R 10 -SO2R 10 -C 1-3 Alkylene-NR 9 R 10 and -C 1-3 Alkylene-OR 10 ; R 7 and R 8 Independently selected from hydrogen and C 1-3 alkyl; R 9 Independently selected from hydrogen, hydroxyl, C 1-4 Alkyl, -C(O)C 1-4 Alkyl and halogenated (C 1-4 )alkyl; and R 10 Independently selected from hydrogen and C 1-6 Alkyl; or Where R 9 and R 10Together with the nitrogen atoms attached to them, they form a 5- to 8-membered heterocyclic alkyl ring comprising one or two heteroatoms independently selected from N, O, and S, wherein the heterocyclic alkyl ring is optionally substituted by one, two, or three substituents independently selected from: halogen, amino, hydroxyl, -C(O)R 10 Oxygen, C 1-4 Alkyl, C 1-4 Alkoxy, halogenated (C 1-4 )alkyl and hydroxyl (C 1-4 )alkyl; The condition is when q is 1 and X 1 When X is N, 2 X 3 and X 4 Not all are CR i .
[0173] To avoid any doubt, when X 1 -X 4 One of them is CR h R i And R h and R i When both are oxygenated, this means X 1 -X 4 Any one of them is C=O.
[0174] In one implementation scheme, each R a and R b The R is independently selected from hydrogen, halogen, or methyl. In one embodiment, each R... a and R b The R is independently selected from hydrogen, fluorine, or methyl. In one embodiment, each R... a and R b The R is independently selected from hydrogen or fluorine. In one embodiment, each R... a and R b It is hydrogen.
[0175] In one implementation, X is independently selected from oxidized and LY.
[0176] In one implementation scheme, each L represents a key, -(CR) a R b ) n -、-O-、-(CR a R b ) n O-、-O(CR a R b ) n -、-(CR a R b ) n O(CR a R b) m -, -SO2-, -SO2CH2-, -C(O)O-, -OC(O)-, -C(O)O(CR a R b ) n -、-C(O)NH(CR a R b ) n -or-NH(CR) a R b ) n - And each Y group is independently selected from hydrogen halogens, hydroxyl groups, cyano groups, C... 1-4 Alkyl, C 1-4 Alkoxy, C 3-7 cycloalkyl, C 5-7 Cycloalkenyl, C 2-4 alkenyl, C 2-6 alkynyl, hydroxyl (C 1-6 )alkyl, halogenated (C 1-4 )alkyl, hydroxyl (C 2-6 ) ynyl group, -NR 9 R 10 -C(O)NR 9 R 10 -CO2R 10 -COR 10 -OSO2R 10 phenyl, 5- or 6-membered heteroaryl, and 4- to 6-membered heterocyclic alkyl rings, wherein the heteroaryl or heterocyclic alkyl ring comprises 1, 2, or 3 heteroatoms independently selected from N, O, and S, wherein the C 3-7 cycloalkyl, C 5-7 The cycloalkenyl, heteroaryl, and heterocyclic alkyl groups may be optionally substituted with one, two, or three independent substituents selected from the following: halogen, amino, C 1-4 Alkyl, C 1-4 Alkoxy and hydroxyl (C 1-4 alkyl; or
[0177] Two adjacent X substituents (or R substituents where applicable) h and R i Together with the carbon atoms they are attached to, they form rings selected from the following: C 5-8 Cycloalkyl, or a 5- to 8-membered heterocyclic alkyl ring comprising one or two independent heteroatoms selected from N or O, wherein the C 5-8 The cycloalkyl or 5- to 8-membered heterocyclic alkyl ring is optionally substituted by one or two independent substituents selected from the following: oxo and C. 1-4 alkyl.
[0178] In one implementation scheme, each L represents a key, -(CR) a R b )n -、-O-、-(CR a R b ) n O-、-O(CR a R b ) n -、-(CR a R b ) n O(CR a R b ) m -, -SO2-, -SO2CH2-, -C(O)O-, -OC(O)-, -C(O)O(CR a R b ) n -、-C(O)NH(CR a R b ) n -or-NH(CR) a R b ) n - And each Y group is independently selected from hydrogen halogens, hydroxyl groups, cyano groups, C... 1-4 Alkyl, C 1-4 Alkoxy, C 3-7 cycloalkyl, C 5-7 Cycloalkenyl, C 2-4 alkenyl, C 2-6 alkynyl, hydroxyl (C 1-6 )alkyl, halogenated (C 1-4 )alkyl, hydroxyl (C 2-6 ) ynyl group, -NR 9 R 10 -C(O)NR 9 R 10 -CO2R 10 -COR 10 -OSO2R 10 phenyl, 5- or 6-membered heteroaryl, and 4- to 6-membered heterocyclic alkyl rings, wherein the heteroaryl or heterocyclic alkyl ring comprises 1, 2, or 3 heteroatoms independently selected from N, O, and S, wherein the C 3-7 cycloalkyl, C 5-7 The cycloalkenyl, heteroaryl, and heterocyclic alkyl groups may be optionally substituted with one, two, or three independent substituents selected from the following: halogen, amino, C 1-4 Alkyl, C 1-4 Alkoxy and hydroxyl (C 1-4 )alkyl.
[0179] In one implementation, the two X substituents (or R substituents where applicable) h and R i Together with the carbon atoms they are attached to, they form rings selected from the following: C5-8 Cycloalkyl or a 5- to 8-membered heterocyclic alkyl ring comprising one or two independent heteroatoms selected from N or O, wherein the C 5-8 The cycloalkyl or 5- to 8-membered heterocyclic alkyl ring is optionally substituted by one, two, or three independent substituents selected from the following: C 1-4 Alkyl, oxo, -C 1-3 Alkylene-NR 9 R 10 and -C 1-3 Alkylene-OR 10 .
[0180] In one implementation, two adjacent X substituents (or R substituents where applicable) h and R i Together with the carbon atoms attached to them, they form a ring selected from the following: cyclohexyl or a 5- or 6-membered heterocyclic alkyl ring containing one or two independent heteroatoms selected from N or O, wherein the cyclohexyl or 5- or 6-membered heterocyclic alkyl ring is optionally substituted by one or two independent substituents selected from the following: oxo and C 1-4 alkyl.
[0181] In one implementation, two adjacent X substituents (or R substituents where applicable) h and R i Together with the carbon atoms to which they are attached, they form a 5-membered heterocyclic alkyl ring containing a heteroatom selected from N and O. In one embodiment, the two X substituents, together with the carbon atoms to which they are attached, form a 6-membered heterocyclic alkyl ring containing a heteroatom selected from N and O. In one embodiment, the two X substituents, together with the carbon atoms to which they are attached, form a cyclohexyl ring.
[0182] In one implementation scheme, each R 9 Independently selected from hydrogen and C 1-4 Alkyl groups. In one embodiment, each R... 9 It is hydrogen.
[0183] In one implementation scheme, each R 10 Independently selected from hydrogen and C 1-6 Alkyl groups. In one embodiment, each R... 10 Independently selected from hydrogen and C 1-4 Alkyl groups. In one embodiment, each R... 10 C 1-4 alkyl.
[0184] In one implementation, R 9 and R 10Together with the nitrogen atoms attached to them, they form a 5- or 6-membered heterocyclic alkyl ring, which contains one or two heteroatoms independently selected from N and O, wherein the heterocyclic alkyl ring is optionally substituted by one or two substituents independently selected from: halogen, amino, C 1-4 Alkyl and halogenated (C 1-4 )alkyl.
[0185] In one implementation, R 9 and R 10 Together with the nitrogen atoms attached to them, they form a 6-membered heterocyclic alkyl ring, which contains one or two independent heteroatoms selected from N and O.
[0186] In one implementation scheme, each R 9 Independently selected from hydrogen and C 1-4 Alkyl; and
[0187] Each R 10 Independently selected from hydrogen and C 1-4 Alkyl; or
[0188] Where R 9 and R 10 Together with the nitrogen atoms attached to them, they form a 6-membered heterocyclic alkyl ring, which contains one or two independent heteroatoms selected from N and O.
[0189] In one implementation scheme, each X is independently represented by LY.
[0190] In one implementation, each X is independently LY, and each L is independently selected from key, -(CR) a R b ) n -、-(CR a R b ) n O-、-O(CR a R b ) n -、-C(O)O- and -C(O)O(CR) a R b ) n -
[0191] In one implementation, each X is independently LY, and each L is independently selected from the bond and -(CR). a R b ) n -
[0192] In one implementation, each X is independently LY, and each L is a key.
[0193] In one implementation, each L represents a bond; and each Y is independently selected from hydrogen, halogen, hydroxyl, cyano, C 1-4Alkyl, C 1-4 Alkoxy, C 3-7 cycloalkyl, C 5-7 Cycloalkenyl, C 2-4 alkenyl, C 2-6 alkynyl, hydroxyl (C 1-6 )alkyl, cyano (C 1-4 )alkyl, halogenated (C 1-4 )alkyl, hydroxyl (C 2-6 ) ynyl group, -NR 9 R 10 -C(O)NR 9 R 10 -C(O)SR 10 -CO2R 10 -C(O)R 10 -CHCHC(O)OR 10 -OSO2R 10 -P(O)(Ph)OR 10 -P(O)(OH)OR 10 -P(S)(Ph)OR 10 -P(O)(CH3)2, phenyl, 5- or 6-membered heteroaryl and 4- to 6-membered heterocyclic alkyl ring, wherein the heteroaryl or heterocyclic alkyl ring comprises 1, 2 or 3 heteroatoms independently selected from N, O and S, wherein the C 3-7 cycloalkyl, C 5-7 The cycloalkenyl, heteroaryl, and heterocycloalkyl groups may optionally be substituted by one or two independent substituents selected from the following: C 1-4 Alkyl and hydroxyl (C 1-4 alkyl; or
[0194] Two adjacent X substituents (or R substituents where applicable) h and R i Together with the carbon atoms they are attached to, they form rings selected from the following: C 5-8 Cycloalkyl or a 5- to 8-membered heterocyclic alkyl ring comprising one or two independent heteroatoms selected from N or O, wherein the C 5-8 The cycloalkyl or 5- to 8-membered heterocyclic alkyl ring is optionally substituted by one, two, or three independent substituents selected from the following: C 1-4 Alkyl, oxo, -C 1-3 Alkylene-NR 9 R 10 and -C 1-3 Alkylene-OR 10 .
[0195] In one implementation, each L represents a bond; and each Y is independently selected from hydrogen, halogen, hydroxyl, cyano, C 1-4 Alkyl, C 1-4Alkoxy, C 3-7 cycloalkyl, C 5-7 Cycloalkenyl, C 2-4 alkenyl, C 2-6 alkynyl, hydroxyl (C 1-6 )alkyl, cyano (C 1-4 )alkyl, halogenated (C 1-4 )alkyl, hydroxyl (C 2-6 ) ynyl group, -NR 9 R 10 -C(O)NR 9 R 10 -C(O)SR 10 -CO2R 10 -C(O)R 10 -CHCHC(O)OR 10 -OSO2R 10 -P(O)(Ph)OR 10 -P(O)(OH)OR 10 -P(S)(Ph)OR 10 -P(O)(CH3)2, phenyl, 5- or 6-membered heteroaryl and 4- to 6-membered heterocyclic alkyl ring, wherein the heteroaryl or heterocyclic alkyl ring comprises 1, 2 or 3 heteroatoms independently selected from N, O and S, wherein the C 3-7 cycloalkyl, C 5-7 The cycloalkenyl, heteroaryl, and heterocycloalkyl groups may optionally be substituted by one or two independent substituents selected from the following: C 1-4 Alkyl and hydroxyl (C 1-4 )alkyl.
[0196] In one implementation, each L represents a bond; and each Y is independently selected from hydrogen, halogen, hydroxyl, cyano, C 1-4 Alkyl, C 1-4 Alkoxy, C 3-6 cycloalkyl, cyclohexenyl, C 2-4 alkenyl, C 2-6 alkynyl, hydroxyl (C 1-6 )alkyl, halogenated (C 1-4 )alkyl, hydroxyl (C 2-6 ) ynyl group, -NR 9 R 10 -C(O)NR 9 R 10 -CO2R 10 -C(O)R 10 -OSO2R 10 phenyl, 5- or 6-membered heteroaryl, and 4- to 6-membered heterocyclic alkyl rings, wherein the heteroaryl or heterocyclic alkyl ring comprises 1, 2, or 3 heteroatoms independently selected from N, O, and S, wherein the C 3-6Cycloalkyl, cyclohexenyl, heteroaryl, and heterocycloalkyl groups are optionally separated by one C 1-3 Alkyl substitution; or
[0197] Two adjacent X substituents (or R substituents where applicable) h and R i Together with the carbon atoms attached thereto, they form a cyclohexyl group or a 5- or 6-membered heterocyclic alkyl ring comprising one or two independent heteroatoms selected from N or O, wherein the cyclohexyl group or 5- or 6-membered heterocyclic alkyl ring is optionally substituted by one or two independent substituents selected from: oxo and C. 1-4 alkyl.
[0198] In one implementation, each L represents a bond; and each Y is independently selected from hydrogen, halogen, hydroxyl, cyano, C 1-4 Alkyl, C 1-4 Alkoxy, C 3-6 cycloalkyl, cyclohexenyl, C 2-4 alkenyl, C 2-6 alkynyl, hydroxyl (C 1-6 )alkyl, halogenated (C 1-4 )alkyl, hydroxyl (C 2-6 ) ynyl group, -NR 9 R 10 -C(O)NR 9 R 10 -CO2R 10 -C(O)R 10 -OSO2R 10 phenyl, 5- or 6-membered heteroaryl, and 4- to 6-membered heterocyclic alkyl rings, wherein the heteroaryl or heterocyclic alkyl ring comprises 1, 2, or 3 heteroatoms independently selected from N, O, and S, wherein the C 3-6 Cycloalkyl, cyclohexenyl, heteroaryl, and heterocycloalkyl groups are optionally separated by one C 1-3 Alkyl substitution.
[0199] In one implementation, each X is independently LY, and each L is independently selected from the bond and -(CR). a R b ) n -; and each Y is independently selected from hydrogen, halogen, hydroxyl, cyano, C 1-3 Alkyl, -CO2R 10 -COR 10 Halogenated (C 1-3 )alkyl, C 1-3 Alkoxy, phenyl and -NR 9 R 10 .
[0200] In one implementation scheme, each Y is independently selected from hydrogen, halogen, hydroxyl, cyano, C1-3 Alkyl, -CO2R 10 -COR 10 Halogenated (C 1-3 )alkyl, C 1-3 Alkoxy, phenyl and -NR 9 R 10 .
[0201] In one embodiment, each Y is independently selected from hydrogen, bromine, fluorine, chlorine, hydroxyl, cyano, methyl, ethyl, -CO2Me, -CO2Et, -C(O)Me, -CF3, -OMe, phenyl and -NHCH3.
[0202] In one implementation scheme, each Y is independently selected from hydrogen, halogen, -CO2R 10 and halogenated (C 1-4 )alkyl.
[0203] In one implementation, each L is a bond, and each Y is independently selected from hydrogen, halogen, hydroxyl, cyano, C 1-3 Alkyl, -CO2R 10 -COR 10 Halogenated (C 1-3 )alkyl, C 1-3 Alkyl and phenyl.
[0204] In one implementation scheme, each Y is independently selected from hydrogen, halogen, cyano, C 1-4 Alkyl and -CO2R 10 In one implementation, each Y is independently selected from hydrogen, fluorine, cyano, methyl, and -CO2Me.
[0205] In one implementation, Y is hydrogen.
[0206] In one implementation, L is a bond and Y is hydrogen.
[0207] In one implementation, Y is a cyano group.
[0208] In one implementation, L is a bond and Y is a cyano group.
[0209] In one implementation, each Y is a halogen or C. 1-4 Alkyl group. In one embodiment, each Y is fluorine or methyl.
[0210] In one embodiment, L is a bond, and each Y is fluorine or methyl.
[0211] In one embodiment, Y is a halogen. In another embodiment, Y is fluorine.
[0212] In one implementation, L is a bond and Y is a halogen, particularly fluorine.
[0213] In one implementation, Y is -CO2R 10 In one implementation, Y is -CO2Me.
[0214] In one implementation, L is a bond and Y is -CO2R. 10 In particular, Y is -CO2Me.
[0215] In one implementation, each L is a bond, and each Y is independently selected from hydrogen, cyano, and C. 1-4 Alkyl, halogen and -CO2R 10 In one embodiment, each L is a bond and each Y is hydrogen. In one embodiment, each L is a bond and each Y is a halogen. In one embodiment, each L is a bond and each Y is fluorine. In one embodiment, each L is a bond and each Y is a halogen or C. 1-4 Alkyl group. In one embodiment, each L is a bond and each Y is fluorine or methyl. In one embodiment, each L is a bond and each Y is cyano. In one embodiment, each L is a bond and each Y is -CO2R. 10 In one implementation, each L is a bond, and each Y is -CO2Me.
[0216] In one implementation, p is 0, 1, or 2. In one implementation, p is 0. In one implementation, p is 1 or 2. In one implementation, p is 1. In one implementation, p is 2.
[0217] In one embodiment, the present invention provides a compound of formula (I) or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or its tautomer thereof.
[0218] (I)
[0219] in
[0220] R 1 It is either hydrogen or a prodrug portion; R 2 Halogenated (C 1-3 )alkyl; R 3 It is an imidazole group or a pyrazole group; Ring A is selected from ; p is 0, 1, 2 or 3; Each X is LY; Each L is independently selected from either the bond or -CF2CH2-; Each Y group is independently selected from hydrogen, halogen, hydroxyl, cyano, C 1-3 Alkyl, -CO2R 10 -COR 10 Halogenated (C 1-3 )alkyl, C 1-3 Alkyl, -NHCH3, and phenyl; and R 10 Independently selected from hydrogen and C 1-6 alkyl.
[0221] In one alternative aspect, the present invention provides a compound of formula (IV) or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or a tautomer thereof.
[0222] (IV)
[0223] in
[0224] R 1 It is either hydrogen or a prodrug portion; R 2 Selected from hydrogen, halogen, cyano, halogen (C 1-3 alkyl, halogenated (C1-3)alkoxy, -S(O)R 7 -C(O)NR 7 R 8 and CO2R 7 Among them, halogenated (C 1-3 Alkyl groups may be optionally substituted with hydroxyl groups or -NR. 7 R 8 Or cyclopropyl; R 3 The 5-membered heteroaryl group with the prodrug moiety is optionally substituted; p is 0, 1, 2 or 3; Each R 4 R 5 R 6 and R 7 Independently designated as -LY; Each L represents a key, -(CR) a R b ) n -、-O-、-(CR a R b ) n O-、-O(CR a R b ) n -、-(CR a R b ) n O(CR a R b ) m-, -SO2-, -SO2(CR) a R b ) n -, -C(O)O-, -OC(O)-, -C(O)O(CR a R b ) n -、-C(O)NH(CR a R b ) n -or-NH(CR) a R b ) n - where each n is independently 1, 2 or 3; Each R a and R b Independently selected from hydrogen, halogen, or C 1-4 alkyl; Each Y group is independently selected from hydrogen, halogen, hydroxyl, cyano, C 1-4 Alkyl, C 1-4 Alkoxy, C 3-7 cycloalkyl, C 5-7 Cycloalkenyl, C 2-4 alkenyl, C 2-6 alkynyl, hydroxyl (C 1-6 )alkyl, halogenated (C 1-4 )alkyl, hydroxyl (C 2-6 ) ynyl group, -NR 9 R 10 -C(O)NR 9 R 10 -CO2R 10 -COR 10 -OSO2R 10 phenyl, 5- or 6-membered heteroaryl, and 4- to 6-membered heterocyclic alkyl rings, wherein the heteroaryl or heterocyclic alkyl ring comprises 1, 2, or 3 heteroatoms independently selected from N, O, and S, wherein the C 3-7 cycloalkyl, C 5-7 The cycloalkenyl, heteroaryl, and heterocyclic alkyl groups may optionally be substituted by one or two independent substituents selected from the following: halogen, amino, C 1-4 Alkyl, C 1-4 Alkoxy and hydroxyl (C 1-4 alkyl; or Two substituents, together with the carbon atom to which they are attached, form a ring selected from the following: C 5-8 Cycloalkyl or a 5- to 8-membered heterocyclic alkyl ring comprising one or two heteroatoms independently selected from N, O, and S, wherein the C 5-8 The cycloalkyl or 5- to 8-membered heterocyclic alkyl ring is optionally substituted by one or two independent substituents selected from the following: oxo and C. 1-4 alkyl; R 7 and R 8 Independently selected from hydrogen and C 1-3 alkyl; R 9 Independently selected from hydrogen, hydroxyl and C 1-4 Alkyl; and R 10 Independently selected from hydrogen and C 1-6 Alkyl; or Where R 9 and R 10 Together with the nitrogen atoms attached to them, they form 5- or 6-membered heterocyclic alkyl rings, which contain one or two independent heteroatoms selected from N and O.
[0225] In one implementation, R 4 R 5 R 6 and R 7 Independently selected from hydrogen, halogen, cyano, -CO2R 10 and C 1-4 alkyl.
[0226] In one implementation, R 6 It is hydrogen.
[0227] In one implementation, R 6 and R 7 It is hydrogen.
[0228] In one implementation, R 4 and R 5 Independently selected from hydrogen, halogens and -CO2R 10 And R 6 and R 7 It is hydrogen.
[0229] In one implementation, R 4 R 6 and R 7 It is hydrogen.
[0230] In one implementation, R 4 R 5 R 6 and R 7 It is hydrogen.
[0231] In one implementation, R 4 R 6 and R 7 It is hydrogen and R 5 It is a halogen.
[0232] In one implementation, R 4 R 6 and R 7 It is hydrogen and R5 It is fluorine.
[0233] In one implementation, R 4 R 6 and R 7 It is hydrogen and R 5 -CO2R 10 .
[0234] In one implementation, R 4 R 6 and R 7 It is hydrogen and R 5 It is -CO2Me.
[0235] In one implementation, R 5 and R 6 For hydrogen, R 7 Let F be the integer part of the integer part, and R be the integer part of the integer part. 4 C 1-4 alkyl.
[0236] In one implementation, R 5 and R 6 For hydrogen, R 7 Let F be the integer part of the integer part, and R be the integer part of the integer part. 4 It is a methyl group.
[0237] In one implementation, R 4 R 5 and R 6 It is hydrogen and R 7 It is a cyano group.
[0238] In one embodiment, the compound of formula (I) is selected from:
[0239] 1-(3-(1 H -imidazol-4-yl)-2-(3-(trifluoromethyl)-1 H -1,2,4-triazol-5-yl)imidazo[1,2-a]pyridin-6-yl)ethyl-1-one, 5-(1 H -imidazol-5-yl)-2-methyl-6-(3-(trifluoromethyl)-1 H -1,2,4-triazol-5-yl)imidazo[2,1-b]oxazol, 7-(1 H -imidazol-5-yl)-6-(3-(trifluoromethyl)-1 H -1,2,4-triazol-5-yl)imidazo[1,2- b [1,2,4]triazine, 3-(1 H -imidazol-5-yl)-2-(3-(trifluoromethyl)-1 H-1,2,4-triazol-5-yl)-5,6-dihydro-8 H -imidazo[2,1- c [1,4]Oxazine, 5-(1 H -imidazol-5-yl)-6-(3-(trifluoromethyl)-1 H -1,2,4-triazol-5-yl)-1 H -imidazo[1,2-a]imidazo, 3-(1 H -imidazol-5-yl)-2-(3-(trifluoromethyl)-1 H -1,2,4-triazol-5-yl)-6,7-dihydro-5 H -pyrrolo[1,2- a Imidazole-6-ol, 6-Fluoro-3-(1 H -imidazol-5-yl)-2-(3-(trifluoromethyl)-1 H -1,2,4-triazol-5-yl)imidazo[1,2-a]pyridine, 2-(3-bromo-1- H -1,2,4-triazol-5-yl)-6,8-difluoro-3-(1 H -imidazol-5-yl)imidazo[1,2- a ]Pyridine, (5-(8-fluoro-3-(1) H -imidazol-5-yl)-7-methylimidazo[1,2-] a ]pyridin-2-yl)-3-(trifluoromethyl)-1 H -1,2,4-triazol-1-yl)methylphosphodihydrogen ester, 6-Bromo-3-(1 H -imidazol-5-yl)-7-methyl-2-(3-(trifluoromethyl)-1 H -1,2,4-triazol-5-yl)imidazo[1,2- a ]Pyridine, 3-(1 H -imidazol-5-yl)-5,7-dimethyl-6-phenyl-2-(3-(trifluoromethyl)-1 H -1,2,4-triazol-5-yl)imidazo[1,2- a ]Pyridine, 7-Bromo-3-(1 H -pyrazole-4-yl)-2-(3-(trifluoromethyl)-1 H -1,2,4-triazol-5-yl)imidazo[1,2-a]pyridine, 3-(1 H-imidazol-4-yl)-2-(3-(trifluoromethyl)-1 H -1,2,4-triazol-5-yl)imidazo[1,2- a ]Pyridine; 8-Fluoro-3-(1 H -imidazol-4-yl)-7-methyl-2-(3-(trifluoromethyl)-1 H -1,2,4-triazol-5-yl)imidazo[1,2- a ]Pyridine, 3-(1 H -imidazol-5-yl)-2-(3-(trifluoromethyl)-1 H -1,2,4-triazol-5-yl)imidazo[1,2-a]pyridine-8-carboxynitrile, 6,7-Difluoro-3-(1 H -imidazol-4-yl)-2-(3-(trifluoromethyl)-1 H -1,2,4-triazol-5-yl)imidazo[1,2- a ]Pyridine, 3-(1 H -imidazol-5-yl)-2-(3-(trifluoromethyl)-1 H -1,2,4-triazol-5-yl)-6,7-dihydro-5 H 9 H -imidazo[2,1- c [1,4]oxazine-heptacyclic hepttriene, 3-(1 H -imidazol-4-yl)-2-(3-(trifluoromethyl)-1 H -1,2,4-triazol-5-yl)imidazo[1,2- a Pyrazine, 3-(1 H -imidazol-4-yl)-2-(3-(trifluoromethyl)-1 H -1,2,4-triazol-5-yl)imidazo[1,2-b]pyridazine, 7-Chloro-3-(1 H -imidazol-4-yl)-2-(3-(trifluoromethyl)-1 H -1,2,4-triazol-5-yl)imidazo[1,2-c]pyrimidine, 3-(1 H -imidazol-4-yl)-6-methoxy-2-(3-(trifluoromethyl)-1 H -1,2,4-triazol-5-yl)imidazo[1,2- a Pyrazine, 2-(3-(difluoromethyl)-1 H-1,2,4-triazol-5-yl)-3-(1 H -imidazol-4-yl)imidazo[1,2- a Pyrazine, 6-Ethyl-3-(1 H -imidazol-4-yl)-2-(3-(trifluoromethyl)-1 H -1,2,4-triazol-5-yl)imidazo[1,2-a]pyrazine, 3-(1 H -imidazol-4-yl)-2-(3-(trifluoromethyl)-1 H Methyl 1,2,4-triazol-5-yl)imidazo[1,2-a]pyrazine-6-carboxylate, 3-(1 H -imidazol-4-yl)-2-(3-(trifluoromethyl)-1 H -1,2,4-triazol-5-yl)imidazo[1,2- a ]Pyridine-7-ol, 3-(1 H -imidazol-4-yl)-2-(3-(trifluoromethyl)-1 H -1,2,4-triazol-5-yl)imidazo[1,2- a Methyl pyridine-7-carboxylate, 2-(3-(1 H -imidazol-4-yl)-2-(3-(trifluoromethyl)-1 H -1,2,4-triazol-5-yl)imidazo[1,2-a]pyridin-6-yl)-2,2-difluoro-N-methylethyl-1-amine, 3-(1 H -pyrazole-4-yl)-2-(5-(trifluoromethyl)-1 H -1,2,4-triazol-3-yl)-5,6-dihydroimidazo[1,2- a ]Pyrazine-7(8 H ethyl formate, and 3-(1 H -imidazol-4-yl)-7-(trifluoromethyl)-2-(3-(trifluoromethyl)-1 H -1,2,4-triazol-5-yl)imidazo[1,2- b ]pyridazine, Or its tautomers, or pharmaceutically acceptable salts of the compound or its tautomers.
[0240] In one embodiment, the compound of formula (I) is , , , ,or .
[0241] Or its tautomers, or pharmaceutically acceptable salts of the compound or its tautomers.
[0242] In one embodiment, the compound of formula (I) is represented by one of the following structures, which shows that when R 3 It is an imidazole group, R 2 Available tautomers for CF3: .
[0243] Or its pharmaceutically acceptable salt.
[0244] In one embodiment, the compound of formula (I) is represented by one of the following structures, which shows that when R 3 It is an imidazole group, R 2 Available tautomers for CF3: .
[0245] Or its pharmaceutically acceptable salt.
[0246] In one embodiment, the compound of formula (I) is represented by one of the following structures, which shows that when R 3 It is an imidazole group, R 2 Available tautomers for CF3: .
[0247] Or its pharmaceutically acceptable salt.
[0248] In one embodiment, the compound of formula (I) is represented by one of the following structures, which shows that when R 3 It is an imidazole group, R 2 Available tautomers for CF3: .
[0249] Or its pharmaceutically acceptable salt.
[0250] In one embodiment, the compound of formula (I) is represented by one of the following structures, which shows that when R 3 It is an imidazole group, R 2 Available tautomers for CF3: .
[0251] Or its pharmaceutically acceptable salt.
[0252] In one embodiment, the compound of formula (I) is a prodrug. , , , ,or .
[0253] Or its tautomers, or pharmaceutically acceptable salts of the compound or its tautomers.
[0254] In one embodiment, the compound of formula (I) is , , , ,or
[0255] Where R 1 It is a prodrug moiety, or a tautomer thereof, or a pharmaceutically acceptable salt of the compound or its tautomer thereof.
[0256] In one embodiment, the compound of formula (I) is in the form of a free base. In one embodiment, the compound of formula (I) in the form of a free base is any one of the compounds of Examples 1 to 146.
[0257] In one embodiment, the compound of formula (I) is in the form of a pharmaceutically acceptable salt. In one embodiment, the pharmaceutically acceptable salt form of the compound of formula (I) is any one of the compounds of Examples 1 to 146.
[0258] Compounds of formula (I) or their tautomers may contain acidic or basic functional groups, and therefore those skilled in the art will understand that pharmaceutically acceptable salts of compounds of formula (I) may be prepared.
[0259] Pharmaceutically acceptable salts include, in particular, those described in Berge, J. Pharm. Sci., 1977, 66, 1–19, or those listed in PH Stahl and CG Wermuth, editors, Handbook of Pharmaceutical Salts; Properties, Selection and Use, Second Edition Stahl / Wermuth: Wiley-VCH / VHCA, 2011 (see http: / / www.wiley.com / WileyCDA / WileyTitle / productCd-3906390519.html).
[0260] Suitable pharmaceutically acceptable salts may include acid addition salts or base addition salts.
[0261] Such base addition salts can be formed by reacting a compound of formula (I) (which, for example, contains a carboxylic acid or other acidic functional group) with a suitable base, optionally in a suitable solvent (e.g., an organic solvent), to obtain the salt.
[0262] Such acid addition salts can be formed by reacting a compound of formula (I) (which, for example, contains a basic amine or other basic functional group) with a suitable acid, optionally in a suitable solvent (e.g., an organic solvent), to obtain the salt.
[0263] Salts can be prepared in situ during the final separation and purification of compounds of formula (I). If a basic compound of formula (I) is separated as a salt, the corresponding free basic form of the compound can be prepared by any suitable method known in the art, including treatment of the salt with an inorganic or organic base. Similarly, if a compound of formula (I) containing a carboxylic acid or other acidic functional group is separated as a salt, the corresponding free acidic form of the compound can be prepared by any suitable method known in the art, including treatment of the salt with an inorganic or organic acid.
[0264] It should be understood that if a compound of formula (I) contains two or more basic moieties, the stoichiometry of the salt formation may include one, two, or more equivalents of acid. Such salts will contain one, two, or more acid counterions, such as dihydrochlorides.
[0265] Pharmaceutically acceptable salts of compounds of formula (I) are included in the scope of this invention in stoichiometric and non-stoichiometric forms, including substoichiometric salts.
[0266] Representative pharmaceutically acceptable acid addition salts include, but are not limited to, 4-acetamidobenzoate, acetate, adipic acid salt, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, hydrogen sulfate, hydrogen tartrate, butyrate, calcium edetate, camphorate, camphor sulfonate (dextrose camphor sulfonate), caprate, caproate, and octanoate. Cinnamate, citrate, cyclohexylaminosulfonate, digluconate, 2,5-dihydroxybenzoate, disuccinate, dodecyl sulfate (propionate lauryl sulfate), edetate (ethylenediaminetetraacetic acid), propionate lauryl sulfate (lauryl sulfate), ethane-1,2-disulfonate (ethanedisulfonate), ethanesulfonate (ethanesulfonate), formate, fumarate, galactarate (mucates), gentianate (2,5-dihydroxybenzoate), glucoheptonate (gluceptate), gluconate, Glucuronate, glutamate, glutarate, glycerophosphate, glycolate, hexylresorcinate, hippurate, hydrabamine (N,N'-di(dehydroabi)-ethylenediamine), hydrobromide, hydrochloride, hydroiodate, hydroxynaphthylcarboxylate, isobutyrate, lactate, lacturonate, laurate, malate, maleate, malonate, mandelate, methanesulfonate, methyl sulfate, mucilage, naphthalene-1,5-disulfonate (napadisylate), naphthalene- 2-Sulfonates (naphthalenesulfonate), nicotinate, nitrate, oleate, palmitate, p-aminobenzenesulfonate, p-aminosalicylate, embonate, pantothenate, pectate, persulfate, phenylacetate, phenethyl barbiturate, phosphate, polygalacturonate, propionate, p-toluenesulfonate, pyroglutamate, pyruvate, salicylate, sebate, stearate, hypoacetate, succinate, aminosulfonate, sulfate, tannin, tartrate, teoclate (8-teoclate), thiocyanate, triethyliodide, undecanoate, undecenoate, and valerate.
[0267] Representative pharmaceutically acceptable base addition salts include, but are not limited to, aluminum, 2-amino-2-(hydroxymethyl)-1,3-propanediol (TRIS), arginine, phenethylbenzylamine (N-benzylphenylethylamine), benzathine (N,N'-dibenzylethylenediamine), bis(2-hydroxyethyl)amine, bismuth, calcium, chloroprocaine, choline, crimidazole (1-p-chlorobenzyl-2-pyrrolidine-1'-ylmethylbenzimidazole), cyclohexylamine, dibenzylethylenediamine, diethylamine, diethyltriamine, dimethylamine, dimethylethanolamine, dopamine, ethanolamine, ethylenediamine, L-histidine, iron, isoquinoline, lepidine, lithium, lysine, magnesium, meglumine (N-methylglucosamine), piperazine, piperidine, potassium, procaine, quinine, quinoline, sodium, strontium, tert-butylamine, and zinc.
[0268] The compounds of this invention can exist in tautomer form. It should be understood that any reference to a named compound or a compound described in a structural description is intended to cover all tautomers of such compounds.
[0269] For example, when R 1 When hydrogen is present, the following tautomers exist: .
[0270] For example, when R 1 It is the prodrug portion and R 3 When the group is imidazole (through carbon bonding), the following tautomers exist: .
[0271] In one implementation, when R 1 It is hydrogen and R 3 When the group is imidazole (via C-bonding), the following tautomers exist: .
[0272] This invention also includes all suitable isotopic variants of the compounds of this invention. An isotopic variant of the compounds of this invention is defined as a variant in which at least one atom is replaced by an atom having the same atomic number but a different atomic mass than that commonly found in nature.
[0273] Examples of isotopes that can be incorporated into the compounds of the present invention include isotopes of hydrogen, carbon, nitrogen, oxygen, fluorine, and chlorine, such as 2H, 3H, 13C, 14C, 15N, 17O, 18O, 18F, and 36Cl, respectively. Certain isotopic variants of the compounds of formula (I) or their salts or solvates, such as those incorporating radioactive isotopes (e.g., 3H or 14C), can be used for drug and / or substrate tissue distribution studies. Tritium (i.e., 3H) and carbon-14 (i.e., 14C) isotopes are particularly preferred due to their ease of preparation and detectability. Furthermore, substitution with isotopes such as deuterium (i.e., 2H) can provide certain therapeutic advantages due to greater metabolic stability, such as increased in vivo half-life or reduced dose requirements, and may therefore be preferred in some cases. Thus, in one embodiment, the present invention comprises the compounds of the present invention wherein one or more hydrogen atoms bonded to a carbon atom are replaced by deuterium. Isotopic variants of the compounds of the present invention can generally be prepared by conventional procedures (e.g., by illustrative methods or by preparations described in the examples below, using appropriate isotopic variants with suitable reagents).
[0274] In one embodiment, the invention includes , , , ,or
[0275] One or more hydrogen atoms bonded to carbon atoms are replaced by deuterium.
[0276] It should be understood that the disclosed implementation plan can be combined with any aspect and other implementation plans.
[0277] Statement of Purpose
[0278] Therapeutic targeting of the cGAS-STING pathway with small molecule cGAS inhibitors can be beneficial in a wide range of autoinflammatory, autoimmune, and immune-mediated diseases.
[0279] In one implementation, "treatment" means improving or stabilizing a specified condition, reducing or eliminating the symptoms of the condition, and slowing or eliminating the progression of the condition.
[0280] The compounds of the present invention can be used to prevent conditions in which downstream elements of cGAS or its pathway can play a known or intended role, such as immune disorders, inflammatory disorders, autoimmune disorders, autoinflammatory diseases, type I interferonopathies, allergies, infectious diseases, organ damage, tissue damage, and other cGAS-dependent or related conditions.
[0281] The compounds of the present invention can be used to treat conditions in which cGAS or downstream elements of its pathway may play a known or intended role. Therefore, the compounds of the present invention can be used to treat a variety of immune disorders, inflammatory disorders, autoimmune disorders, autoinflammatory diseases, type I interferon disorders, allergies, infectious diseases, organ damage, tissue damage, and other cGAS-dependent or related conditions.
[0282] The compounds of this invention can be used to treat cGAS-related diseases or disorders.
[0283] The compounds of this invention can be used to prevent cGAS-related diseases or disorders.
[0284] The compounds of this invention can be used to treat autoimmune diseases selected from, but not limited to, STING-associated vasculitis (SAVI) beginning in infancy, Aicardiosis, etc. Goutieres syndrome (AGS), familial frostbite lupus, ataxia-telangiectasia (also known as Louis-Bar syndrome), retinal vascular disease with leukodystrophy (RVCL), systemic lupus erythematosus (SLE), cutaneous lupus, lupus nephritis (LN), psoriasis, diabetes (including insulin-dependent diabetes mellitus (IDDM)), dermatomyositis, human immunodeficiency virus (HIV), AIDS, polymyositis, systemic sclerosis (scleroderma) and Sjögren's syndrome (SS), rheumatoid arthritis (RA), psoriatic arthritis, polyarteritis, myasthenia gravis, polyarteritis nodosa, vasculitis, cutaneous vasculitis, antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, Henoch-Schonlein purpura, autoimmune hepatitis, primary sclerosing cholangitis, Wegener's granulomatosis, microscopic polyangiitis, Behcet's disease Diseases including spondylitis, giant cell arteritis, polymyalgia rheumatica, Raynaud's phenomenon, primary biliary cirrhosis, primary vasculitis of the central nervous system, microscopic polyangiitis, neuromyelitis optica, and mixed connective tissue disease.
[0285] The compounds of this invention can be used to treat acute or chronic inflammation of any tissue or organ in the human body, including but not limited to musculoskeletal inflammation, vascular inflammation, cardiovascular inflammation, neurological inflammation, digestive system inflammation, respiratory system inflammation, renal system inflammation, reproductive system inflammation, ocular inflammation, periodontal inflammation, and other inflammations (as illustrated below) and subsequent tissue and organ damage.
[0286] The compounds of this invention can be used to treat musculoskeletal inflammation (i.e., any inflammatory condition of the musculoskeletal system), including but not limited to conditions affecting skeletal joints (including joints of the hand, wrist, elbow, shoulder, jaw, spine, neck, hip, knee, ankle, and foot), and conditions affecting tissues connecting muscles and bones (e.g., tendons). Examples of musculoskeletal inflammations that can be treated with the compounds of this invention include arthritis (including, for example, osteoarthritis, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, acute and chronic infectious arthritis, arthritis associated with gout and pseudogout, and juvenile idiopathic arthritis), tendinitis, synovitis, tenosynovitis, bursitis, fibrositis (fibromyalgia), epicondylitis, myositis, and osteitis (including, for example, Paget's disease, osteitis pubis, and osteitis fibrosus).
[0287] The compounds of this invention can be used to treat inflammation of the vascular or lymphatic system, including but not limited to atherosclerosis, arthritis, phlebitis, vasculitis, and lymphangitis.
[0288] The compounds of this invention can be used to treat cardiovascular diseases and cardiomyopathy, including but not limited to heart failure, myocardial infarction, cardiac hypertrophy, cardiac fibrosis, endocardial myocardial fibrosis, aortic aneurysm and dissection (AAD).
[0289] The compounds of this invention can be used to treat inflammation of the nervous system, including but not limited to encephalitis, sepsis-associated encephalopathy (SAE), ischemic stroke, traumatic brain injury (TBI), ataxia-telangiectasia, Guillain-Barré syndrome, meningitis, neuromuscular rigidity, narcolepsy, multiple sclerosis, myelitis, CNS vasculitis, and schizophrenia.
[0290] The compounds of the present invention can be used to treat inflammatory conditions of the digestive system, including but not limited to cholangitis, cholecystitis, enteritis, enterocolitis, gastritis, gastroenteritis, inflammatory bowel disease (e.g., Crohn's disease and ulcerative colitis), ileitis, proctitis, and colorectal cancer.
[0291] The compounds of this invention can be used to treat inflammation of the respiratory system, including but not limited to lung inflammation, chronic lung inflammation, cystic fibrosis, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF), silicosis, asthma, and COVID-19. The compounds of this invention can be used to improve lung inflammation, endothelial and vascular damage, and skin lesions caused by COVID-19 infection.
[0292] The compounds of this invention can be used to treat inflammatory conditions and diseases of the liver and kidneys, including but not limited to cirrhosis, liver fibrosis, viral hepatitis, non-alcoholic fatty liver disease (NAFLD), steatosis, non-alcoholic steatohepatitis (NASH), alcohol-related liver disease (ALD), hepatocellular carcinoma (HCC), hepatic ischemia-reperfusion injury (IRI), acute kidney injury (AKI), chronic kidney disease (CKD), and renal fibrosis.
[0293] The compounds of this invention can be used to treat metabolic disorders, including but not limited to diabetes, obesity, insulin resistance, and glucose intolerance.
[0294] The compounds of this invention can be used to treat inflammatory conditions of the reproductive system, including but not limited to cervicitis, chorioamnionitis, endometritis, epididymitis, omphalitis, oophoritis, orchitis, salpingitis, tubo-ovarian abscess, urethritis, vaginitis, vulvitis, and vulvar pain.
[0295] The compounds of this invention can be used to treat ocular inflammation, including but not limited to inflammation of any structure of the eye, including the eyelids. Examples of ocular inflammations that can be treated with the compounds of this invention include blepharitis, blepharospasm, conjunctivitis, dacryoadenitis, keratitis, fungal keratitis, keratoconjunctivitis sicca (dry eye syndrome), scleritis, trichiasis, and uveitis. Furthermore, they can treat other eye-related disorders, including age-related macular degeneration (AMD).
[0296] The compounds of this invention can be used to treat inflammatory periodontal diseases (also known as gingival diseases), including but not limited to gingivitis, odontoblastic inflammation, chronic periodontitis, aggressive periodontitis, necrotizing ulcerative gingivitis / periodontitis, and combined periodontal-pulp disease.
[0297] The compounds of this invention can be used to treat autoimmune diseases with inflammatory components, including but not limited to acute disseminated alopecia universalis, Behcet's disease, Chagas disease, STING-associated vasculitis (SAVI) beginning in infancy, Aicardi-Goutieres syndrome (AGS), frostbite-like lupus, ataxia-telangiectasia (also known as Louis-Bar syndrome), retinal vasculopathy with leukodystrophy of the brain (RCVL), ANCA-associated vasculitis, chronic fatigue syndrome, dysautonomia, encephalomyelitis, ankylosing spondylitis, aplastic anemia, hidradenitis suppurativa, autoimmune hepatitis, autoimmune oophoritis, celiac disease, Crohn's disease, type 1 diabetes, giant cell arteritis, Goodpasture's syndrome, and Graves' disease. Guillain-Barré syndrome, Hashimoto's disease, Henoch-Schonlein purpura, Kawasaki disease, lupus erythematosus, microscopic colitis, microscopic polyarteritis, mixed connective tissue disease, multiple sclerosis, myasthenia gravis, oculoclonus myoclonus syndrome, optic neuritis, Ord thyroiditis, pemphigus, polyarteritis nodosa, polymyalgia, rheumatoid arthritis, Reiter's syndrome, Sjögren's syndrome, temporal arteritis, Wegener's granulomatosis, warm autoimmune hemolytic anemia, interstitial cystitis, Lyme disease, morphine scleroderma, psoriasis, sarcoidosis, scleroderma, ulcerative colitis, and vitiligo.
[0298] The compounds of the present invention can be used to treat T-cell-mediated hypersensitivity diseases with inflammatory components, including but not limited to contact hypersensitivity, contact dermatitis (including contact dermatitis caused by poison ivy), urticaria, skin allergies, respiratory allergies (hay fever, allergic rhinitis) and gluten-sensitive enteropathy (celiac disease).
[0299] The compounds of this invention can be used to treat other inflammatory conditions, including but not limited to appendicitis, dermatitis, dermatomyositis, endocarditis, fibrositis, gingivitis, glossitis, hepatitis, hidradenitis suppurativa, iritis, laryngitis, mastitis, myocarditis, nephritis, otitis, pancreatitis, mumps, pericarditis, peritonitis, pharyngitis, pleurisy, pneumonia, prostatitis, pyelonephritis and stomatitis, transplant rejection (involving organs such as kidney, liver, heart, lung, pancreas (e.g., islet cells), bone marrow, cornea, small intestine, skin allogeneic transplant, skin allogeneic transplant and heart valve xenograft, serum sickness and graft-versus-host disease), acute pancreatitis, chronic pancreatitis, acute respiratory syndrome, Sezary syndrome, congenital adrenal hyperplasia, and non-suppurative inflammatory diseases. Thyroiditis, cancer-related hypercalcemia, pemphigus, bullous herpes, severe erythema multiforme, exfoliative dermatitis, seborrheic dermatitis, seasonal or perennial allergic rhinitis, bronchial asthma, contact dermatitis, atopic dermatitis, drug hypersensitivity, allergic conjunctivitis, keratitis, ocular herpes zoster, iritis and iridocyclitis, chorioretinitis, optic neuritis, symptomatic sarcoidosis, chemotherapy for fulminant or diffuse tuberculosis, adult idiopathic thrombocytopenic purpura, adult secondary thrombocytopenia, acquired (autoimmune) hemolytic anemia, adult leukemia and lymphoma, childhood acute leukemia, regional enteritis, autoimmune vasculitis, multiple sclerosis, chronic obstructive pulmonary disease, solid organ transplant rejection, sepsis.
[0300] The compounds of the present invention can be used to treat one or more afflicting diseases characterized by cell proliferation disorders in the field of angiogenesis and / or vascular permeability, including angiogenesis disorders (including arthritis (rheumatoid arthritis) and restenosis); fibrotic disorders, including cirrhosis and atherosclerosis; mesangial cell proliferation disorders, including glomerulonephritis, diabetic nephropathy, malignant nephrosclerosis, thrombotic microangiopathy syndrome, proliferative retinopathy, organ transplant rejection, and glomerulonephropathy; and other disorders, including psoriasis, diabetes, and chronic wound healing.
[0301] The compounds of this invention can be used to treat neurodegenerative diseases, including but not limited to multiple sclerosis, Huntington's disease, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD).
[0302] The compounds of this invention can be used to treat inflammatory conditions originating from infectious diseases, any disease caused by or occurring concurrently with a pathogen infection. A pathogen can be broadly defined as any species or organism foreign to the human tissue environment. Common pathogenic pathogens include bacteria (many such as TB), viruses (many such as HBV, HIV, influenza), and parasitic protozoa (such as Plasmodium falciparum, which causes malaria). The compounds of this invention can be used to treat infectious diseases originating from bacteria, such as TB infection (Mycobacterium tuberculosis), Chlamydia, tularemia infection (Franciseiia tuiarensis), Plasmodium infection, or infections from DNA or RNA viruses. The compounds of this invention can be used to treat infectious diseases originating from DNA virus families: Herpesviridae (Herpes simplex virus-1, Kaposi's sarcoma-associated virus, and Epstein-Barr virus), Papillomaviridae (human papillomavirus), adenovirus, and Hepadnaviridae (hepatitis B virus). Examples of RNA virus families include the Retroviridae (human immunodeficiency virus), Flaviviridae (dengue virus, Zika virus, hepatitis C virus), Orthomyxoviridae (influenza), and Coronaviridae (human coronavirus, MERS, SARS, and SARS-CoV2 coronavirus).
[0303] The compounds of the present invention can be used to improve organ damage or impairment caused by cGAS-mediated diseases or disorders, such as acute kidney injury, liver injury, lung injury, heart injury, etc.
[0304] The compounds of the present invention can be used in particular to treat systemic lupus erythematosus (SLE), cutaneous lupus erythematosus (CLE), lupus nephritis, Sjögren's syndrome, dermatomyositis and scleroderma, especially systemic lupus erythematosus and lupus nephritis.
[0305] The compounds of the present invention can be used in particular to treat neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS), Parkinson's disease (PD) and Alzheimer's disease (AD), acute kidney injury, chronic kidney disease, diabetic nephropathy or injury, myocardial infarction, stroke, cardiac hypertrophy / heart failure, non-alcoholic steatohepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD).
[0306] Aicardi-Goutières syndrome (AGS) is an early-onset disease characterized by autoinflammatory and autoimmune features, including progressive encephalopathy and frostbite-like skin lesions, and is biochemically characterized by increased type I interferon (Stetson et al. Cell 134(4) 587–598, 2008; Crow et al. Nat Rev Immunol 15(7) 429–440, 2015; Uggenti et al. Annu Rev Immunol 37: 247–267, 2019). Many AGS patients exhibit systemic autoimmune features, such as antinuclear and antiDNA autoantibodies, similar to SLE. More than 75% of AGS patients carry mutations in Trex1 or RnaseH2, leading to the accumulation of cytoplasmic DNA due to insufficient DNA clearance (Trex1) or DNA damage-driven micronucleus formation (RnaseH2). Importantly, knocking out these nucleases and / or knocking inactivating AGS mutations leads to a fatal autoimmune disease in mice that can be rescued by cGAS or STING deletion (Gray et al. 2015 J Immunol 195(5) 1939-1943, 2015; Gao et al. PNAS USA 112(42) E5699-E5705, 2015; Pokatayevet et al. J Exp Med 213(3) 329-336, 2016; Mackenzie et al. EMBO J 35(8) 831-844, 2016). Besides AGS, Trex1 mutations have also been associated with familial frostbite lupus (FCL) (the cutaneous form of systemic lupus erythematosus) and retinal vascular disease (RVCL) with leukodystrophy of the brain (Rice et al. J Clin Immunol 35(3) 235-243, 2015). Recently, biallelic mutations in the LSM11 and RNU7-1 genes, which encode components of the histone pre-mRNA processing complex, have been identified in genetically non-characteristic AGS patients and are associated with excessive cGAS signaling (Uggenti et al. Nat Genet 52(12) 1364–1372, 2020).
[0307] Direct evidence that STING activation leads to inflammatory diseases comes from the identification of gain-of-function mutations in the TMEM173 gene encoding STING in patients presenting with early-onset vasculopathy and lung inflammation (Liu et al., N Engl J Med 371(6) 507-518, 2014). Diseases caused by such mutations (now classified as SAVI (STING-associated vasculopathy starting in infancy)) are characterized by recurrent fever, ulcerative skin lesions, vasculitis, and interstitial lung disease. SAVI-associated STING mutations are thought to lead to spontaneous dimerization and activation of STING in the absence of cGAMP (Ergun et al., Cell, 178(2) 290-301, 2019).
[0308] COPA syndrome (named for a deficiency in the COPa protein, which is involved in Golgi-ER transport) is also associated with aberrant cGAS-STING signaling. It is believed that due to the COPA mutation, STING spends a proportionally longer time in the activated state of the Golgi apparatus, resulting in constitutive signaling (Lepelley et al. J Exp Med 217(11)e20200600,2020; Mukai et al. Nat Commun 12(1)61, 2021). Although all COPA patients present with lung disease, a small percentage develop arthritis and nephropathy.
[0309] DNA cell deletion was first described in humans in 2017. Affected patients exhibited severe neonatal anemia, membranoproliferative glomerulonephritis, deforming arthropathy, and elevated levels of anti-dsDNA antibodies (Rodero et al., Nature Communications 8(1) 2176, 2017). Although dsDNA seII is an endosomal nuclease, it is presumed that the accumulation of dsDNA in lysosomes eventually leads to its rupture, thereby exposing the DNA to cGAS. Dnase II-deficient mice died during embryonic development due to severe anemia and, when crossed with IFNAR-deficient mice, developed chronic polyarthritis (Kawane et al., Science 292(5521) 1546-1549, 2001; Yoshida et al., Nat Immunol 6(1) 49-56, 2005). Interestingly, deletion of cGAS or STING completely rescued DnaseII-deficient mice from embryonic lethality and chronic arthritis (Gao et al. PNAS USA 112(42) E5699–E5705, 2015).
[0310] Multiple pieces of evidence suggest that the same mechanisms involved in the pathogenesis of monogenic diseases contribute to the development of complex autoimmune diseases such as SLE. Desense Trex1 mutations have been identified in 0.5–2% of SLE patients and have re-emerged as a lupus-like phenotype in mice carrying the Trex1D18N mutation, which causes familial frostbite lupus (Namjou et al. Genes and Immunity 12(4) 270–279, 2011; Lee-Kirsch et al. Nat Genet 39(9) 1065–1067, 2007; Barizzone et al. Biomed Res Int 2013:471703, 2013). Similarly, in addition to AGS, mutations impairing RNase H2 function are also associated with SLE (Günther et al. J Clin Invest 125(1) 413–424, 2015). Furthermore, elevated cGAMP levels were reported in 15% of SLE patients, and cGAMP-positive patients exhibited higher SLEDAI scores (An et al. Arthritis Rheumatol 69(4) 800–807, 2017).
[0311] Based on the presence of interferon signatures and overlapping clinical presentations, diseases including various subtypes of cutaneous lupus erythematosus (CLE), lupus nephritis (LN), and dermatomyositis are expected to be (at least in part) driven by the same mechanisms associated with the pathogenesis of SLE. UV-induced DNA damage may also activate the cGAS-STING pathway and contribute to disease pathology (Skopelja-Gardner et al. Sci Rep 10(1) 7908, 2020).
[0312] Excessive cGAS-STING activation and cGAS-STING-dependent pathogenesis have been suggested in several other autoimmune diseases, including rheumatoid arthritis (RA), psoriasis, and inflammatory bowel disease (IBD). cGAS deficiency rescued the polyarthritis phenotype in DnaseII-KO mice and reduced joint swelling in a K / BxN arthritis mouse model (Gao et al., PNAS USA 112(42) E5699–E5705, 2015; Willemsen et al., Cell Rep 37(6) 109977, 2021). Similarly, STING deficiency attenuated IMQ-induced psoriatic symptoms and skin inflammation (Yu et al., J InvestDermatol 142(3) 898-906, 2022). In IBD, the cGAS-STING pathway plays both protective and detrimental roles. While elimination of cGAS reduces intestinal inflammation and improves colitis associated with IL-10 deficiency, other studies have highlighted the beneficial roles of cGAS and STING in intestinal homeostasis (Ahn et al. Cell Reports 21(13) 3873-3884, 2017; Canesso et al. Mucosal Immunol 11(3) 820-834, 2018; Hu et al. PNAS 118(23)e2105747118, 2021).
[0313] Inflammation is a prominent hallmark of many neurodegenerative diseases, including Parkinson's disease, amyotrophic lateral sclerosis (ALS), Huntington's disease (HD), and Alzheimer's disease. In the case of Parkinson's disease, mutations in the PARKIN and PINK1 genes lead to defects in mitophagy, leakage of mtDNA into the cytosol, and cGAS-STING-dependent cytokine production. Importantly, the motor deficits and neuronal cell loss observed in Parkin mutant mice can be rescued by STING ablation (Slitter et al., Nature 561(7722) 258-262, 2018). Recently, the cGAS-STING pathway has been associated with neuropathological processes related to ALS and frontotemporal degeneration. In a preclinical model of ALS driven by overexpression of the human TDP-43 (A315T) allele, STING ablation suppressed neuroinflammation, slowed rapid disease progression, and prevented early death (Yu et al., Cell 183(3) 636–649, 2020). Furthermore, in the SOD1-ALS mouse model, administration of cGAS or STING inhibitors improved ongoing inflammation, improved motor function, and increased survival (Tan et al., iScience 25:104404, 2022). Finally, ALS patients with C9orf72 repeat amplification exhibited enhanced type I interferon signatures, which were at least partially driven by STING activation (McCauley et al., Nature 585(7823) 96-101, 2020). Increased cGAS activity was also associated with inflammatory responses in HD striatal cells, while activation of microglia with Tau was associated with the PQBP1-cGAS-STING pathway (Sharma et al., PNAS 117(27) 5989–15999, 2020; Jin et al., Nat Commun 12(1) 6565, 2021).
[0314] Activation of the cGAS-STING pathway using mtDNA is considered a potential mechanism for obesity-induced inflammation and metabolic dysfunction. STING deficiency and / or inhibition (at least partially) prevent diet-induced adipose tissue inflammation, obesity, insulin resistance, and glucose intolerance, and reduce pancreatic β-cell senescence (Mao et al., Arterioscler Thromb Vasc Biol 37(5)920-929, 2017; Hu et al., FASEB J 36(5) e22266, 2022). Furthermore, excessive cGAS-STING signaling is associated with other metabolic diseases such as NAFLD and NASH. Independent laboratories have demonstrated that STING deficiency reduces the severity of hepatic steatosis, inflammation, and fibrosis in mouse models of methionine / choline deficiency diet (MCD) and high-fat diet (HFD) (Luo et al. Gastroenterology 155(6) 1971-1984, 2018; Yu et al. J Clin Invest 129(2) 546-555, 2019; Zhang et al. Front Immunol 13: 931176, 2022).
[0315] Enhanced cGAS-STING signaling has been demonstrated in acute kidney injury (AKI), chronic kidney disease (CKD), and other fibrosis-related indications. Cisplatin-induced mtDNA leakage triggers renal tubular inflammation and progression of AKI, which can be salvaged by STING deletion or treatment with STING inhibitors (Maekawa et al., Cell Rep 29(5) 1261-1273, 2019; Gong et al., Am J Physiol Renal Physiol 320(4) F608-F616, 2021). Chronic kidney disease (CKD) (characterized by kidney injury, inflammation, and tissue fibrosis) is associated with impaired mitochondrial integrity and mtDNA release. Furthermore, gene ablation or pharmacological inhibition of STING improved TFAM loss-induced and FA-induced renal inflammation and fibrosis, and improved renal function in APOL1 transgenic mice expressing the G2 risk allele (Chung et al. Cell Metab 30(4) 784-799, 2019; Wu et al. J Clin Invest 131(20) e136329, 2021). Recently, Zhang et al. proposed that cGAS-STING-driven fibrosis is promoted by the non-canonical cGAS–STING–PERK pathway (Zhang et al. Nat Cell Biol 24(5) 766-782, 2022).
[0316] Idiopathic pulmonary fibrosis (IPF) is characterized by progressive lung scarring. This pathophysiology is believed to depend on repetitive local micro-trauma leading to DNA damage, cell death, and fibrosis. The contribution of the cGAS-STING pathway to the pathology of the disease in the classic bleomycin-induced mouse model of pulmonary fibrosis is controversial. While Savigny et al. suggested that STING plays a protective role in the bleomycin model by limiting pulmonary fibrosis, Zhang et al. reported a less severe fibrotic phenotype in STING-deficient mice compared to WT mice (Savigny et al. FrontImmunol 11:588799, 2021; Zhang et al. Nat Cell Biol 24(5) 766-782, 2022). Administration of STING inhibitors also improved intestinal ischemia-reperfusion mediated acute lung injury, as demonstrated by reduced lung injury scores and attenuated fibrosis (Yang et al. Eur J Med Res 27(1)79, 2022). Furthermore, cGAS-STING signaling induces lung inflammation in response to cigarette smoke exposure (a major cause of chronic obstructive pulmonary disease (COPD)) and silica particles (Nascimento et al. Sci Rep 9(1) 14848, 2019; Benmerzoug et al. Nat Com 9(1) 5226, 2018).
[0317] Myocardial infarction (MI) leads to ischemic cell death in the heart, releasing fragments of dead cells. The released cardiomyocyte DNA is phagocytosed by infiltrating macrophages, resulting in cGAS-STING-mediated production of type I IFN. Genetic or drug blockade of the cGAS-STING pathway has prevented MI-induced adverse ventricular remodeling, improved systolic function, and increased survival rates after myocardial infarction (King et al. Nat Med 23(12) 1481-1487, 2017; Cao et al. Circulation 137(24) 2613-2634, 2018; Lai et al. J Am Heart Assoc 10(15) e020754, 2021; Rech et al. Life Sci 291:120263, 2022). Furthermore, cGAS-STING knockdown blunted pressure overload-induced cardiac hypertrophy and improved cardiac function in a mouse model of transverse aortic coarctation (TAC) (Hu et al., Am J Physiol Heart circ Physiol 318(6)H1525-H1537, 2020). Activation of the cGAS-STING pathway is also associated with the development of atherosclerosis and ischemic stroke-related brain injury (Pham et al., Eur Heart J 42(42) 4336-4348, 2021; Li et al., EMBO Mol Med 12(4)e11002, 2020).
[0318] Excessive cGAS-STING signaling leads to acute and chronic inflammation in a variety of tissues, and in addition to the diseases mentioned above, the cGAS-STING pathway is also associated with the pathogenesis of age-related macular degeneration (AMD) (Kerur et al. Nat Med 24(1) 50-61, 2018), acute pancreatitis (Zhao et al. Gastroenterology 154(6):1822-1835, 2018), acne (Fischer et al. Front Immunol 11: 571334, 2020) and sepsis (Hu et al., EBioMedicme 41: 497-508, 2019).
[0319] In the last five years, several studies have shown that the release of chromatin fragments into the cytosol can activate the cGAS–STING pathway and induce senescence (Yang et al., PNAS Sci USA 114(23) E4612-E4620, 2017; Gluck et al., NatCellBiol 19(9) 1061-1070, 2017). Senescent cells possess a unique secretory phenotype (senescence-associated secretory phenotype), defined as changes in the expression of pro-inflammatory cytokines, chemokines, extracellular matrix components, and matrix metalloproteinases (MMPs). The senescence-associated secretory phenotype is thought to contribute to many age-related chronic diseases, including atherosclerosis and cardiovascular disease, arthritis, type 2 diabetes, neurodegenerative diseases, and others. Inhibition of cGAS can reduce chronic inflammation and provide benefits in many indications relevant to older patient populations.
[0320] Infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the cause of COVID-19 disease. SARS-CoV-2 interaction with host cells has been reported to activate the cGAS-STING pathway via a non-canonical pathway (Neufeldt et al. 2022, Commun Biol 5(1) 45, 2022; Di Domizio et al. Nature 603(7899) 145-151, 2022). SARS-CoV-2 fusion with host cells leads to the binding and activation of cGAS-binding cytosolic micronuclei to induce an interferon response (Liu et al. Sci Signal 5(729) eabg8744, 2022). While activation of the cGAS-STING pathway during SARS-CoV-2 infection produces cytokines that suppress viral replication, overactivation can lead to an uncontrolled immune response, resulting in COVID-19 immunopathology (Di Domizio et al. Nature 603(7899) 145-151, 2022). Pharmacological inhibition of the cGAS-STING pathway is expected to modulate the post-infection immune response and thus potentially alleviate immunopathology associated with disease symptoms. SARS-CoV-2-infected mice administered a STING antagonist two days post-infection showed reduced pathology in their lungs and decreased levels of type I IFN and other cytokines (Di Domizio et al., Nature 603(7899) 145-151, 2022). Activation of the cGAS-STING pathway is also associated with a variety of other viral and bacterial pathogens.
[0321] Multiple laboratories have investigated the role of the cGAS-STING pathway in cancer. Many cancer cells exhibit genomic instability, which leads to micronucleus formation and cGAS activation. Induced cGAS-STING signaling can result in anti-tumor or pro-tumorigenic processes, depending on the specific context. On the one hand, for more effective tumor surveillance, cytokines (e.g., type I IFN) produced by the activated cGAS-STING pathway enhance natural killer (NK) cell responses and initiate CD8+ T cell activation (Marcus et al., Immunity 9(4) 754-763, 2018; Woo et al., Immunity 41(5) 830-842, 2014). On the other hand, activation of the cGAS-STING pathway is associated with metastasis and immune evasion. It has been proposed that tumor cells with high genomic instability (a hallmark of metastatic tumors) utilize the cGAS-STING pathway to promote cell invasion (Bakhoum et al., Nature 553(7689) 467–472, 2018). Furthermore, cGAS and STING shape the immunosuppressive tumor microenvironment by recruiting regulatory T cells and myeloid suppressor cells and upregulating immune checkpoint inhibitors (such as programmed death-ligand 1 (PD-L1)) (Ding et al., Biochim Biophys Acta 1852(11) 2494–2503, 2015; Liang et al., NatCommun 8(1) 1736, 2017; Nakamura et al., J Immunother Cancer 9(7) e002852, 2021).
[0322] In one embodiment, the present invention relates to compounds, compositions containing the same, and their use in treating various disorders, particularly autoimmune diseases, autoinflammatory diseases, or immune-mediated diseases, such as systemic lupus erythematosus (SLE), cutaneous lupus erythematosus (CLE), lupus nephritis, Sjögren's syndrome, dermatomyositis, scleroderma, amyotrophic lateral sclerosis (ALS), Parkinson's disease (PD) and Alzheimer's disease (AD), acute kidney injury, chronic kidney disease, diabetic nephropathy or injury, APOL1 nephropathy, focal segmental glomerulosclerosis, membranous nephropathy, idiopathic pulmonary fibrosis, interstitial lung disease, myocardial infarction, stroke, cardiac hypertrophy / heart failure, nonalcoholic steatohepatitis (NASH) and nonalcoholic fatty liver disease (NAFLD), particularly systemic lupus erythematosus, cutaneous lupus erythematosus, and lupus nephritis.
[0323] In one embodiment, the present invention relates to compounds, compositions containing the same, and their use in treating various disorders, particularly autoimmune diseases, autoinflammatory diseases, or immune-mediated diseases, such as systemic lupus erythematosus (SLE), cutaneous lupus erythematosus (CLE), lupus nephritis, Sjögren's syndrome, dermatomyositis, scleroderma, amyotrophic lateral sclerosis (ALS), Parkinson's disease (PD) and Alzheimer's disease (AD), acute kidney injury, chronic kidney disease, diabetic kidney injury, myocardial infarction, stroke, cardiac hypertrophy / heart failure, non-alcoholic steatohepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD), especially systemic lupus erythematosus.
[0324] In one aspect of the invention, a method is provided for treating an autoimmune disease, an autoinflammatory disease, or an immune-mediated disease in a person in need, comprising administering to the person a therapeutically effective amount of a compound of formula (I) or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or a tautomer thereof.
[0325] In a further aspect, a compound of formula (I) or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or a tautomer thereof, is provided for use in therapy.
[0326] In a further aspect, a compound of formula (I) or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or a tautomer thereof, is provided for the treatment of autoimmune diseases, autoinflammatory diseases, or immune-mediated diseases.
[0327] In a further aspect, the use of a compound of formula (I) or a tautomer thereof, or a pharmaceutically acceptable salt thereof, in the preparation of a medicament for treating autoimmune diseases, autoinflammatory diseases, or immune-mediated diseases is provided.
[0328] In one embodiment, the autoimmune disease, autoinflammatory disease, or immune-mediated disease is selected from systemic lupus erythematosus (SLE), cutaneous lupus erythematosus (CLE), lupus nephritis, Sjögren's syndrome, dermatomyositis, and scleroderma, particularly systemic lupus erythematosus.
[0329] In one embodiment, the autoimmune disease, autoinflammatory disease, or immune-mediated disease is systemic lupus erythematosus (SLE). In one embodiment, the systemic lupus erythematosus is characterized as moderate to severe.
[0330] In one implementation, the autoimmune disease, autoinflammatory disease, or immune-mediated disease is lupus nephritis.
[0331] In one embodiment, the autoimmune disease, autoinflammatory disease, or immune-mediated disease is selected from amyotrophic lateral sclerosis (ALS), Parkinson's disease (PD) and Alzheimer's disease (AD), acute kidney injury, chronic kidney disease, diabetic kidney injury, myocardial infarction, stroke, cardiac hypertrophy / heart failure, non-alcoholic steatohepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD).
[0332] In one embodiment, a method for treating systemic lupus erythematosus in a person in need is provided, comprising administering to the person a therapeutically effective amount of a compound of formula (I) or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or a tautomer thereof.
[0333] In one embodiment, a compound of formula (I) or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or a tautomer thereof, is provided for the treatment of systemic lupus erythematosus.
[0334] In one implementation, the systemic lupus erythematosus is characterized as moderate to severe.
[0335] Therefore, in one embodiment, a compound of formula (I) or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or a tautomer thereof, is provided for the treatment of moderate to severe systemic lupus erythematosus.
[0336] In one embodiment, the systemic lupus erythematosus is characterized as active systemic lupus erythematosus.
[0337] In one embodiment, the systemic lupus erythematosus is active, moderate to severe systemic lupus erythematosus.
[0338] In one embodiment, a compound of formula (I) or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or a tautomer thereof, is provided for the treatment of lupus nephritis.
[0339] In one embodiment, a compound of formula (I) or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or a tautomer thereof, is provided for the treatment of lupus nephritis identified by biopsy.
[0340] In one embodiment, a compound of formula (I) or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or its tautomer, is provided for the treatment of cutaneous lupus erythematosus. In one embodiment, said cutaneous lupus erythematosus is subacute or chronic.
[0341] In a further embodiment, the use of a compound of formula (I) or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or a tautomer thereof, in the preparation of a medicament for the treatment of systemic lupus erythematosus is provided.
[0342] In a further embodiment, the use of a compound of formula (I) or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or a tautomer thereof, in the preparation of a medicament for the treatment of lupus nephritis is provided.
[0343] In a further embodiment, the use of a compound of formula (I) or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or a tautomer thereof, in the preparation of a medicament for treating cutaneous lupus erythematosus is provided.
[0344] In one embodiment, a compound having the following structure or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or a tautomer thereof, is provided. , , , ,or .
[0345] It is used to treat systemic lupus erythematosus.
[0346] In one embodiment, a compound having the following structure or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or a tautomer thereof, is provided. , , , ,or .
[0347] It is used to treat lupus nephritis.
[0348] In one embodiment, a compound having the following structure or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or a tautomer thereof, is provided. , , , ,or .
[0349] It is used to treat cutaneous lupus erythematosus.
[0350] Drug composition / route of administration / dosage
[0351] Although the compounds of the present invention can be administered as original chemicals for therapeutic purposes, the active ingredients are typically presented as pharmaceutical compositions.
[0352] In a further aspect, the present invention provides a pharmaceutical composition comprising (a) a compound of formula (I) or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or a tautomer thereof; and (b) a pharmaceutically acceptable excipient. The excipient must be acceptable in the sense of compatibility with the other components of the composition and not harmful to the recipient.
[0353] Pharmaceutical compositions are suitable for administration via any suitable route, such as oral (including buccal or sublingual), rectal, inhalation, intranasal, topical (including buccal, sublingual, or transdermal), ocular (including topical, intraocular, subconjunctival, suprascleral, and sub-Tenon), and parenteral (including subcutaneous, intramuscular, intravenous, or intradermal). Such compositions can be prepared by any method known in the pharmaceutical field, such as by combining the active ingredient with one or more excipients.
[0354] In one embodiment, the pharmaceutical composition is presented for oral administration, such as as a tablet or capsule. Other suitable compositions for oral administration may be powders or granules; solutions or suspensions in aqueous or non-aqueous liquids; edible foams or whisks; or oil-in-water or water-in-oil liquid emulsions.
[0355] Compounds of formula (I) or their tautomers, or pharmaceutically acceptable salts of said compounds or their tautomers, may be used alone or in combination with other therapeutic agents. Therefore, the combination therapy according to the invention comprises administering at least one compound of formula (I) or its pharmaceutically acceptable salt or tautomer, and using at least one other therapeutically active agent. Compounds of formula (I) or their pharmaceutically acceptable salts or tautomers, and other therapeutically active agents may be formulated and administered together in a single pharmaceutical composition, or may be formulated and administered separately. When formulated and administered separately, administration may be performed simultaneously or sequentially in any order.
[0356] The compound of formula (I) or its tautomer, or a pharmaceutically acceptable salt thereof, may be used in combination with one or more other therapeutic agents that may be used to treat autoimmune diseases, autoinflammatory diseases, or immune-mediated diseases.
[0357] Therefore, in a further aspect of the invention, the following combination is provided: (i) a compound of formula (I) or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or a tautomer thereof; and (ii) an immunomodulator.
[0358] In one implementation, the immunomodulator is belimumab, also known as BENLYSTA.
[0359] In one embodiment, the present invention provides a pharmaceutical combination comprising a compound of formula (I) or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or a tautomer thereof, and an immunomodulator.
[0360] In one embodiment, the present invention provides a combination therapy of a compound of formula (I) or a tautomer thereof, or a pharmaceutically acceptable salt thereof, together with an immunomodulator for the treatment of autoimmune diseases, autoinflammatory diseases, or immune-mediated diseases, particularly systemic lupus erythematosus.
[0361] In one embodiment, the present invention provides a method for treating autoimmune diseases, autoinflammatory diseases, or immune-mediated diseases, comprising administering a compound of formula (I) or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or tautomer thereof, together with an immunomodulator.
[0362] In one embodiment, the compound of formula (I) or its tautomer, or a pharmaceutically acceptable salt of said compound or its tautomer, may be used in combination with one or more other therapeutic agents (e.g., antimalarial drugs, steroids, and immunosuppressants) used for standard care in the treatment of systemic lupus erythematosus.
[0363] In one implementation, a compound of formula (I) or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or a tautomer thereof, may be used to treat SLE patients who do not respond to standard care.
[0364] In one embodiment, a compound of formula (I) or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or a tautomer thereof, may be used to treat a patient with SLE who is receiving standard care and is unresponsive to at least one immunosuppressant.
[0365] In one embodiment, the compound of formula (I) or its tautomer, or a pharmaceutically acceptable salt of said compound or its tautomer, may be used to treat patients with active, moderate to severe SLE who are receiving standard care and are unresponsive to at least one immunosuppressant.
[0366] In one implementation, a compound of formula (I) or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or a tautomer thereof, may be used to treat a patient with SLE that cannot be controlled by standard care alone.
[0367] Example
[0368] General Synthetic Methods
[0369] The compounds of the present invention can be prepared using the synthetic procedures shown in the reaction schemes below and the knowledge of a skilled organic chemist. The syntheses provided in these schemes are suitable for producing compounds of the present invention having various substituents using appropriate precursors (which may be appropriately protected if desired), to achieve compatibility with the reactions outlined herein. Deprotection is then performed, if desired, to obtain compounds having the generally disclosed properties. Suitable protecting groups and methods for protecting and deprotecting different substituents using such suitable protecting groups are well known to those skilled in the art; examples can be found in "Greene's Protective Groups in Organic Synthesis" (Peter GMNuts, 5th edition, J. Wiley and Sons, 2014). Intermediates (compounds used to prepare the compounds of the present invention) may also be present as salts.
[0370] General Method 1
[0371] A suitably protected haloketone triazole compound (A) and a cyclo-2-amine (B) are mixed in a suitable solvent such as EtOH and heated to provide the resulting fused imidazocyclic system (C). The imidazocyclic ring is halogenated with a suitable reagent such as N-bromosuccinimide to give (D), where W is a halogen. Catalyst-mediated coupling of (D) with a suitable reagent such as a borate ester (E) yields a substituted imidazo compound (F), where -GZ is R protected by a suitable protecting group. 3 By any suitable method, such as acid hydrolysis, the triazole protecting group (Y) and any other potential protecting groups are removed to obtain the substituted fused imidazole ring system of the desired formula (IAA).
[0372]
[0373] General Method 2 (Imidazopyridine Core)
[0374] A suitably protected haloketone triazole compound (A) and pyridine-2-amine (B) are mixed in a suitable solvent such as EtOH and heated to give imidazopyridine (C). The imidazopyridine is halogenated with a suitable reagent such as N-bromosuccinimide to give (D), where W is a halogen. Catalyst-mediated coupling of (D) with a suitable reagent such as a borate ester (E) yields a substituted imidazopyridine (F), where -GZ is R protected by a suitable protecting group. 3 The triazole protecting group (Y) and any other potential protecting groups are removed by any suitable method, such as acid hydrolysis, to obtain the 1H-triazole of the desired formula (IFF).
[0375]
[0376] General Method 3 (Alternative Route for Imidazopyridine Core)
[0377] General Method 3 employs a late-stage triazole formation synthetic strategy. This synthetic sequence is suitable for forming triazoles on a core other than imidazopyridine. Imidazopyridine (W) is formed via a reaction of U and V. Amide formation and subsequent halogenation of imidazopyridine with a suitable reagent such as N-bromosuccinimide yield AA. Catalyst-mediated coupling of the AA with a suitable reagent such as borate ester E yields substituted imidazopyridine BB. Two-step triazole formation, via reaction with R... 2 The reagent (CC) condenses to form amidine, which is then condensed with hydrazine and cyclized to form a triazole (DD). Removal of the protecting group Z can be achieved in this step or by a separate deprotection step to give the 1H-triazole compound of formula (IFF).
[0378]
[0379] General Method for Preparation of Prodrugs (Exemplified on Imidazopyridine Core)
[0380] Triazole (IFF) prepared by one of the general methods described above can be reacted with appropriate reagents to obtain a prodrug of formula (I) (PM = prodrug portion), which may contain other protecting groups. If a protecting group is present, the synthesis is completed by removing the protecting group in step 6 by appropriate methods. The prodrug portion may also be added in the early stages of the synthesis.
[0381]
[0382] Unless otherwise stated, the starting materials used to prepare intermediates and examples are available from, for example, PharmaTech and Sigma Aldrich.
[0383] Unless otherwise stated, the LCMS analysis run time is 2 minutes.
[0384] Quality-oriented automated preparative HPLC (MDAP)
[0385] The compounds of this invention were prepared using mass-oriented automated preparative HPLC under the following conditions. UV detection was performed using the average signal at wavelengths from 210 nm to 350 nm, and mass spectrometry was recorded on the mass spectrometer using alternating positive and negative mode electrospray ionization.
[0386] MDAP Method A
[0387] Method A, at an ambient temperature of Xselect CSH C 18 The procedure is performed on a column (typically 150 mm x 30 mm, id 5 μm packing diameter). The solvent used is: A = 0.1% v / v trifluoroacetic acid solution in water B = 0.1% v / v trifluoroacetic acid in acetonitrile.
[0388] The gradient used is:
[0389] MDAP Method B
[0390] Method B, at an ambient temperature of Xselect CSH C 18 The procedure is performed on a column (typically 150 mm x 30 mm, id 5 μm packing diameter). The solvent used is: A = 0.1% v / v formic acid in water solution B = 0.1% v / v formic acid in acetonitrile.
[0391] The gradient used is:
[0392] MDAP Method C
[0393] Method C, at an ambient temperature of Xselect CSH C 18 The procedure is performed on a column (typically 150 mm x 30 mm, id 5 μm packing diameter). The solvent used is: A = 0.1% v / v formic acid in water solution B = 0.1% v / v formic acid in acetonitrile solution.
[0394] The gradient used is:
[0395] MDAP Method D
[0396] Method D at ambient temperature Xselect CSH C 18 The procedure is performed on a column (typically 150 mm x 30 mm, id 5 μm packing diameter). The solvent used is: A = 0.1% v / v formic acid in water solution B = 0.1% v / v formic acid in acetonitrile solution.
[0397] The gradient used is:
[0398] MDAP Method E
[0399] Method E at ambient temperature Xselect CSH C 18The procedure is performed on a column (typically 150 mm x 30 mm, id 5 μm packing diameter). The solvent used is: A = 0.1% v / v trifluoroacetic acid solution in water B = 0.1% v / v trifluoroacetic acid in acetonitrile solution.
[0400] The gradient used is:
[0401] MDAP method F
[0402] Method F is used in ambient temperatures at Xselect CSH C 18 The procedure is performed on a column (typically 150 mm x 30 mm, id 5 μm packing diameter). The solvent used is: A = 0.1% v / v formic acid in water solution B = 0.1% v / v formic acid in acetonitrile solution.
[0403] The gradient used is:
[0404] MDAP method G
[0405] Method G at ambient temperature Xselect CSH C 18 The procedure is performed on a column (typically 150 mm x 30 mm, id 5 μm packing diameter). The solvent used is: A = 0.1% v / v formic acid in water solution B = 0.1% v / v formic acid in acetonitrile solution.
[0406] The gradient used is:
[0407] MDAP method H
[0408] Method H at ambient temperature Xselect CSH C 18 The procedure is performed on a column (typically 150 mm x 30 mm, id 5 μm packing diameter). The solvent used is: A = 0.1% v / v trifluoroacetic acid solution in water B = 0.1% v / v trifluoroacetic acid in acetonitrile solution.
[0409] The gradient used is:
[0410] MDAP method I
[0411] Method I, at an ambient temperature of Xselect CSH C 18 The procedure is performed on a column (typically 150 mm x 30 mm, id 5 μm packing diameter). The solvent used is: A = 10 mM ammonium bicarbonate aqueous solution, adjusted to pH 10 with ammonia. B = Acetonitrile.
[0412] The gradient used is:
[0413] MDAP method J
[0414] Method J operates at ambient temperature Xselect CSH C 18 The procedure is performed on a column (typically 150 mm x 30 mm, id 5 μm packing diameter). The solvent used is: A = 0.1% v / v trifluoroacetic acid solution in water B = 0.1% v / v trifluoroacetic acid in acetonitrile solution.
[0415] The gradient used is:
[0416] MDAP method K
[0417] Method K at ambient temperature Xselect CSH C 18 The procedure is performed on a column (typically 150 mm x 30 mm, id 5 μm packing diameter). The solvent used is: A = 10 mM ammonium bicarbonate aqueous solution, adjusted to pH 10 with ammonia. B = Acetonitrile.
[0418] The gradient used is:
[0419] Intermediate 1
[0420] 1-(3-bromo-1-(4-methoxybenzyl)-1H-1,2,4-triazol-5-yl)-2-chloroethyl ketone
[0421] Step 1: 3,5-Dibromo-1-(4-methoxybenzyl)-1H-1,2,4-triazole
[0422] To a solution of 200 g (882 mmol) of 3,5-dibromo-1H-1,2,4-triazole in AcCN (300 mL), DIEA (308 mL, 176 mmol), 1-(chloromethyl)-4-methoxybenzene (143 mL, 1058 mmol), and KI (14.63 g, 88 mmol) were added at room temperature. After 16 hours, the reaction mixture was diluted with water (200 mL) and extracted with EtOAc (2 x 500 mL). The combined organic layers were washed with water (500 mL) and brine (500 mL), dried over Na2SO4, and concentrated. The residue was dissolved in DCM (250 mL) and adsorbed onto silica (100 g), then purified by column chromatography (100-200 mesh silica gel [1 kg]), eluting with 5-10% EtOAc in hexane to give the title compound (190 g, 531 mmol, 60% yield) as a grayish-white solid. LCMS: t RET = 1.46 minutes, [M+H] + = 347.92
[0423] Step 2: 1-(3-bromo-1-(4-methoxybenzyl)-1H-1,2,4-triazol-5-yl)-2-chloroethyl ketone
[0424] A solution of 3,5-dibromo-1-(4-methoxybenzyl)-1H-1,2,4-triazole (100 g, 280 mmol) in THF (800 mL) was added at -40 °C with 559 mL of 1 M lithium isopropyl magnesium chloride in THF (559 mmol). After 2 hours, 2-chloro- N -Methoxy- N A solution of methylacetamide (42.3 g, 307 mmol) in THF (200 mL) was prepared. After 1 hour, the reaction was quenched with saturated aq NH4Cl (500 mL) and extracted with EtOAc (2 x 1 L). The combined organic extracts were washed with brine (500 mL), dried over Na2SO4, and concentrated. The residue was adsorbed onto silica (100 g) and purified by column chromatography (100-200 mesh silica gel [400 g]), eluted with a 10-20% hexane solution of EtOAc to give the title compound (23.45 g, 66.5 mmol, 24% yield) as a grayish-white solid. 1H NMR (400 MHz, CDCl3) d ppm7.33 - 7.41 (m, 2 H), 6.83 - 6.90 (m, 2 H), 5.66 (s, 2 H), 4.87 (s, 2 H), 3.78 (s, 3H). LCMS:t RET = 2.46 minutes, [M+H] + = 345.92
[0425] Intermediate 2
[0426] N , N -Dimethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborhecyclopentan-2-yl)-1H-imidazol-1-sulfonamide
[0427] A mixture of (1,5-cyclooctadiene)(methoxy)iridium(I) dimer (3.0 g, 4.53 mmol) and bis(pinacol)diboron (44.0 g, 173 mmol) in THF (150 mL) was stirred at 45 °C for 20 minutes, and then treated with a solution of 4,4'-di-tert-butyl-2,2'-bipyridine (1.50 g, 5.59 mmol) in THF (50 mL). After 20 minutes, [the mixture was then added...] N , N A solution of 1-dimethyl-1H-imidazolium-1-sulfonamide (20.0 g, 114 mmol) in THF (80 mL) was prepared and the temperature was raised to 65 °C. After 2 hours, the reaction was concentrated and the resulting residue was ground with pentane to give the title compound (32.2 g, 102 mmol, 89% yield) as a brown solid. 1 H NMR (400 MHz, CDCl3) d ppm 8.02 (d, J = 1.01 Hz, 1H), 7.73 (d, J = 1.01 Hz, 1 H), 2.89 (s, 6 H), 1.39 (s, 12 H). LCMS:t RET = 0.26 minutes, [M+H] + = 220.1 (boric acid)
[0428] Intermediate 3
[0429] 2-Chloro-1-(1-(4-methoxybenzyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)ethyl ketone
[0430] Step 1: 3-(trifluoromethyl)-1H-1,2,4-triazol-5-amine
[0431] The mixture was split and dispensed into two containers: hydrazine carbonate (150 g, 1.102 mol) and 2,2,2-trifluoroacetic acid (110 mL, 1.102 mol). The mixture was stirred at room temperature for 30 min. A Dean Stark condenser was attached to both containers, toluene (1.20 L) was added, and the reaction was heated at 115 °C overnight. The mixture was combined and concentrated, water (1.2 L) was added, and the mixture was extracted with EtOAc (2 x 700 mL). The organic extracts were combined, washed with saturated aq NaHCO3 solution (500 mL), and concentrated to give the title compound (116 g, 763 mmol, 77% yield) as a white solid. 1 H NMR (400 MHz, DMSO- d 6 ) d ppm 12.72 (s, 1 H), 6.47 (s, 2 H). LCMS:t RET = 1.082 minutes, [M+H] + = 152.9
[0432] Step 2: 5-Bromo-3-(trifluoromethyl)-1H-1,2,4-triazole
[0433] 3-(trifluoromethyl)-1H-1,2,4-triazol-5-amine (116 g, 763 mmol) was slowly added to a solution of tert-butyl nitrite (118 g, 1.14 mol) and copper(II) bromide (511 g, 2.29 mol) in AcCN (1.40 L). The reaction mixture was stirred at 60 °C for 3 h, treated with water (2 L), and extracted with EtOAc (2 x 1.5 L). The combined organic extracts were washed with brine (1.5 L), dried over Na2SO4, and concentrated. The residue was purified by column chromatography over silica (2 kg) and eluted with 3:1 petroleum ether:EtOAc to give the title compound (119 g, 551 mmol, 72% yield) as a yellow oil. 1 H NMR (400 MHz, DMSO- d 6 ) d ppm 15.86 (s, 1 H). LCMS:t RET= 1.437 minutes, [M+H] + = 215.7, 217.8
[0434] Step 3: 5-Bromo-1-(4-methoxybenzyl)-3-(trifluoromethyl)-1H-1,2,4-triazole
[0435] A mixture of 5-bromo-3-(trifluoromethyl)-1H-1,2,4-triazole (119 g, 551 mmol), 1-(chloromethyl)-4-methoxybenzene (104 g, 661 mmol), and K₂CO₃ (152 g, 1.10 mol) in DMF (800 mL) was stirred overnight at room temperature. The reaction mixture was diluted with water (1 L) and extracted with EtOAc (3 x 700 mL). The combined organic layers were washed with brine (700 mL), dried over Na₂SO₄, and concentrated. The residue was purified by column chromatography on silica gel (1 kg) and eluted with 15:1 petroleum ether:EtOAc to give the title compound (82 g, 244 mmol, 44% yield) as a yellow oil. 1 H NMR (400 MHz, DMSO- d 6 ) d ppm 7.28 (d, J = 8.3 Hz, 2 H), 6.96 (d, J = 8.4 Hz, 2 H), 5.46 (s, 2 H), 3.75 (s, 3 H).
[0436] Step 4: 2-Chloro-1-(1-(4-methoxybenzyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)acetone (Intermediate 3)
[0437] Add 2.4 M to a solution of 5-bromo-1-(4-methoxybenzyl)-3-(trifluoromethyl)-1H-1,2,4-triazole (40 g, 119 mmol) in THF (500 mL) at -78 °C. n -BuLi (54.5 mL, 131 mmol). After 1 hour, 2-chloro- N -Methoxy- NA solution of methylacetamide (19.7 g, 143 mmol) in THF (60 mL) was prepared, and the reaction was heated to 0 °C. After 1 hour, the reaction was treated with 6N HCl and extracted with EtOAc (2 x 500 mL). The combined organic extracts were dried over Na2SO4 and concentrated. The residue was purified by column chromatography on silica gel (150 g) and eluted with 5:1 petroleum ether:EtOAc to give the title compound (19 g, 57 mmol, 48% yield) as a white solid. 1 H NMR (400 MHz, DMSO- d 6 ) dppm 7.33 (d, J = 8.5 Hz, 2 H), 6.94 (d, J = 8.6 Hz, 2 H), 5.74 (s, 2 H), 5.19 (s, 2H), 3.74 (s, 3 H).
[0438] Intermediate 3, alternative preparation
[0439] 2-Chloro-1-(1-(4-methoxybenzyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)ethyl-1-one
[0440] Step 1: 1-(4-methoxybenzyl)-3-(trifluoromethyl)-1H-1,2,4-triazole
[0441] A 25 wt% methanol solution of sodium methoxide (60.0 g, 278 mmol) was added to a stirred mixture of (4-methoxybenzyl)hydrazine hydrochloride (50.0 g, 265 mmol) in methanol (500 mL). After stirring the white suspension for 15 minutes, methyl 2,2,2-trifluoroacetate (36.0 g, 281 mmol) was added dropwise over 30 minutes. The reaction was then stirred for another 2 hours. (LCMS showed a new peak at 92% (UV) at t...) RET 0.75 minutes. A weaker M+Na was observed in acylated PMB hydrazine. + Peak 271.2. PMB hydrazine SM t RET 0.33 minutes. MS(ES) [M+H] + 121.0.). The reaction was treated with formamidine acetate (30.0 g, 288 mmol), heated to reflux at 85 °C, and stirred for 24 hours. (LCMS showed a new peak at 47% (UV) at t RET 0.95 minutes, with weak MS(ES) [M+H] +258.2). The reaction mixture was evaporated to dryness, dissolved in EtOAc, washed with aq. NaHCO3, dried (Na2SO4), filtered, and evaporated to dryness. Purification was performed by silica gel chromatography (Isco RediSep Rf Gold 330 g, 0% for 4 min, increased to 30% over 2 min, then to 70% over 15 min, EtOAc solution in heptane). The purified fraction was fractionated and evaporated to dryness to give product 1-(4-methoxybenzyl)-3-(trifluoromethyl)-1H-1,2,4-triazole (45.4 g), a yellow oil that solidified under vacuum to form a yellow solid. This substance was used directly in the next reaction without further purification. The reaction was repeated 5 times, yielding a total of 260.5 g of product. 1 H NMR (400 MHz, CDCl3) d 8.06 (s, 1H), 7.35-7.30 (m, 2H), 6.97 (d, J =8.9 Hz, 2H), 5.36 (s, 2H), 3.87 (s, 3H). LCMS m / z 258.2 [M+H] +
[0442] Step 2: The following reaction was performed twice on a half-scale, and then combined after purification.
[0443] 1.0 N (400 mL, 400 mmol) of a 2,2,6,6-tetramethylpiperidinyl magnesium chloride-lithium chloride complex was added dropwise under nitrogen at -10 °C (ice, NaCl) to a stirred solution of 1-(4-methoxybenzyl)-3-(trifluoromethyl)-1H-1,2,4-triazole (64.0 g, 249 mmol) in tetrahydrofuran (THF) (400 mL). The reaction was stirred for 30 min and then treated with a solution of 2-chloro-N-methoxy-N-methylacetamide (58.0 g, 422 mmol) in tetrahydrofuran (THF) (140 mL). The reaction was stirred for 1 hr and then carefully quenched with 1 N aq. HCl (500 mL) (pH ~4). The reaction was extracted with EtOAc (300 mL), washed with brine, dried (Na2SO4), filtered, and concentrated under vacuum. Purified by silica gel chromatography (Isco RediSep Rf Gold 330 g, 25 to 60% CH2Cl2 solution in heptane; solid loaded with 30 g IsoluteHM-N). The pure fraction was separated and evaporated to dryness to give the product 2-chloro-1-(1-(4-methoxybenzyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)ethyl-1-one (53.21 g, 159 mmol, 64.1% yield), a white solid. 1 H NMR (400 MHz, CDCl3) d 7.44 (d, J =8.9 Hz, 2H), 6.91 (d, J =8.6 Hz, 2H), 5.78 (s, 2H), 4.97 (s, 2H), 3.83 (s, 3H).
[0444] Intermediate 4
[0445] 2-Chloro-1-(3-(difluoromethyl)-1-(4-methoxybenzyl)-1H-1,2,4-triazol-5-yl)ethyl-1-one
[0446] Step 1: 3,5-Dibromo-1-(4-methoxybenzyl)-1H-1,2,4-triazole
[0447] 1-(chloromethyl)-4-methoxybenzene (13.75 mL, 101 mmol) was added to a solution of 3,5-dibromo-1H-1,2,4-triazole (20 g, 88 mmol) and K₂CO₃ (24.37 g, 176 mmol) in AcCN (267 mL). The reaction was heated to 65 °C and maintained for 14 h, then filtered and concentrated. The residue was dissolved in EtOAc, washed with water and brine, dried over sodium sulfate, and concentrated. The residue was purified by column chromatography on silica gel (330 g column) by elution with 0–15% EtOAc in petroleum ether to give the title compound (19.5 g, 52.7 mmol, 60% yield) as a white solid. LCMS: t RET = 1.107 minutes, [M+H] + = 347.95.
[0448] Step 2: 5-Bromo-1-(4-methoxybenzyl)-1H-1,2,4-triazole-3-carboxaldehyde
[0449] A 1.3 M isopropyl magnesium chloride-lithium chloride complex (12.2 mL, 15.9 mmol) was added dropwise to a solution of 3,5-dibromo-1-(4-methoxybenzyl)-1H-1,2,4-triazole (5 g, 14.4 mmol) in THF (40 mL) at -10 °C. After 30 minutes, DMF (2.01 mL, 25.9 mmol) was added dropwise, and the reaction was warmed to room temperature. After 1 hour, the reaction was cooled to 0 °C, quenched with NH4Cl solution (60 mL), and extracted with EtOAc (3 x 30 mL). The combined organic extracts were washed with brine (60 mL), dried over sodium sulfate, and concentrated to give the title compound (4.1 g, 13.9 mmol, 96% yield) as a pale yellow oil. LCMS: t RET = 1.510 minutes, [M+H] + = 296.00.
[0450] Step 3: 5-Bromo-3-(difluoromethyl)-1-(4-methoxybenzyl)-1H-1,2,4-triazole
[0451] A solution of 5-bromo-1-(4-methoxybenzyl)-1H-1,2,4-triazol-3-carboxaldehyde (4.1 g, 13.9 mmol) in DCM (60 mL) was added dropwise at 0 °C with diethylaminosulfur trifluoride (3.66 mL, 27.7 mmol). The reaction was stirred for 10 min, then kept at room temperature for 10 min, and then heated to 50 °C. After 2 hours, the reaction was cooled to 0 °C, quenched with NaHCO3 solution to pH = 7–8, and extracted with EtOAc (3 × 40 mL). The combined organic layers were washed with brine (60 mL), dried over Na2SO4, and concentrated. The residue was purified by column chromatography on silica gel (80 g) and eluted with 3:1 petroleum ether:EtOAc to give the title compound (2.4 g, 588 mmol, 42% yield) as a pale yellow oil. 1 H NMR (400 MHz, DMSO- d 6 )d ppm 7.28 (d, J = 8.3 Hz, 2 H), 6.96 (d, J = 8.4 Hz, 2 H), 5.46 (s, 2 H), 3.75 (s, 3H). LCMS:t RET = 1.559 minutes, [M+H] + = 319.95.
[0452] Step 4: 2-Chloro-1-(3-(difluoromethyl)-1-(4-methoxybenzyl)-1H-1,2,4-triazol-5-yl)ethyl-1-one
[0453] To a solution of 5-bromo-3-(difluoromethyl)-1-(4-methoxybenzyl)-1H-1,2,4-triazole (50 mg, 0.157 mmol) in THF (2 mL), 1.3 M isopropyl magnesium chloride-lithium chloride complex (0.242 mL, 0.314 mmol) was added dropwise at -10 °C. After 30 minutes, 2-chloro- N -Methoxy- NA solution of methylacetamide (25.9 mg, 0.189 mmol) in THF (1 mL) was prepared. After more than 30 minutes, the reaction was warmed to room temperature. After 30 minutes, the reaction was cooled to 0 °C, quenched with NH4Cl solution (1 mL), filtered, and extracted with EtOAc (3 x 5 mL). The combined organic extracts were washed with brine (5 mL), dried over sodium sulfate, and concentrated to give the title compound (30 mg, 0.074 mmol, 47% yield) as a pale yellow oil. 1 H NMR (400 MHz, DMSO- d 6 ) d ppm 7.61 (t, J = 51.4 Hz), 7.30 (d, J = 8.4Hz, 2 H), 6.95 (d, J = 8.4 Hz, 2 H), 5.60 (s, 2 H), 5.10 (s, 2 H), 3.75 (s, 3 H). LCMS:t RET = 1.115 minutes, [M+H+H2O] + = 334.20.
[0454] Intermediate 4, alternative preparation
[0455] 2-Chloro-1-(3-(difluoromethyl)-1-(4-methoxybenzyl)-1H-1,2,4-triazol-5-yl)ethyl-1-one
[0456] Step 1
[0457] 2,2-Difluoroacetic anhydride (25 mL, 201 mmol) was added dropwise to a mixture of (4-methoxybenzyl)hydrazine hydrochloride (25 g, 133 mmol) and potassium carbonate (37.5 g, 271 mmol) in 2-methyltetrahydrofuran (2-MeTHF) (250 mL) over 30 minutes. The reaction was stirred for 30 min and then diluted with EtOAc (300 mL) and water (500 mL). The ethyl acetate phase was removed, washed with brine, dried (Na₂SO₄), filtered, and evaporated under vacuum. The residue was dissolved in ethanol (250 mL) and treated with formamidine acetate (20 g, 192 mmol) at 100 °C for 24 hr, followed by the addition of acetic acid (75 mL, 1310 mmol) after 4 hours. The reaction was cooled to room temperature and evaporated under vacuum. The residue was dissolved in EtOAc, washed with aq. NaHCO₃, dried (Na₂SO₄), filtered, and evaporated under vacuum. Purification by silica gel chromatography (Isco RediSep Rf Gold 220 g, 20 to 80% EtOAc solution in heptane) yielded 3-(difluoromethyl)-1-(4-methoxybenzyl)-1H-1,2,4-triazole (26 g, 75% yield), which was a pale yellow oil. 1 ¹H NMR (400 MHz, chloroform-d) δ 8.06 (s, ¹H), 7.28–7.31 (m, ²H), 6.93–6.99 (m, ²H), 6.75 (t, ¹H) J =53.7 Hz, 1H), 5.33 (s, 2H), 3.86 (s, 3H). LCMS m / z 240.2 [M+H] +
[0458] Step 2
[0459] A stirred solution of 3-(difluoromethyl)-1-(4-methoxybenzyl)-1H-1,2,4-triazole (25 g, 105 mmol) in tetrahydrofuran (200 mL) was added dropwise under nitrogen at -10 °C (ice, NaCl) to a solution of 2,2,6,6-tetramethylpiperidinyl magnesium chloride lithium chloride complex in THF / toluene (180 mL, 180 mmol). The reaction mixture was stirred for 30 min and then treated with a solution of 2-chloro-N-methoxy-N-methylacetamide (25 g, 182 mmol) in tetrahydrofuran (50 mL). The reaction was stirred for 1 hr and then carefully quenched with 1 N aq. HCl (450 mL) (pH ~4). The reaction was extracted with EtOAc (300 mL), washed (with brine), dried (with Na2SO4), filtered, and concentrated under vacuum. The crude substance was purified by silica gel chromatography (Isco RediSep Rf Gold 330 g, 10 to 50% EtOAc solution in heptane). The desired fractions were separated and concentrated under vacuum to give 2-chloro-1-(3-(difluoromethyl)-1-(4-methoxybenzyl)-1H-1,2,4-triazol-5-yl)ethyl-1-one (19.6 g, 59.4% yield), which was a white solid. 1 ¹H NMR (400 MHz, chloroform-d) δ 7.42 (d, J =8.87 Hz, 2H), 6.90 (d, J =8.87 Hz, 2H), 6.76 (t, J =53.3 Hz, 1H), 5.76 (s, 2H), 4.98 (s, 2H), 3.83 (s, 3H). LCMS m / z 316.0 [M+H] + (weak).
[0460] Example 1
[0461] 1-(3-(1H-imidazol-4-yl)-2-(3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)imidazo[1,2-a]pyridin-6-yl) ethyl-1-one, trifluoroacetate
[0462] Step 1
[0463] 2-Chloro-1-(1-(4-methoxybenzyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)ethyl-1-one (intermediate 3) (1.0 g, 3.00 mmol), 5-iodopyridin-2-amine (1.0 g, 4.55 mmol), and sodium bicarbonate (960 mg, 11.43 mmol) were stirred in acetonitrile (10 mL) at 100 °C for 16 h. The reaction was cooled to room temperature and diluted with DCM (50 mL). The slurry was filtered and the filtered solids were washed with DCM (50 mL) and EtOAc (50 mL). The filtrate was concentrated under vacuum. EtOAc (50 mL) was added to the residue. The slurry was mixed and filtered. The filtrate was concentrated under vacuum, dissolved in DMSO (15 mL), and subjected to rapid C24-. 18 Purification was performed using silica (105 g column) with a gradient of 50–100% ACN:H₂O (0.1% NH₄OH) for 8 min. 6-Iodo-2-(1-(4-methoxybenzyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)imidazo[1,2-a]pyridine (710 mg, 1.323 mmol, 44% yield) was isolated as a pale orange solid. 1 H NMR (400 MHz, DMSO- d 6 ) dppm 9.03 (t, J=1.22 Hz, 1H), 8.61 (s, 1H), 7.62 (dd, J=2.20, 1.22 Hz, 2H), 7.28 - 7.40 (m, 2H), 6.85 - 6.94 (m, 2H), 6.13 (s, 2H), 3.71 (s, 3H). LCMS m / z 500.0 [M+H] + , t ret = 1.31 minutes [TFA].
[0464] Step 2
[0465] 6-Iodo-2-(1-(4-methoxybenzyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)imidazo[1,2-a]pyridine (420 mg, 0.841 mmol) was stirred in toluene (10 mL), followed by the sequential addition of di(triphenylphosphine)palladium(II) chloride (60 mg, 0.085 mmol) and tributyl(1-ethoxyvinyl)stanane (500 µL, 1.480 mmol). The reaction was stirred at 100 °C for 24 h under nitrogen. The reaction was then cooled to room temperature. The container was placed in an ice bath, and 5 mL of 2M hydrochloric acid aqueous solution (850 mL concentrated hydrochloric acid diluted with 4.15 mL H2O) was added to the dark solution. The reaction was stirred for 72 h, allowing it to rise to room temperature during this period. The reaction mixture was filtered. 5 mL of 10% NH4F aqueous solution was added to the filtrate. The mixture was stirred at room temperature for 2 h, and then filtered. The filtrate was washed with saturated brine (1 × 10 mL), separated, dried over sodium sulfate, filtered, and concentrated under reduced pressure. The crude product was purified by flash silica gel (12 g column) using a 0–20% EtOAc:DCM gradient over 8 min. 1-(2-(1-(4-methoxybenzyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)imidazo[1,2-a]pyridin-6-yl)ethyl-1-one was isolated as a white solid (120 mg). 1 H NMR (400 MHz, DMSO- d 6 ) δ ppm 9.51 (s, 1H), 8.78 (s, 1H), 7.83 (d, J =0.98 Hz, 2H), 7.36 (m, J =8.80 Hz, 2H), 6.91 (m, J =8.80 Hz, 2H), 6.14 (s, 2H), 3.71 (s, 3H), 2.65 (s, 3H). LCMS m / z 416.1 [M+H] + , t ret = 1.15 minutes [TFA].
[0466] Step 3
[0467] 1-(2-(1-(4-methoxybenzyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)imidazo[1,2-a]pyridin-6-yl)ethyl-1-one (120 mg, 0.289 mmol) was stirred in DCM (5 mL), followed by the sequential addition of NBS (65 mg, 0.365 mmol) and TFA (5 µL, 0.065 mmol). The reaction mixture was stirred at room temperature under nitrogen for 1 h, followed by vacuum concentration. The crude product was purified by flash silica gel (12 g column) elution using a 0–10% EtOAc:DCM gradient over 7 min. 1-(3-bromo-2-(1-(4-methoxybenzyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)imidazo[1,2-a]pyridin-6-yl)ethyl-1-one was isolated as a white solid (100 mg). 1 H NMR (400 MHz, DMSO- d6 ) δ ppm 9.01 (t, J =1.40 Hz, 1H), 7.92 (t, J =1.22 Hz, 2H), 7.35 (d, J =8.80 Hz, 2H), 6.90 (d, J =8.80 Hz, 2H), 6.05 (s, 2H), 3.72 (s, 3H), 2.75 (s, 3H). LCMS m / z 496.0 [M+H] + , t ret = 1.25 minutes [TFA].
[0468] Step 4
[0469] Add 1-(3-bromo-2-(1-(4-methoxybenzyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)imidazo[1,2-a]pyridin-6-yl) ethyl-1-one (93 mg, 0.188 mmol), N,N-dimethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborhexacyclopentan-2-yl)-1H-imidazol-1-sulfonamide (intermediate 2) (75 mg, 0.249 mmol), PdCl2(dppf)-CH2Cl2 adduct (20 mg, 0.024 mmol), and tripotassium phosphate (160 mg, 0.754 mmol) to a round-bottom flask. Place the container under nitrogen atmosphere and add 1,4-dioxane (2 mL) and water (0.5 mL). Attach a condenser to the container and stir the reaction at 100 °C. Two hours later, the reaction mixture was cooled to room temperature and concentrated under reduced pressure. The crude product was purified by flash silica gel (4 g column) elution using a 0–10% EtOAc:DCM gradient over 8 minutes, and held at 10% EtOAc until all product was eluted from the column. 4-(6-acetyl-2-(1-(4-methoxybenzyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)imidazo[1,2-a]pyridin-3-yl)-N,N-dimethyl-1H-imidazol-1-sulfonamide was isolated as a white solid (40 mg). 1 H NMR (400 MHz, DMSO- d 6 ) δ ppm 9.96 (d, J=1.47 Hz, 1H), 8.59 (d, J=1.47 Hz, 1H), 8.46 (d, J=1.47 Hz, 1H), 8.14 - 8.21 (m, 2H), 7.39 (d, J=8.80 Hz, 2H), 6.91 (d, J=8.80 Hz, 2H), 5.96 (s, 2H), 3.72 (s, 3H), 2.88 (s, 6H), 2.66 (s, 3H). LCMS m / z 589.2 [M+H] + , t ret = 1.30 minutes [TFA].
[0470] Step 5
[0471] 4-(6-acetyl-2-(1-(4-methoxybenzyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)imidazo[1,2-a]pyridin-3-yl)-N,N-dimethyl-1H-imidazol-1-sulfonamide (36 mg, 0.061 mmol) was stirred in TFA (2.0 mL, 26.0 mmol) at 80 °C for 3 h, then cooled to room temperature and stirred overnight. The volatiles were removed under vacuum. The crude substance was dissolved in DMSO (1 mL) and purified by reversed-phase HPLC using a gradient of 5–35% ACN: H₂O (0.1% TFA). The TFA salt of the title compound (15 mg) was isolated as a white solid. 1 H NMR (400 MHz, DMSO- d 6 δ ppm 9.87 (br s, 1H) 8.70 (br s, 1H) 8.45 (d, J=0.98 Hz, 1H) 7.91 (dd, J=9.54, 1.71 Hz, 1H) 7.82 (d, J=9.34 Hz, 1H) 2.65 (s, 3H), 2H signal not observed. LCMS m / z 362.1 [M+H] + , t ret = 0.47 minutes [TFA].
[0472] Example 2
[0473] 5-(1H-imidazol-5-yl)-2-methyl-6-(3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)imidazo[2,1-b]oxazole, trifluoroacetate
[0474] Step 1
[0475] In five equivalent batches, suspensions of 2-chloro-1-(1-(4-methoxybenzyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)ethyl-1-one (intermediate 3) (66 mg, 0.198 mmol) and 5-methyloxazol-2-amine (38.8 mg, 0.396 mmol) in acetonitrile (20 mL) were heated in a microwave reactor at 80 °C for 2 min, followed by heating at 170 °C to 200 °C for a total of 30–45 min. The five independent reaction mixtures were combined with two smaller-scale reaction batches (prepared under similar reaction conditions, starting with 20 mg / 0.060 mmol and 9.4 mg / 0.028 mmol intermediate 3) and concentrated. The residue was purified by silica gel chromatography (ISCO RediSep Rf Gold 24 g SiO2 column, eluted with a solution of 5-100% EtOAc in heptane) to give 6-(1-(4-methoxybenzyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)-2-methylimidazo[2,1-b]oxazole (31 mg), a brown solid, which was used in the next step without further purification. 1 H NMR (400 MHz, CDCl3) δ ppm 7.72 (s, 1H), 7.48 - 7.42 (m, 2H), 7.12 - 7.08 (m, 1H), 6.90- 6.84 (m, 2H), 6.00 (s, 2H), 3.81 (s, 3H), 2.46 (d, J=1.5 Hz, 3H). LCMS m / z 378.1 [M+H] + , t ret = 1.18 minutes [TFA].
[0476] Step 2
[0477] To a solution of 2.5 mL of acetonitrile containing 26 mg (0.069 mmol) of trifluoroacetic acid and 16 mg (0.071 mmol) of N-iodosuccinimide, a solution of 0.1 mL of acetonitrile containing 0.266 µL (0.00345 mmol) of trifluoroacetic acid was added. The reaction mixture was stirred at room temperature for 1 hour. This reaction mixture was then combined with a separate reaction batch prepared under similar reaction conditions (starting from 4.3 mg / 0.011 mmol of 6-(1-(4-methoxybenzyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)-2-methylimidazo[2,1-b]oxazole). The combined reaction mixture was diluted with DCM and washed with a saturated aqueous solution of NaHCO3. The organic layer was washed with brine, dried over MgSO4, and concentrated. The residue was purified by silica gel chromatography (ISCO RediSep Rf Gold 12g SiO2 column, eluted with 5-100% EtOAc in heptane) to give 5-iodo-6-(1-(4-methoxybenzyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)-2-methylimidazo[2,1-b]oxazole (25 mg, 0.050 mmol, 62%) as a white solid. 1 H NMR (400 MHz, CDCl3) δ ppm 7.41 - 7.34 (m, 2H), 7.06 - 7.01 (m, 1H), 6.88 - 6.81 (m, 2H), 5.91 (s, 2H), 3.79 (s, 3H), 2.47 (d, J=1.5 Hz, 3H). LCMS m / z 504.3 [M+H] + , t ret = 1.28 minutes [TFA].
[0478] Step 3
[0479] To a suspension of 5-iodo-6-(1-(4-methoxybenzyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)-2-methylimidazo[2,1-b]oxazole (19.2 mg, 0.038 mmol), N,N-dimethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborhecyclopentan-2-yl)-1H-imidazo-1-sulfonamide (intermediate 2) (18 mg, 0.059 mmol), and PdCl2(dppf)-CH2Cl2 adduct (4.7 mg, 5.7 µmol) in DME (1 mL), 2.0 M aqueous solution of K3PO4 (0.048 mL, 0.095 mmol) was added (0.048 mL, 0.095 mmol). Nitrogen gas was bubbled into the reaction mixture. The reaction mixture was heated in a microwave reactor at 100 °C for 45 min. The reaction mixture was combined with a separate reaction batch prepared under similar reaction conditions (starting from 4.8 mg / 0.0095 mmol of 5-iodo-6-(1-(4-methoxybenzyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)-2-methylimidazo[2,1-b]oxazole). The combined reaction mixtures were diluted with DCM and washed with a saturated aqueous solution of NH4Cl. The aqueous layer was extracted with DCM. The combined organic layers were dried over MgSO4 and concentrated. The residue was purified by silica gel chromatography (ISCO RediSep Rf Gold 12g SiO2 column, eluted with 10-100% EtOAc in heptane) to give 4-(6-(1-(4-methoxybenzyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)-2-methylimidazo[2,1-b]oxazol-5-yl)-N,N-dimethyl-1H-imidazo-1-sulfonamide (19.6 mg, 0.036 mmol, 75%), which was a pink solid. 1 H NMR (400 MHz, CDCl3) δ ppm 8.86 (d, J=1.3 Hz, 1H), 7.97 (d, J=1.3 Hz, 1H), 7.91 - 7.88 (m, 1H), 7.47 - 7.40 (m, 2H), 6.88 - 6.82 (m, 2H), 6.06 (s, 2H), 3.79 (s, 3H), 2.97 (s, 6H), 2.47 (d, J=1.3 Hz, 3H). LCMS m / z 551.4 [M+H] + , t ret = 1.40 minutes [TFA].
[0480] Step 4
[0481] A solution of 4-(6-(1-(4-methoxybenzyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)-2-methylimidazo[2,1-b]oxazol-5-yl)-N,N-dimethyl-1H-imidazo-1-sulfonamide (18.8 mg, 34.1 µmol) in trifluoroacetic acid (TFA) (0.7 mL) was heated at 80 °C for 3 hours in a sealed flask. This reaction mixture was combined with the product of a smaller-scale reaction (starting from 0.6 mg / 0.001 mmol of 4-(6-(1-(4-methoxybenzyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)-2-methylimidazo[2,1-b]oxazol-5-yl)-N,N-dimethyl-1H-imidazo-1-sulfonamide). The combined reaction mixture was concentrated, and the residue was purified by reversed-phase HPLC (MDAP method E) to give 5-(1H-imidazol-5-yl)-2-methyl-6-(3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)imidazo[2,1-b]oxazole, trifluoroacetate (10.3 mg, 23.6 µmol, 67%). 1 H NMR (400 MHz, DMSO- d 6) δ ppm 15.4 (br s, 1H), 13.2 (br s, 1H), 8.46-8.34 (m, 2H), 8.13-8.11 (m, 1H), 2.45 (d, 3H). LCMS m / z 324.0 [M+H] + , t ret =0.53 minutes [TFA].
[0482] Example 3
[0483] 7-(1H-imidazol-5-yl)-6-(3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)imidazo[1,2-b][1,2,4]triazine
[0484] Step 1
[0485] Add 2-chloro-1-(1-(4-methoxybenzyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)ethyl-1-one (intermediate 3) (2.0 g, 5.99 mmol), 1,2,4-triazine-3-amine (1.0 g, 10.41 mmol), and acetonitrile (20 mL) to a 100 mL round-bottom flask. Reflux the mixture (heat to 90 °C) and stir for 24 hours. Cool the reaction to room temperature. Evaporate to dryness under vacuum, alkalize with a saturated aqueous solution of NaHCO3, extract with EtOAc, dry to Na2SO4, filter, and evaporate to dryness under vacuum. Load the solid into 10 g Isolute HM-N and purify by silica gel chromatography (Isco RediSepRf Gold 80 g, 0 to 100% EtOAc in CH2Cl2 solution). Combine the purified fractions and evaporate to dryness under vacuum. The residue was ground with hexane, filtered, and dried under vacuum to give the product 6-(1-(4-methoxybenzyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)imidazo[1,2-b][1,2,4]triazine (0.42 g, 1.063 mmol, 17.7% yield), as an orange solid. This reaction was repeated once and combined with the above product to give a total of (0.84 g, 2.24 mmol) of product. 1 H NMR (400 MHz, DMSO- d 6 ) d ppm 9.11 (s, 1H), 8.82 (d, J =1.96 Hz, 1H), 8.76 (d, J =1.96 Hz, 1H), 7.35-7.38 (m, 2H), 6.89-6.93 (m, 2H), 6.12 (s, 2H), 3.71 (s, 3H). LCMS m / z 375.9 [M+H] + , t ret = 1.06 minutes [TFA].
[0486] Step 2
[0487] Sodium acetate (0.30 g, 3.66 mmol) was added to a stirred solution of 6-(1-(4-methoxybenzyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)imidazo[1,2-b][1,2,4]triazine (0.84 g, 2.238 mmol) in acetic acid (20 mL), followed by dropwise addition of bromine (120 µL, 2.329 mmol). The reaction mixture was stirred for 15 minutes (to form a thick suspension). The reaction mixture was evaporated to dryness under vacuum, absorbed with CHCl3, washed with a saturated aqueous solution of NaHCO3, dried over Na2SO4, filtered, and concentrated under vacuum. The residue was purified by silica gel chromatography (Isco RediSep Rf Gold 80 g, 0 to 50% EtOAc in CH2Cl2 solution). The pure fractions were combined, evaporated to dryness under vacuum, ground with hexane, filtered, and dried under vacuum to give the product 7-bromo-6-(1-(4-methoxybenzyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)imidazo[1,2-b][1,2,4]triazine (0.77 g, 1.610 mmol, 72.0% yield), which is a pale yellow solid. 1 H NMR (400 MHz, DMSO- d 6 )d ppm 8.95 (d, J =1.96 Hz, 1H), 8.81 (d, J =1.96 Hz, 1H), 7.36 (d, J =8.80 Hz, 2H), 6.87-6.94 (m, 2H), 6.02 (s, 2H), 3.72 (s, 3H). LCMS m / z 454.0, 456.0 [M+H] + [M+H+2] t ret =1.12 minutes [TFA].
[0488] Step 3
[0489] Add 7-bromo-6-(1-(4-methoxybenzyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)imidazo[1,2-b][1,2,4]triazine (0.77 g, 1.695 mmol), N,N-dimethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborhecyclopentan-2-yl)-1H-imidazol-1-sulfonamide (intermediate 2) (1.0 g, 3.32 mmol), PdCl2(dppf)-CH2Cl2 adduct (0.35 g, 0.429 mmol), potassium phosphate (0.55 g, 2.59 mmol), 1,4-dioxane (20 mL), and water (1.0 mL) to a 100 mL round-bottom flask. Purge the reaction mixture with nitrogen, heat to 100 °C, and stir for 4 hours. The reaction mixture was cooled to room temperature and evaporated to dryness under vacuum. The remaining solid was ground with CH2Cl2, filtered to remove insoluble matter, and washed with CH2Cl2. The filtrate was loaded directly onto a silica gel column and purified by silica gel chromatography (Isco RediSep Rf Gold 80 g, CH2Cl2 solution of 0 to 80% EtOAc). The pure fractions were combined and concentrated under vacuum. The later eluent fraction containing a small amount of debrominated starting material was discarded. The residue was ground with CH2Cl2 / hexane, filtered, washed with hexane, and dried under vacuum to give the product 4-(6-(1-(4-methoxybenzyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)imidazo[1,2-b][1,2,4]triazin-7-yl)-N,N-dimethyl-1H-imidazol-1-sulfonamide (0.88 g, 1.524 mmol, 90% yield), as a yellow solid. 1 H NMR (400 MHz, DMSO-d6) d ppm 8.97 (d, J =1.96 Hz, 1H), 8.84 (d, J =1.96 Hz, 1H), 8.38 (d, J =1.47 Hz, 1H), 8.23 (d, J =1.47 Hz, 1H), 7.21 (d, J =8.80 Hz, 2H), 6.81-6.87 (m, 2H), 5.52 (s, 2H), 3.70 (s, 3H), 2.87 (s, 6H). LCMS m / z 549.1 [M+H] + , t ret = 1.06 minutes [TFA].
[0490] Step 4
[0491] A solution of 4-(6-(1-(4-methoxybenzyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)imidazo[1,2-b][1,2,4]triazin-7-yl)-N,N-dimethyl-1H-imidazol-1-sulfonamide (870 mg, 1.586 mmol) in trifluoroacetic acid (15 mL, 195 mmol) was heated to 70 °C and stirred for 12 hours. At this point, LCMS showed that the reaction was only 63% complete, and 33% of the product still contained dimethylaminosulfonyl groups. The reaction was heated at 80 °C and stirred for another 18 hours, at which point LCMS showed that the reaction was complete. The reaction was cooled to room temperature and evaporated to dryness under vacuum. The residue was adjusted to near pH 6 with a saturated NaHCO3 aqueous solution, treated with 0.2 M sodium hydrogen phosphate buffer (pH 6.3), ground, filtered, washed with water, filtered, ground with a small amount of EtOH, filtered, ground with CH2Cl2, filtered, and dried under vacuum to give the product 7-(1H-imidazol-5-yl)-6-(3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)imidazo[1,2-b][1,2,4]triazine (520 mg, 1.538 mmol, 97% yield), which was an orange solid. Note: This product forms a turbid suspension in DMSO-d6, so one drop of TFA was added to dissolve it before further processing. 1 HNMR determination. 1 ¹H NMR (400 MHz, DMSO-d⁶ w / TFA) d ppm 9.33 (s, ¹H), 8.96 (s, ¹H), 8.90 (s, ¹H), 8.41 (s, ¹H), no 2H signal observed. LCMS m / z 322.0 [M+H] + , t ret = 0.44 minutes [TFA].
[0492] Example 4
[0493] 3-(1H-imidazol-5-yl)-2-(3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)-5,6-dihydro-8H-imidazo[2,1-c][1,4]oxazine, trifluoroacetate
[0494] Step 1
[0495] Me3OBF4 (3.66 g, 24.73 mmol) was added to a solution of morpholino-3-one (1 g, 9.89 mmol) in dichloromethane (DCM) (15 mL). The reaction was stirred overnight at room temperature. LCMS analysis showed the desired product and the consumption of the starting material. The mixture was concentrated to remove the organic solvent. The crude product was extracted with EtOAc (3 × 15 mL). The combined organic phases were washed with brine (15 mL), dried over Na2SO4, filtered, and concentrated to give crude 5-methoxy-3,6-dihydro-2H-1,4-oxazine (400 mg, 3.09 mmol), which was a colorless oil.
[0496] Step 2
[0497] NH₄Cl (0.929 g, 17.37 mmol) was added to a solution of 5-methoxy-3,6-dihydro-2H-1,4-oxazine (1 g, 8.69 mmol) in methanol (50 mL). The mixture was stirred at 80 °C for 2 h. LCMS analysis showed the desired product and the consumption of the starting material. The mixture was extracted with EtOAc (30 mL × 3). The combined organic phases were washed with brine (40 mL), dried over Na₂SO₄, filtered, and concentrated to give a crude white solid, 5,6-dihydro-2H-1,4-oxazine-3-amine (1 g, 8.49 mmol).
[0498] Step 3
[0499] Add 2-chloro-1-(1-(4-methoxybenzyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-ethyl-1-one (intermediate 3) (1833 mg, 5.49 mmol) and Et3N (0.696 mL, 4.99 mmol) to a solution of 5,6-dihydro-2H-1,4-oxazin-3-amine (500 mg, 4.99 mmol) in acetonitrile (5 mL). The reaction was carried out in a microwave reactor and stirred at 130 °C for 1 hour. LCMS analysis showed the desired product and the consumption of starting materials. The mixture was cooled to room temperature and concentrated to remove the organic solvent. The crude mixture was extracted with EtOAc (15 mL × 3), the combined organic phases were washed with brine (15 mL), dried over NaSO4, filtered and concentrated to give a crude yellow solid. This was combined with the crude product from a smaller-scale reaction (starting with 20 mg / 0.200 mmol of 5,6-dihydro-2H-1,4-oxazine-3-amine) to give crude 2-(1-(4-methoxybenzyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)-5,6-dihydro-8H-imidazo[2,1-c][1,4]oxazine (380 mg, 0.892 mmol). LCMSm / z 380.1 [M+H] + , t ret = 1.04 minutes [TFA].
[0500] Step 4
[0501] NIS (249 mg, 1.107 mmol) was added to a solution of 2-(1-(4-methoxybenzyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)-5,6-dihydro-8H-imidazo[2,1-c][1,4]oxazine (350 mg, 0.923 mmol) in dichloromethane (DCM) (10 mL) and AcOH (2.000 mL). The reaction was stirred at room temperature for 2 hours. LCMS analysis showed the desired product and the consumption of starting materials. The mixture was extracted with EtOAc (13 mL × 3). The combined organic phases were washed with saturated Na₂S₂O₃ aqueous solution (13 mL) and brine (14 mL), then dried over Na₂SO₄ and concentrated to give crude 3-iodo-2-(1-(4-methoxybenzyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)-5,6-dihydro-8H-imidazo[2,1-c][1,4]oxazine (270 mg, 0.476 mmol). LCMS m / z 506.0 [M+H] + t ret = 1.14 minutes [TFA].
[0502] Step 5
[0503] To a solution of 3-iodo-2-(1-(4-methoxybenzyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)-5,6-dihydro-8H-imidazo[2,1-c][1,4]oxazine (240 mg, 0.475 mmol) in 1,4-dioxane (8 mL) and water (1.600 mL), N,N-dimethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborhecyclopentan-2-yl)-1H-imidazo-1-sulfonamide (intermediate 2) (215 mg, 0.713 mmol), Pd(dppf)Cl2 CH2Cl2 (78 mg, 0.095 mmol), and K3PO4 (202 mg, 0.950 mmol) were added. The reaction mixture was stirred overnight at 110 °C. LCMS analysis showed that the desired product was obtained and the starting material was consumed. The mixture was cooled to room temperature and concentrated to remove the organic solvent. The crude mixture was extracted with EtOAc (15 mL × 3), the combined organic phases were washed with brine (15 mL), dried over Na₂SO₄, filtered, and concentrated to give crude 4-(2-(1-(4-methoxybenzyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)-5,6-dihydro-8H-imidazo[2,1-c][1,4]oxazin-3-yl)-N,N-dimethyl-1H-imidazo-1-sulfonamide (200 mg, 0.333 mmol), which was a yellow solid. m / z 553.2 [M+H] + , t ret = 0.68 minutes (TFA, 1 minute run time).
[0504] Step 6
[0505] A solution of 4-(2-(1-(4-methoxybenzyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)-5,6-dihydro-8H-imidazo[2,1-c][1,4]oxazin-3-yl)-N,N-dimethyl-1H-imidazo-1-sulfonamide (200 mg, 0.362 mmol) in trifluoroacetic acid (TFA) (8 mL) was stirred at 75 °C for 2.5 h. LCMS analysis showed that the desired product was obtained and the starting material was consumed. The reaction mixture was concentrated under vacuum, redissolved in DMF (3 mL), and purified by preparative HPLC (Sunfire Prep C18 OBD column, eluent 10-30% ACN:water containing 0.05% TFA). The product was collected, concentrated, and lyophilized to give 3-(1H-imidazol-5-yl)-2-(3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)-5,6-dihydro-8H-imidazo[2,1-c][1,4]oxazine, trifluoroacetate, as a white solid (63.1 mg, 39.2% yield). 1 H NMR (400 MHz, DMSO- d 6 d ppm 8.88 (s, 1H), 8.07 (s, 1H), 4.90 (s, 2H), 4.15 (t, J = 4.4 Hz, 2H), 4.08 (t, J = 4.8 Hz, 2H), no 2H signal observed. LCMS m / z 326.1 [M+H] + , t ret = 0.69 minutes [TFA, 3-minute run time].
[0506] Example 5
[0507] 5-(1H-imidazol-5-yl)-6-(3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)-1H-imidazo[1,2-a]imidazolium, trifluoroacetate
[0508] Step 1 6-(1-(4-methoxybenzyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)-1H-imidazo[1,2-a]imidazolium
[0509] To a 20 mL microwave-safe flask, add 1H-imidazol-2-amine (600 mg, 7.22 mmol), 2-chloro-1-(1-(4-methoxybenzyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)ethyl-1-one (intermediate 3) (2650 mg, 7.94 mmol), and K₂CO₃ (998 mg, 7.22 mmol), followed by acetonitrile (15 mL). Heat the mixture in a microwave reactor to 130 °C and maintain for 1 hour. LC-MS analysis showed the desired product. Add silica gel (1.5 g) to adsorb the reaction mixture onto the silica gel and concentrate under vacuum. Purified by silica gel (80 g column, 2:1 PE:EtOAc), the target product fractions were combined and concentrated to give a yellow solid, 6-(1-(4-methoxybenzyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)-1H-imidazo[1,2-a]imidazole (500 mg, 1.328 mmol, 18.4% yield). LCMS m / z 363.1 [M+H] + , t ret = 1.17 minutes [TFA, 3-minute run time].
[0510] Step 2
[0511] In a 100 mL round-bottom flask, 6-(1-(4-methoxybenzyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)-1H-imidazo[1,2-a]imidazole (1.2 g, 3.31 mmol) was dissolved in dichloromethane (DCM) (25 mL). Di-tert-butyl dicarbonate (0.761 mL, 3.31 mmol) and triethylamine (0.460 mL, 3.31 mmol) were added to this solution. The mixture was stirred overnight at room temperature, and LCMS analysis showed the formation of the desired product. The reaction mixture was adsorbed onto silica gel (2 g) and concentrated under vacuum. Purified by silica gel (80 g column, 3:1 PE:EtOAc), the target fractions were combined and concentrated to give a white solid, 6-(1-(4-methoxybenzyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)-1H-imidazo[1,2-a]imidazo-1-carboxylic acid tert-butyl ester (1.3 g, 2.75 mmol, 83% yield). LCMS m / z 463.2 [M+H] + , t ret = 1.24 minutes [TFA].
[0512] Step 3
[0513] Add 1.2 g (2.59 mmol) of 6-(1-(4-methoxybenzyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)-1H-imidazo[1,2-a]imidazo-1-carboxylic acid tert-butyl ester and 1.751 g (7.78 mmol) to a 100 mL round-bottom flask. Add 25 mL of acetonitrile. Stir the reaction mixture at 50 °C for 2 h. LC-MS analysis showed the formation of the desired product. Quench the reaction with 30 mL of saturated Na₂S₂O₃ aqueous solution and then extract with EtOAc (3 × 50 mL). The combined organic layers were washed with a saturated aqueous NaCl solution (50 mL), dried over anhydrous Na₂SO₄, filtered, and concentrated to give crude tert-butyl 5-iodo-6-(1-(4-methoxybenzyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)-1H-imidazo[1,2-a]imidazo-1-carboxylic acid (1.3 g, 2.210 mmol), which was a yellow solid. LCMS m / z 533.0 [M+H-tBu] + , t ret = 2.52 minutes [TFA, 4-minute run time].
[0514] Step 4
[0515] Add 5-iodo-6-(1-(4-methoxybenzyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)-1H-imidazo[1,2-a]imidazo-1-carboxylic acid tert-butyl ester (300 mg, 0.510 mmol), N,N-dimethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborhecyclopentan-2-yl)-1H-imidazo-1-sulfonamide (intermediate 2) (184 mg, 0.612 mmol), cesium fluoride (155 mg, 1.020 mmol), and 1,1'-bis(diphenylphosphino)ferrocene-palladium(II) dichloromethane complex (83 mg, 0.102 mmol) to a 20 mL microwave-safe bottle. 1,2-Dimethoxyethane (DME) (20 mL) was added to the mixture, and the mixture was heated to 100 °C in a microwave reactor under N2 and maintained for 30 minutes. LCMS analysis showed the formation of the desired product. The solvent was removed under reduced pressure to obtain the crude product. The crude product was dissolved in 20 mL of EtOAc and adsorbed onto silica gel (0.6 g) under vacuum. It was then purified by silica gel (40 g column, 5:1 PE:EtOAc), the target fractions were combined and concentrated to give a yellow solid, 5-(1-(N,N-dimethylaminosulfonyl)-1H-imidazol-4-yl)-6-(1-(4-methoxybenzyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)-1H-imidazo[1,2-a]imidazol-1-carboxylic acid tert-butyl ester (300 mg, 0.429 mmol, 84% yield, 91% purity). LCMS m / z 636.3 [M+H] + , t ret = 2.09 minutes [TFA, 3-minute run time].
[0516] Step 5
[0517] Add 5-(1-(N,N-dimethylaminosulfonyl)-1H-imidazol-4-yl)-6-(1-(4-methoxybenzyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)-1H-imidazo[1,2-a]imidazol-1-carboxylic acid tert-butyl ester (200 mg, 0.315 mmol) and trifluoroacetic acid (TFA) (10 mL) to a 100 mL round-bottom flask. Stir the reaction mixture at 80 °C for 5 h. LCMS analysis showed that the desired product was formed and the starting material was consumed. The solution was concentrated under vacuum, dissolved in DMF (2 mL), and purified by preparative HPLC (SunFire C18 OBD column, eluent 10 to 35% ACN:water containing 0.05% TFA). The product fractions were collected, concentrated, and lyophilized to obtain the desired product, 5-(1H-imidazol-5-yl)-6-(3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)-1H-imidazo[1,2-a]imidazolium, trifluoroacetate (60 mg, 0.141 mmol, 44.8% yield). 1 H NMR (400 MHz, DMSO- d 6 δ ppm 12.16 (s, 1H), 8.84 (s, 1H), 8.28 (s, 1H), 7.83 (s, 1H), 7.51 (s, 1H), no 2H signal observed. LCMS m / z 309.0 [M+H] + , t ret = 0.78 minutes [TFA, 3-minute run time].
[0518] Example 6
[0519] 3-(1H-imidazol-5-yl)-2-(3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)-6,7-dihydro-5H-pyrrolo[1,2-a]imidazol-6-ol, trifluoroacetate
[0520] Step 1
[0521] 4-hydroxypyrrolidone-2-one (1.5 g, 14.84 mmol), tert-butylchlorodimethylsilane (2.68 g, 17.80 mmol), 1H-imidazolium (2.020 g, 29.7 mmol), and N,N-dimethylpyridinium-4-amine (0.200 mL, 1.484 mmol) were added to a 50 mL flask containing DCM (20 mL). The reaction was stirred at room temperature for 4 h. The solution was treated with water (100 mL), extracted with DCM (3 × 40 mL), and the combined organic phases were washed with brine (3 × 30 mL), dried over Na2SO4, filtered, and concentrated to give a crude white solid, 4-((tert-butyldimethylsilyl)oxy)pyrrolidone-2-one (3.4 g, 15.79 mmol).
[0522] Step 2
[0523] In a round-bottom flask, 4-((tert-butyldimethylsilyl)oxy)pyrrolidine-2-one (2 g, 9.29 mmol) was dissolved in dichloromethane (DCM) (10 mL), and trimethyloxonium tetrafluoroborate (4.12 g, 27.9 mmol) was added. The reaction was stirred at room temperature for 2 hours. LCMS analysis showed the formation of the desired product. A saturated aqueous solution of NaHCO3 (20 mL) was added to the mixture (initially dropwise). The mixture was extracted with DCM (3 × 100 mL), the combined organic phases were washed with brine, dried over Na2SO4, filtered, and concentrated to give a crude white solid, 3-((tert-butyldimethylsilyl)oxy)-5-methoxy-3,4-dihydro-2H-pyrrole (1.2 g, 5.19 mmol). LCMS m / z 230.2 [M+H] + , t ret = 0.64 minutes [TFA, 1.2 minutes run time].
[0524] Step 3
[0525] In a round-bottom flask containing 10 mL of methanol, 1.2 g (5.23 mmol) of 3-((tert-butyldimethylsilyl)oxy)-5-methoxy-3,4-dihydro-2H-pyrrole (0.839 g, 15.69 mmol) and NH4Cl (0.839 g, 15.69 mmol) were added. The reaction mixture was stirred at 70 °C for 2 h. The mixture was concentrated and DCM (50 mL) was added. The solid was filtered off and the mixture was washed with DCM. The collected crude white solid 3-((tert-butyldimethylsilyl)oxy)-3,4-dihydro-2H-pyrrole-5-amine (1.2 g, 5.60 mmol) was used in the next step without purification.
[0526] Step 4
[0527] To a microwave-safe reaction flask containing a solution of 3-((tert-butyldimethylsilyl)oxy)-3,4-dihydro-2H-pyrrolo-5-amine (100 mg, 0.466 mmol) in acetonitrile (10 mL), 2-chloro-1-(1-(4-methoxybenzyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)ethyl-1-one (intermediate 3) (171 mg, 0.513 mmol) and triethylamine (0.130 mL, 0.933 mmol) were added. The mixture was heated in a microwave reactor at 130 °C for 1 hour. LCMS analysis showed the formation of the desired product. The mixture was concentrated under vacuum, and the residue was purified by preparative TLC (25% EtOAc in petroleum ether solution) to obtain the target material as a red oily substance 6-((tert-butyldimethylsilyl)oxy)-2-(1-(4-methoxybenzyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)-6,7-dihydro-5H-pyrrolo[1,2-a]imidazole (20 mg, 0.038 mmol, 8.1% yield). LCMS m / z 494.2 [M+H] + , t ret = 1.44 minutes [formic acid].
[0528] Step 5
[0529] N-iodosuccinimide (71.1 mg, 0.316 mmol) was added to a solution of 6-((tert-butyldimethylsilyl)oxy)-2-(1-(4-methoxybenzyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)-6,7-dihydro-5H-pyrrolo[1,2-a]imidazole (130 mg, 0.263 mmol) in acetic acid (5 mL). The mixture was stirred at room temperature for 1 h. LCMS analysis showed the formation of the desired product. The mixture was quenched with saturated Na₂S₂O₃ aqueous solution (1 mL) and diluted with water (10 mL). The mixture was extracted with EtOAc (3 × 20 mL), the combined organic phases were washed with brine (20 mL), dried over Na₂SO₄, filtered, and concentrated. The residue was purified by preparative TLC with 15% EtOAc in petroleum ether as the eluent. The target material was isolated as a light red solid, 6-((tert-butyldimethylsilyl)oxy)-3-iodo-2-(1-(4-methoxybenzyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)-6,7-dihydro-5H-pyrrolo[1,2-a]imidazole (60 mg, 0.091 mmol, 34.6% yield). LCMS m / z 620.1 [M+H] + , t ret = 1.48 minutes [formic acid].
[0530] Step 6
[0531] Add N,N-dimethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborane-2-yl)-1H-imidazolium-1-sulfonamide (intermediate 2) (29.4 mg, 0.098 mmol), cesium fluoride (27.0 mg, 0.178 mmol), and 1,1'-bis(diphenylphosphino)ferrocene-palladium(II) dichloromethane complex (7.25 mg) to a solution of 6-((tert-butyldimethylsilyl)oxy)-3-iodo-2-(1-(4-methoxybenzyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)-6,7-dihydro-5H-pyrrolo[1,2-a]imidazole (55 mg, 0.089 mmol) in 1,2-dimethoxyethane (DME) (3 mL) to a solution of 6-((tert-butyldimethylsilyl)oxy)-3-iodo-2-iodo-2-(1-(4-methoxybenzyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)-6,7-dihydro-5H-pyrrolo[1,2-a]imidazole (55 mg, 0.089 mmol) in 1,2-dimethoxyethane (DME) (3 mL) to an intermediate 1,2-dimethoxyethane (DME) (7.25 mg, 0.098 mmol), to a solution of 6-((tert-butyldimethylsilyl)oxy)-3-iodo-2-iodo-2-(1-(4-methoxybenzyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)-6,7-dihydro-5H-pyrrolo[1,2-a]imi (mg, 8.88 µmol). The mixture was heated to 120 °C under N2 and held for 1 hour. LCMS analysis showed that the desired product was obtained. The reaction was concentrated under vacuum, and the residue was purified by preparative TLC with 40% EtOAc in petroleum ether as the eluent. The target product was isolated as a pale yellow solid, 4-(6-((tert-butyldimethylsilyl)oxy)-2-(1-(4-methoxybenzyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)-6,7-dihydro-5H-pyrrolo[1,2-a]imidazol-3-yl)-N,N-dimethyl-1H-imidazol-1-sulfonamide (38.4 mg, 0.058 mmol, 64.9% yield). LCMS m / z 667.3 [M+H] + , t ret = 1.50 minutes [formic acid].
[0532] Step 7
[0533] 4-(6-((tert-butyldimethylsilyl)oxy)-2-(1-(4-methoxybenzyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)-6,7-dihydro-5H-pyrrolo[1,2-a]imidazol-3-yl)-N,N-dimethyl-1H-imidazol-1-sulfonamide (36 mg, 0.054 mmol) was dissolved in trifluoroacetic acid (TFA) (1 mL). The solution was stirred and heated to 80 °C for 1 hour. LCMS analysis showed the formation of the desired product. The mixture was concentrated under vacuum and then redissolved in MeCN (0.5 mL) and DMF (0.6 mL). The solids were filtered off, and the filtrate was purified by preparative HPLC (SunFire C18 OBD column, eluent 10% to 30% ACN:water, containing 0.05% TFA). The product fraction was collected, concentrated, and then lyophilized to obtain the desired product, which was a white solid 3-(1H-imidazol-5-yl)-2-(3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)-6,7-dihydro-5H-pyrrolo[1,2-a]imidazol-6-ol, trifluoroacetate (12.1 mg, 0.028 mmol, 51.0% yield). 1 H NMR (400 MHz, methanol-) d 4 δ ppm 8.90 (s, 1H), 7.99 (s, 1H), 5.10–5.15 (m, 1H), 4.52–4.57 (dd, J = 11.6, 5.6 Hz, 1H), 4.16–4.19 (d, J = 11.6 Hz, 1H), 3.35–3.49 (m, 1H), 2.89–2.94 (d, J = 17.2 Hz, 1H), 3H signal not observed. LCMS m / z 326.2 [M+H] + , t ret = 0.77 minutes [formic acid, 3-minute run time].
[0534] Example 7
[0535] 6-Fluoro-3-(1H-imidazol-5-yl)-2-(3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)imidazo[1,2-a]pyridine
[0536] Step 1
[0537] 5-Fluoropyridine-2-amine (501 mg, 4.47 mmol) and 2-chloro-1-(1-(4-methoxybenzyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)ethyl-1-one (intermediate 3) (1.513 g, 4.53 mmol) were added to a microwave reaction flask and suspended in 19 mL of 2-methyltetrahydrofuran (2-MeTHF). The mixture was heated to 110 °C and maintained for 16 hours. The mixture was concentrated and then purified on silica gel (80 g; 25-40-100% EtOAc / heptane). The target fractions were combined and concentrated to give 6-fluoro-2-(1-(4-methoxybenzyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)imidazo[1,2-a]pyridine (849 mg, 1.931 mmol, 43.2% yield). LCMS m / z 392.1 [M+H] + , t ret = 1.20 minutes [NH4HCO3].
[0538] Step 2
[0539] 6-Fluoro-2-(1-(4-methoxybenzyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)imidazo[1,2-a]pyridine (848 mg, 2.167 mmol) was dissolved in acetonitrile (30 mL), followed by the addition of NBS (400 mg, 2.247 mmol) and TFA (0.025 mL, 0.324 mmol). The mixture was stirred at room temperature for 1 hour, and most of the solvent was removed under vacuum. The solution was then directly transferred to silica gel for purification (80 g; 15-40-50-100% EtOAc / heptane). The target fractions were combined and concentrated to give 3-bromo-6-fluoro-2-(1-(4-methoxybenzyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)imidazo[1,2-a]pyridine (951 mg, 2.022 mmol, 93% yield). LCMS m / z 470.0, 472.0 [M+H] + (Br isotope pattern), t ret =1.31 min [NH4HCO3].
[0540] Step 3
[0541] 3-Bromo-6-fluoro-2-(1-(4-methoxybenzyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)imidazo[1,2-a]pyridine (453 mg, 0.963 mmol), N,N-dimethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborhecyclopentan-2-yl)-1H-imidazol-1-sulfonamide (intermediate 2) (418 mg, 1.388 mmol), cesium fluoride (611 mg, 4.02 mmol), and Pd(dppf)Cl2 (96 mg, 0.131 mmol) were added to a microwave reaction flask and suspended in 1,2-dimethoxyethane (DME) (11 mL). The mixture was heated to 135 °C in a microwave reactor and maintained for 80 minutes. The reaction mixture was added directly to a silica gel stopper and then purified on silica gel (80 g; 25-40-55-100% EtOAc / heptane). The target fractions were combined and concentrated to give 4-(6-fluoro-2-(1-(4-methoxybenzyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)imidazo[1,2-a]pyridin-3-yl)-N,N-dimethyl-1H-imidazol-1-sulfonamide (428 mg, 0.758 mmol, 79% yield). LCMS m / z 565.0 [M+H] + , t ret = 1.35 min [NH4HCO3].
[0542] Step 4
[0543] 4-(6-fluoro-2-(1-(4-methoxybenzyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)imidazo[1,2-a]pyridin-3-yl)-N,N-dimethyl-1H-imidazol-1-sulfonamide (234 mg, 0.415 mmol) was dissolved in TFA (6 mL, 0.415 mmol). The solution was stirred at 65 °C for 4.5 h. The reaction mixture was diluted with DCM and concentrated under vacuum (repeated 3 times). The residue was dissolved in 1:1 DCM / EtOAc (5 mL) and concentrated (repeated 2 times). The residue began to solidify. The solid was suspended in an aqueous solution of IPA / EtOAc / saturated NaHCO3. The solid was filtered and washed with water, IPA, and EtOAc / ethyl ether / heptane to give 6-fluoro-3-(1H-imidazol-5-yl)-2-(3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)imidazo[1,2-a]pyridine (117 mg, 0.333 mmol, 80% yield). 1H NMR (400 MHz, DMSO-d6) d ppm 13.56 - 14.50 (m,2H), 9.63 (br s, 1H), 8.40 (br s, 1H), 7.95 (d, J=0.98 Hz, 1H), 7.72 (dd, J=10.03, 5.62 Hz, 1H), 7.37 - 7.50 (m, 1H). LCMS m / z 338.0 [M+H] + , t ret = 0.42min [NH4HCO3].
[0544] Example 8
[0545] 2-(3-Bromo-1H-1,2,4-triazol-5-yl)-6,8-difluoro-3-(1H-imidazol-5-yl)imidazo[1,2-a]pyridine, trifluoroacetate
[0546] Step 1
[0547] A mixture of 3,5-difluoropyridin-2-amine (300 mg, 2.306 mmol) and 1-(3-bromo-1-(4-methoxybenzyl)-1H-1,2,4-triazol-5-yl)-2-chloroethyl-1-one (intermediate 1) (954 mg, 2.77 mmol) in ethanol (20 mL) was heated to 90 °C and stirred overnight in a flask. The mixture was cooled to room temperature, and a solid precipitated. The reaction mixture was filtered, and the solid was air-dried overnight to give crude 2-(3-bromo-1-(4-methoxybenzyl)-1H-1,2,4-triazol-5-yl)-6,8-difluoroimidazo[1,2-a]pyridine (330 mg). LCMS m / z 420.1 [M+H] + , t ret = 1.19 min [TFA].
[0548] Step 2
[0549] To a mixture of 2-(3-bromo-1-(4-methoxybenzyl)-1H-1,2,4-triazol-5-yl)-6,8-difluoroimidazolo[1,2-a]pyridine (330 mg, 0.785 mmol) in dichloromethane (DCM) (10 mL), 1-iodopyrrolidine-2,5-dione (265 mg, 1.178 mmol) was added at room temperature, and the resulting mixture was stirred at 23 °C. After overnight incubation, LCMS showed a major product peak with almost no starting material remaining. The mixture was washed twice with saturated aqueous Na₂CO₃ solution. The organic phase was dried over Na₂SO₄, filtered, and concentrated to give a crude product, which was purified using a Combiflash Rf200 with a gradient from 100% DCM to 5% MeOH / DCM. The product fraction was collected and concentrated to give 2-(3-bromo-1-(4-methoxybenzyl)-1H-1,2,4-triazol-5-yl)-6,8-difluoro-3-iodoimidazole[1,2-a]pyridine (142 mg), a white solid. LCMS m / z 545.9 [M+H] + , t ret = 1.30 min[TFA].
[0550] Step 3
[0551] A mixture of 2-(3-bromo-1-(4-methoxybenzyl)-1H-1,2,4-triazol-5-yl)-6,8-difluoro-3-iodoimidazole[1,2-a]pyridine (100 mg, 0.183 mmol), N,N-dimethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborhecyclopentan-2-yl)-1H-imidazol-1-sulfonamide (intermediate 2) (66.2 mg, 0.220 mmol), K3PO4 (117 mg, 0.549 mmol), and PdCl2dppf (14.95 mg, 0.018 mmol) in 1,4-dioxane (3 mL) and water (1 mL) was purged with nitrogen in a microwave-safe flask. The mixture was then heated to 110 °C in a microwave reactor and held for 30 minutes. LC-MS analysis showed a major product peak and no remaining starting material. The mixture was concentrated with an isolute, and the residue was purified using a Combiflash Rf200 with a gradient from 100% hexane to 60% EA:EtOH in a 3:1 ratio. The product fraction was collected and concentrated to give 4-(2-(3-bromo-1-(4-methoxybenzyl)-1H-1,2,4-triazol-5-yl)-6,8-difluoroimidazolo[1,2-a]pyridin-3-yl)-N,N-dimethyl-1H-imidazole-1-sulfonamide (100 mg), as a yellow solid. LCMS m / z 595.2, 596.1 [M+H] + , t ret= 1.34 min[TFA].
[0552] Step 4
[0553] A mixture of 4-(2-(3-bromo-1-(4-methoxybenzyl)-1H-1,2,4-triazol-5-yl)-6,8-difluoroimidazo[1,2-a]pyridin-3-yl)-N,N-dimethyl-1H-imidazo-1-sulfonamide (100 mg, 0.169 mmol) in TFA (8 mL, 0.169 mmol) was stirred at 65 °C. After overnight incubation, LCMS showed a major product peak with no remaining starting material. The mixture was cooled to room temperature, and the TFA was removed under reduced pressure. The residue was purified by reversed-phase HPLC (MDAP method A) to give 2-(3-bromo-1H-1,2,4-triazol-5-yl)-6,8-difluoro-3-(1H-imidazo-5-yl)imidazo[1,2-a]pyridine trifluoroacetate (15 mg) as a white solid. 1 ¹H NMR (400 MHz, DMSO-d⁶) δ ppm 9.49–9.61 (m, 1H), 8.43 (s, 1H), 8.26 (br s, 1H), 7.77 (t, J=2.03 Hz, 1H), no 2H signal observed. LCMS m / z 367.9 [M+H] + , t ret = 0.43 min [TFA].
[0554] Example 9
[0555] (5-(8-fluoro-3-(1H-imidazol-5-yl)-7-methylimidazo[1,2-a]pyridin-2-yl)-3-(trifluoromethyl)-1H-1,2,4-triazol-1-yl)methyl phosphate dihydrogen ester hydrochloride
[0556] Step 1
[0557] A solution of 3-fluoro-4-methylpyridin-2-amine (810 mg, 6.42 mmol) and 2-chloro-1-(1-(4-methoxybenzyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)ethyl-1-one (intermediate 3) (2571 mg, 7.71 mmol) in ethanol (20 mL) was heated overnight at 90 °C in a microwave-safe reaction flask. The mixture was cooled to room temperature, and a solid precipitated. The mixture was filtered, and the solid was air-dried overnight to give 8-fluoro-2-(1-(4-methoxybenzyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)-7-methylimidazo[1,2-a]pyridine (1080 mg, 2.66 mmol, 41%) as a white solid. LCMS m / z 406.2 [M+H] + ,t ret = 1.24 min [TFA].
[0558] Step 2
[0559] A TFA (15 mL, 195 mmol) solution of 8-fluoro-2-(1-(4-methoxybenzyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)-7-methylimidazo[1,2-a]pyridine (2570 mg, 6.34 mmol) was stirred overnight at 65 °C. LCMS showed a new major peak with no starting material remaining. The mixture was then cooled to room temperature and concentrated under reduced pressure. The residue was purified by silica gel chromatography (0–10% MeOH in DCM solution) to give 8-fluoro-7-methyl-2-(3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)imidazo[1,2-a]pyridine (1660 mg, 5.82 mmol, 92%) as a yellow solid. 1 ¹H NMR (400MHz, DMSO-d6) δ ppm 8.66 (d, J=2.79 Hz, 1H), 8.40 (d, J=6.84 Hz, 1H), 6.95 (t, J=6.72 Hz, 1H), 2.26 - 2.39 (m, 3H), no 1H signal observed.
[0560] Step 3
[0561] To a mixture of 8-fluoro-7-methyl-2-(3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)imidazo[1,2-a]pyridine (1660 mg, 5.82 mmol) in dichloromethane (DCM) (40 mL), NIS (1440 mg, 6.40 mmol) was added at room temperature, and the resulting mixture was stirred overnight at 40 °C. LCMS showed a major peak with very little of the starting material remaining. 3 mL of saturated Na₂CO₃ aqueous solution was added to the reaction mixture. The mixture was concentrated, and the residue was purified by silica gel chromatography (0-5% MeOH in DCM solution) to give 8-fluoro-3-iodo-7-methyl-2-(3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)imidazo[1,2-a]pyridine (2000 mg, 4.86 mmol, 84%) as a yellow solid. LCMS m / z 412.0 [M+H] + , t ret =1.01 min [TFA].
[0562] Step 4
[0563] A mixture of 8-fluoro-3-iodo-7-methyl-2-(3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)imidazo[1,2-a]pyridine (2000 mg, 4.86 mmol), di-tert-butyl(chloromethyl) phosphate (2517 mg, 9.73 mmol), potassium carbonate (2017 mg, 14.59 mmol), and sodium iodide (72.9 mg, 0.486 mmol) in N,N-dimethylformamide (DMF) (25 mL) was stirred overnight at 50 °C. LC-MS analysis showed no residual starting material. Water and EA were added to the reaction mixture. The aqueous layer was separated and extracted twice with ethyl acetate. The combined organic phases were concentrated and purified by silica gel chromatography (hexane solution of 0-70% ethyl acetate) to give di-tert-butyl((5-(8-fluoro-3-iodo-7-methylimidazo[1,2-a]pyridin-2-yl)-3-(trifluoromethyl)-1H-1,2,4-triazol-1-yl)methyl) phosphate (1290 mg, 2.04 mmol, 42%), as a white solid. 1 H NMR(400 MHz, DMSO-d6) δ ppm 8.34 (d, J=7.10 Hz, 1H), 7.14 (s, 1H), 6.63 (d, J=11.15 Hz, 2H), 2.38 (d, J=2.28 Hz, 3H), 1.24 - 1.32 (m, 18H). LCMS m / z 634.2[M+H] + , t ret= 1.32 min [TFA].
[0564] Step 5
[0565] In a microwave-safe reaction flask, a mixture of di-tert-butyl((5-(8-fluoro-3-iodo-7-methylimidazo[1,2-a]pyridin-2-yl)-3-(trifluoromethyl)-1H-1,2,4-triazol-1-yl)methyl) phosphate (1290 mg, 2.037 mmol), N,N-dimethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborhecyclopentan-2-yl)-1H-imidazol-1-sulfonamide (intermediate 2) (736 mg, 2.444 mmol), PdCl2dppf (166 mg, 0.204 mmol), and CsF (774 mg, 5.09 mmol) in 1,2-dimethoxyethane (DME) (10 mL) was purged with nitrogen. The reaction mixture was then heated in a microwave-safe environment at 115 °C for 30 minutes. The reaction mixture was concentrated, and the residue was purified by silica gel chromatography (0-10% MeOH in DCM solution) to give di-tert-butyl((5-(3-(1-(N,N-dimethylaminosulfonyl)-1H-imidazol-4-yl)-8-fluoro-7-methylimidazo[1,2-a]pyridin-2-yl)-3-(trifluoromethyl)-1H-1,2,4-triazol-1-yl)methyl) phosphate (1300 mg, 1.91 mmol, 94%), as a yellow solid. 1 H NMR (400 MHz, DMSO-d6) δ ppm 8.98 (d, J=7.35 Hz, 1H), 8.54 (d, J=1.27Hz, 1H), 8.44 (d, J=1.52 Hz, 1H), 7.09 (s, 1H), 6.61 (d, J=11.66 Hz, 2H), 2.84 - 2.90 (m, 6H), 2.39 (d, J=2.03 Hz, 3H), 1.24 (s, 18H). LCMS m / z 681.3 [M+H] + , t ret = 1.35 min [TFA].
[0566] Step 6
[0567] A mixture of di-tert-butyl((5-(3-(1-(N,N-dimethylaminosulfonyl)-1H-imidazol-4-yl)-8-fluoro-7-methylimidazo[1,2-a]pyridin-2-yl)-3-(trifluoromethyl)-1H-1,2,4-triazol-1-yl)methyl) phosphate (1300 mg, 1.910 mmol) and a dioxane solution of 4N HCl (20 mL, 80 mmol) in dichloromethane (DCM) (20 mL) was stirred overnight at room temperature. LC-MS showed a major product peak with no remaining starting material. The reaction mixture was concentrated. MeOH (10 mL) was added to dissolve the residue, followed by slow addition of diethyl ether (30 mL) until the mixture became cloudy. The final mixture was allowed to stand at room temperature, and a solid precipitated. The mixture was filtered and the solid was air-dried overnight to give (5-(8-fluoro-3-(1H-imidazol-5-yl)-7-methylimidazo[1,2-a]pyridin-2-yl)-3-(trifluoromethyl)-1H-1,2,4-triazol-1-yl)methyl phosphate dihydrogen ester hydrochloride (520 mg, 0.99 mmol, 52%), as a grayish-white solid. 1 ¹H NMR (400 MHz, DMSO-d⁶) δ ppm: 8.90 (d, J=7.10 Hz, 1H), 8.37 (s, 1H), 8.08 (d, J=1.27 Hz, 1H), 7.05 (t, J=6.84 Hz, 1H), 6.42 (d, J=11.41 Hz, 2H), 2.34 - 2.41 (m, 3H), no 3H signal observed. LCMS m / z: 462.2 [M+H] + , t ret = 0.50 min [TFA].
[0568] Example 10
[0569] 6-Bromo-3-(1H-imidazol-5-yl)-7-methyl-2-(3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)imidazo[1,2-a]pyridine, bis(trifluoroacetate)
[0570] Step 1
[0571] A mixture of 5-bromo-4-methylpyridin-2-amine (1 g, 5.35 mmol), 2-chloro-1-(1-(4-methoxybenzyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)ethyl-1-one (intermediate 3) (1.784 g, 5.35 mmol), and sodium bicarbonate (0.494 g, 5.88 mmol) in ethanol (30 mL) was heated to 85 °C and stirred overnight. The reaction mixture was cooled to 0 °C, the precipitate was filtered off, and the solid was washed with cold EtOH (twice) and water (twice) and dried to give 6-bromo-2-(1-(4-methoxybenzyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)-7-methylimidazo[1,2-a]pyridine (1.328 g, 2.85 mmol, 53.3% yield) as a grayish-white solid. 1 H NMR (400 MHz, DMSO-d6) δ ppm 9.01 (s, 1H), 8.56 (s, 1H), 7.80 (s,1H), 7.30-7.40 (m, 2H), 6.84-6.94 (m, 2H), 6.12 (s, 2H), 3.72 (s,3H), 2.44 (s,3H). LCMS m / z 466.12, 468.10 [M+H] + ; t ret = 1.39 min [NH4HCO3].
[0572] Step 2
[0573] A solution of 6-bromo-2-(1-(4-methoxybenzyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)-7-methylimidazo[1,2-a]pyridine (1.322 g, 2.84 mmol), NIS (0.829 g, 3.69 mmol), and TFA (10.92 µl, 0.142 mmol) in dichloromethane (DCM) (25 mL) was stirred over a period of time at room temperature. The mixture was washed with water (twice), 10% Na2SO3 aqueous solution (twice), water (twice), and brine (once), dried over sodium sulfate, and concentrated to give 6-bromo-3-iodo-2-(1-(4-methoxybenzyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)-7-methylimidazo[1,2-a]pyridine (1.579 g, 2.67 mmol, 94% yield), a pale yellow solid. 1H NMR (400 MHz, DMSO-d6) δ ppm 8.64 (s, 1H), 7.86 (s,1H), 7.26-7.38 (m, 2H), 6.85-6.95 (m, 2H), 5.99 (s, 2H), 3.72 (s, 3H), 2.49(s, 3H). LCMS m / z 592.06, 594.04 [M+H] + ; t ret = 1.51 min [NH4HCO3].
[0574] Step 3
[0575] A mixture of 6-bromo-3-iodo-2-(1-(4-methoxybenzyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)-7-methylimidazo[1,2-a]pyridine (0.666 g, 1.125 mmol), N,N-dimethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborhecyclopentan-2-yl)-1H-imidazol-1-sulfonamide (intermediate 2) (0.423 g, 1.406 mmol), PdCl2 (dppf) (0.123 g, 0.169 mmol), and CsF (0.342 g, 2.249 mmol) in 1,2-dimethoxyethane (DME) (10.5 mL) was heated in a microwave reactor at 110 °C for 75 minutes. The mixture was filtered, and the filtrate was concentrated. The off-white solid was washed with AcN and DCM and concentrated to give 206 mg of 4-(6-bromo-2-(1-(4-methoxybenzyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)-7-methylimidazo[1,2-a]pyridin-3-yl)-N,N-dimethyl-1H-imidazo-1-sulfonamide, an off-white solid. The solid filtered from the reaction mixture was washed with water (3 times) and dried to give 257 mg of 4-(6-bromo-2-(1-(4-methoxybenzyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)-7-methylimidazo[1,2-a]pyridin-3-yl)-N,N-dimethyl-1H-imidazo-1-sulfonamide. A third batch of product was separated from the filtrate after partial evaporation (filtration). The combined batches yielded 778 mg of product (quantitative). 1H NMR (400 MHz, DMSO-d6) δ ppm 9.56 (s, 1H), 8.53 (d, J=0.98 Hz, 1H), 8.42 (d, J=0.98 Hz, 1H), 7.90 (s, 1H), 7.33-7.44 (m, 2H), 6.80-6.95 (m, 2H), 5.96 (s, 2H), 3.72 (s, 3H), 2.87 (s, 6H), 2.49 (s, 3H). LCMS m / z 639.14, 641.12 [M+H] + ; t ret = 1.52 min [NH4HCO3].
[0576] Step 4
[0577] A solution of 4-(6-bromo-2-(1-(4-methoxybenzyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)-7-methylimidazo[1,2-a]pyridin-3-yl)-N,N-dimethyl-1H-imidazo-1-sulfonamide (17 mg, 0.027 mmol) in trifluoroacetic acid (TFA) (4 mL) was heated and stirred overnight at 75 °C. The TFA was removed by evaporation, and the residue was purified by reversed-phase HPLC (MDAP method E) to give 6-bromo-3-(1H-imidazo-5-yl)-7-methyl-2-(3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)imidazo[1,2-a]pyridinium bis(trifluoroacetate) (12 mg, 0.019 mmol, 70.5% yield) as a white lyophilized product. 1 ¹H NMR (400MHz, DMSO-d⁶) δ ppm 9.33 (br s, 1H), 8.80 (br s, 1H), 8.34 (d, J=0.98 Hz, 1H), 7.79 (d, J=0.98 Hz, 1H), 2.50 (br s, 3H), no 2H signal observed. LCMS m / z 411.94, 413.94 [M+H] + ; t ret = 0.56 min [TFA].
[0578] Example 11
[0579] 3-(1H-imidazol-5-yl)-5,7-dimethyl-6-phenyl-2-(3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)imidazo[1,2-a]pyridine, 1,5-trifluoroacetate
[0580] Step 1
[0581] A mixture of 5-bromo-4,6-dimethylpyridin-2-amine (931 mg, 4.63 mmol), 2-chloro-1-(1-(4-methoxybenzyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)ethyl-1-one (intermediate 3) (2318 mg, 6.95 mmol) and sodium bicarbonate (661 mg, 7.87 mmol) in ethanol (30 mL) was heated to 85 °C and stirred overnight. The reaction mixture was cooled to 0 °C, the precipitate was filtered off, and the solid was washed with cold EtOH (2x) and water (2x) and dried to give 6-bromo-2-(1-(4-methoxybenzyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)-5,7-dimethylimidazo[1,2-a]pyridine (940 mg, 1.957 mmol, 42.3% yield), which was a grayish-white solid. 1 H NMR (400 MHz, DMSO- d 6 ) δ ppm 8.64 (s, 1H), 7.72 (s, 1H), 7.30-7.39 (m, 2H), 6.85-6.94 (m, 2H), 6.15 (s, 2H), 3.71 (s, 3H), 2.88 (s, 3H), 2.48 (s, 3H). LCMS m / z 466.12, 468.10 [M+H] + ; t ret =1.47 minutes [NH4HCO3].
[0582] Step 2
[0583] A mixture of 6-bromo-2-(1-(4-methoxybenzyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)-5,7-dimethylimidazo[1,2-a]pyridine (938 mg, 1.953 mmol), NIS (571 mg, 2.54 mmol), and TFA (7.52 µL, 0.098 mmol) in dichloromethane (DCM) (20 mL) was stirred overnight at room temperature. The temperature was raised to 40 °C, and the reaction mixture was stirred for 6 hours. The reaction was still not complete, so more NIS (114 mg, 0.51 mmol) was added, and the reaction mixture was stirred overnight at 40 °C. TFA (20 µL) was added, and stirring was continued for 1 day. The dark brown mixture was then washed with water (once), 10% Na₂SO₃ aqueous solution (twice), water (twice), and brine (once), dried over sodium sulfate, and concentrated. The residue was purified on silica gel (40 g Isco RediSep Rf Gold column, eluted with 0–30% (EtOAc / EtOH 3 / 1) heptane solution) to give 6-bromo-3-iodo-2-(1-(4-methoxybenzyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)-5,7-dimethylimidazo[1,2-a]pyridine (996 mg, 1.643 mmol, 84% yield) as a yellow solid. LCMS m / z 606.01, 608.08 [M+H] + ; t ret = 1.44 minutes [TFA].
[0584] Step 3
[0585] A mixture of 6-bromo-3-iodo-2-(1-(4-methoxybenzyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)-5,7-dimethylimidazo[1,2-a]pyridine (50 mg, 0.082 mmol), N,N-dimethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborhecyclopentan-2-yl)-1H-imidazol-1-sulfonamide (intermediate 2) (37.3 mg, 0.124 mmol), PdCl2 (dppf) (9.05 mg, 0.012 mmol), CsF (25.06 mg, 0.165 mmol), and DME (1.5 mL) was heated at 130 °C for 1.5 h. LCMS showed that the reaction mixture contained approximately 41% of the desired product. Four additional 50 mg reactions were conducted, varying the temperature (110–150 °C) and the base (K₃PO₄), with similar results (the reactions were not complete). All five reaction mixtures were combined and used directly in the next step.
[0586] Step 4
[0587] 4,4,5,5-Tetramethyl-2-phenyl-1,3,2-dioxaborhecyclopentane (168 mg, 0.823 mmol), cesium carbonate (402 mg, 1.235 mmol), and PdCl2 (dppf) (45.2 mg, 0.062 mmol) were added to the combined reaction mixture. The reaction mixture was heated in a microwave reactor at 120 °C for 1.5 h. The mixture was filtered through a Celite filter and concentrated. The residue was partitioned between water and EtOAc, and the organic layer was washed (once) with brine and then evaporated. The residue was purified by reversed-phase HPLC (MDAP method J) to give 4-(2-(1-(4-methoxybenzyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)-5,7-dimethyl-6-phenylimidazo[1,2-a]pyridin-3-yl)-N,N-dimethyl-1H-imidazo-1-sulfonamide (75 mg, 0.115 mmol, 28.0% yield). LCMS m / z 651.0 [M+H] + ; t ret = 1.36 minutes [TFA].
[0588] Step 5
[0589] A solution of 4-(2-(1-(4-methoxybenzyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)-5,7-dimethyl-6-phenylimidazo[1,2-a]pyridin-3-yl)-N,N-dimethyl-1H-imidazo-1-sulfonamide (75 mg, 0.115 mmol) in trifluoroacetic acid (TFA) (4 mL) was heated and stirred overnight at 75 °C. TFA was removed by evaporation, and the residue was purified by reversed-phase HPLC (MDAP method E) to give 3-(1H-imidazol-5-yl)-5,7-dimethyl-6-phenyl-2-(3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)imidazo[1,2-a]pyridine, 1,5-trifluoroacetate (29 mg, 0.049 mmol, 42.3% yield), which was a white lyophilized product. 1 H NMR (DMSO- d 6δ ppm 9.21 (s, 1H), 7.96 (d, J=1.0 Hz, 1H), 7.70 (s, 1H), 7.44–7.56 (m, 3H), 7.24–7.28 (m, 2H), 2.09 (s, 3H), 1.99 (s, 3H), no 2H signal observed. LCMS m / z 424.3 [M+H] + ; t ret = 0.66 minutes [TFA].
[0590] Example 12
[0591] 7-Bromo-3-(1H-pyrazol-4-yl)-2-(3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)imidazo[1,2-a]pyridine
[0592] Step 1
[0593] A mixture of 4-bromopyridin-2-amine (10 g, 57.8 mmol), ethyl 4-bromo-3-oxobutyrate (14.50 g, 69.4 mmol), and sodium carbonate (6.13 g, 57.8 mmol) in ethanol (100 mL) was refluxed at 85 °C for 16 h. The reaction was cooled to room temperature and the solvent was removed under reduced pressure. The residue was purified by silica gel column chromatography (2:1 to 2:3 petroleum ether / ethyl acetate) to give ethyl 7-bromoimidazolo[1,2-a]pyridin-2-carboxylate (11 g, 70.7%) as a pale yellow solid. 1 HNMR (400 MHz, DMSO- d 6 ) δ ppm 8.58 (s, 1H), 8.53 (d, J = 8.0 Hz, 1H), 7.98 (s, 1H), 7.19 (dd, J = 8.0, 1.6 Hz, 1H), 4.32 (q, J = 6.8 Hz, 2H), 1.32 (t, J = 7.2 Hz, 3H). LCMS m / z 270.8 [M+H] + , t ret = 1.34 minutes [formic acid, 2.5 minutes run time].
[0594] Step 2
[0595] A mixture of ethyl 7-bromoimidazolo[1,2-a]pyridine-2-carboxylate (10 g, 37.2 mmol) and a methanol solution of 7M ammonia (220 mL, 1540 mmol) was added to a sealed tube and heated at 65 °C for 18 hours. The solvent was removed under vacuum to give 7-bromoimidazolo[1,2-a]pyridine-2-carboxamide (9 g, 81%), which was a brown solid. 1 H NMR (400 MHz, DMSO- d 6 ) δ ppm 8.55 (d, J = 7.2Hz, 1H), 8.37 (s, 1H), 7.90 (d, J = 0.8 Hz, 1H), 7.73 (s, 1H), 7.47 (s, 1H), 7.16 (dd, J = 7.4, 1.8 Hz, 1H). LCMS m / z 239.8, 241.8 [M+H] + , t ret =1.16 minutes [formic acid, 2.5 minutes run time].
[0596] Step 3
[0597] A solution of 7-bromoimidazolo[1,2-a]pyridine-2-carboxamide (9 g, 30.0 mmol) in pyridine (180 mL) was cooled to -20 °C, and pure 2,2,2-trifluoroacetic anhydride (15.75 g, 75.0 mmol) was added dropwise. After the addition was complete, the reaction was allowed to warm to room temperature and stirred for 1 hour. The reaction mixture was diluted with EtOAc and washed with 1.0 M NaOH aqueous solution. The aqueous layer was then extracted with EtOAc (3 × 300 mL), and the combined organic phases were dried over MgSO4. The solvent was removed under vacuum to give 7-bromoimidazolo[1,2-a]pyridine-2-carboxynitrile (7.5 g, 96%) as a yellow solid. 1 H NMR (400 MHz, DMSO- d 6 ) δ ppm 8.80 (s, 1H), 8.58 (d, J = 7.2 Hz, 1H), 8.05 (s, 1H), 7.27 (dd, J = 7.4, 1.4 Hz, 1H). LCMS m / z 222.1 [M+H] + , t ret = 1.38 minutes [formic acid, 2.5 minutes run time].
[0598] Step 4
[0599] Hydrazine hydrate (117 g, 2342 mmol) was added to a solution of 7-bromoimidazolo[1,2-a]pyridine-2-carboxynitrile (13 g, 58.5 mmol) in methanol (200 mL) at room temperature. The reaction was stirred at room temperature for 18 h, and the resulting suspension was filtered. The collected solid was washed with EtOAc, and the filtrate was concentrated under reduced pressure. The previously collected solid was combined with the concentrate and then dried under vacuum to give 7-bromoimidazolo[1,2-a]pyridine-2-methylimine hydrazide (carboximidohydrazide) (12 g, 81%), which was a beige solid. 1 H NMR (400 MHz, DMSO- d 6 ) δ ppm 8.50 (d, J = 7.2 Hz, 1H), 8.07 (s, 1H), 7.83 (s, 1H), 7.08 (dd, J = 7.2, 1.8 Hz, 1H), 5.58 (s, 2H), 5.13 (s, 2H). LCMS m / z 253.8 [M+H] + , t ret = 1.01 minutes [formic acid, 2.5 minutes run time].
[0600] Step 5
[0601] To a solution of 7-bromoimidazolo[1,2-a]pyridine-2-methyliminohydrazide (12 g, 47.2 mmol) in THF (250 mL), 2,2,2-trifluoroacetic anhydride (24.80 g, 118 mmol) was added dropwise at room temperature. After the addition was complete, the reaction mixture was heated at 90 °C for 18 hours. The reaction mixture was then cooled to room temperature, and the solvent was removed under reduced pressure to give a residue, which was washed with DCM (3 × 200 mL) to give 7-bromo-2-(3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)imidazo[1,2-a]pyridine (12 g, 77%) as a white solid. 1 H NMR (400 MHz, DMSO- d 6 ) δ ppm 15.63 (s, 1H), 8.65 (s, 1H), 8.62 (d, J = 7.2 Hz, 1H), 8.00 (s, 1H), 7.24 (dd, J= 7.2, 1.6 Hz, 1H). LCMS m / z 331.7, 333.7 [M+H] + , t ret = 1.45 minutes [formic acid, 2.5 minutes run time].
[0602] Step 6
[0603] A solution of 7-bromo-2-(3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)imidazo[1,2-a]pyridine (12 g, 36.1 mmol) in acetonitrile (220 mL) was added to a three-necked round-bottom flask equipped with a magnetic stir bar, thermocouple, nitrogen inlet tube, and cooling ice bath. N-iodosuccinimide (9.76 g, 43.4 mmol) was added in portions to the stirred solution at 0 °C. The resulting yellow suspension was allowed to warm to room temperature and stirred for 18 hours. The precipitate was collected by filtration, washed with acetonitrile (3 × 80 mL), and purified by silica gel column chromatography (2:1 to 3:4 petroleum ether / ethyl acetate) to give 7-bromo-3-iodo-2-(3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)imidazo[1,2-a]pyridine (10 g, 60.4%), which is a white solid. 1 HNMR (400 MHz, DMSO- d 6 ) δ ppm 15.67 (s, 1H), 8.46 (d, J = 7.6 Hz, 1H), 8.04 (s, 1H), 7.31 (dd, J = 7.2, 1.6 Hz, 1H). LCMS m / z 457.5, 459.5 [M+H] + , t ret = 1.59 minutes [formic acid, 2.5 minutes run time].
[0604] Step 7
[0605] A mixture of 7-bromo-3-iodo-2-(3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)imidazo[1,2-a]pyridine (3 g, 6.55 mmol), (1H-pyrazol-4-yl)boronic acid (1.099 g, 9.83 mmol), PdCl2(PPh3)2 (1.839 g, 2.62 mmol) and K2CO3 (2.72 g, 19.65 mmol) in 1,4-dioxane (50 mL) and water (5 mL) was stirred at 110 °C for 24 hours under nitrogen. The reaction mixture was cooled to room temperature and concentrated under reduced pressure to obtain a residue, which was purified by silica gel column chromatography (20:1 to 0:100 petroleum ether / ethyl acetate) to obtain a crude solid. This crude solid was further purified by preparative HPLC to obtain 7-bromo-3-(1H-pyrazol-4-yl)-2-(3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)imidazo[1,2-a]pyridine (30 mg 1.2%), which was a white solid. 1 H NMR (400 MHz, DMSO- d 6 ) δ ppm 15.50 (s, 1H), 8.39 (d, J = 7.6 Hz, 1H), 8.21 (s, 2H), 8.02 (s, 1H), 7.18 (dd, J = 7.2, 1.6 Hz, 1H), the 1H signal was not observed. LCMS m / z 398.1, 400.0 [M+H] + , t ret = 0.82 minutes [formic acid].
[0606] Example 13
[0607] 3-(1H-imidazol-4-yl)-2-(3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)imidazo[1,2-a]pyridine
[0608] Step 1
[0609] Sodium bicarbonate (166 mg, 1.978 mmol) was added to a mixture of pyridine-2-amine (203 mg, 2.158 mmol) and 2-chloro-1-(1-(4-methoxybenzyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)ethyl-1-one (intermediate 3) (600 mg, 1.798 mmol) in 1-butanol (10 mL). The reaction mixture was heated at 80 °C for 18 hours and then cooled to room temperature. The reaction mixture was diluted with water and extracted with EtOAc. The combined extracts were evaporated to the residue, which was then suspended in a mixture of MeOH / water (1:4 v / v) to obtain a suspension, which was then filtered. The collected solid was thoroughly washed with water and dried to obtain 2-(1-(4-methoxybenzyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)imidazo[1,2-a]pyridine (500 mg, 74.5%), which was a white solid. 1 H NMR (400 MHz, DMSO- d 6 ) δ ppm 8.73 (s, 1H), 8.64 (d, J =6.84 Hz, 1H), 7.76 (d, J = 9.12 Hz, 1H), 7.42 (ddd, J = 9.06, 6.91, 1.01 Hz, 1H), 7.36(d, J = 8.62 Hz, 2H), 7.04-7.13 (m, 1H), 6.90 (d, J = 8.62 Hz, 2H), 6.16 (s, 2H), 3.71 (s, 3H). LCMS m / z 374.1 [M+H] + , t ret = 1.09 minutes [TFA].
[0610] Step 2
[0611] N-iodosuccinimide (542 mg, 2.411 mmol) was added to a solution of 2-(1-(4-methoxybenzyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)imidazo[1,2-a]pyridine (500 mg, 1.339 mmol) in DCM (20 mL) at 35 °C. Stirring was continued at the same temperature for 12 hours, and the reaction mixture was then diluted with a saturated aqueous solution of NaHCO3 and extracted with DCM. The organic extract was evaporated to a residue, which was purified by silica gel chromatography (0-35% EtOAc / hexane) to give 3-iodo-2-(1-(4-methoxybenzyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)imidazo[1,2-a]pyridine (530 mg, 75%) as a white solid. 1 H NMR (400 MHz, DMSO- d 6 ) δ ppm 8.54 (d, J = 6.5 Hz, 1H), 7.80 (d, J = 8.9 Hz, 1H), 7.52 (ddd, J = 9.1, 6.8, 1.3 Hz, 1H), 7.36-7.28 (m, 2H), 7.22 (td, J = 6.8, 1.3 Hz, 1H), 6.92-6.87 (m, 2H), 6.03 (s, 2H), 3.71 (s, 3H). LCMS m / z 500.1 [M+H] + , t ret = 1.29 minutes [TFA].
[0612] Step 3
[0613] A suspension of 3-iodo-2-(1-(4-methoxybenzyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)imidazo[1,2-a]pyridine (520 mg, 1.042 mmol) and N,N-dimethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborhecyclopentan-2-yl)-1H-imidazo-1-sulfonamide (intermediate 2) (408 mg, 1.354 mmol) in DME (10 mL) was added to the mixture. Pd(dppf)Cl2-CH2Cl2 adduct (85 mg, 0.104 mmol) and CsF (316 mg, 2.083 mmol) were added to the mixture. The reaction flask was sealed with an aluminum cap and then heated at 110 °C for 35 minutes with stirring. The reaction mixture was filtered through diatomaceous earth and washed with MeOH. The filtrate was evaporated to a brown residue, which was ground with MeOH / Et2O (1:8 v / v) to give crude 4-(2-(1-(4-methoxybenzyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)imidazo[1,2-a]pyridin-3-yl)-N,N-dimethyl-1H-imidazol-1-sulfonamide (700 mg), a brown solid, which was used directly in the next step without purification. 1 H NMR (400 MHz, DMSO- d 6 ) δ ppm 9.17 (d, J = 7.4Hz, 1H), 8.51 (s, 1H), 8.34 (s, 1H), 7.85 (d, J = 9.1 Hz, 1H), 7.54 (br. d, J = 16.0Hz, 1H), 7.38 (d, J = 8.6 Hz, 2H), 7.18 (t, J = 6.5 Hz, 1H), 6.90 (d, J = 8.6 Hz, 2H), 5.97 (s, 2H), 3.72 (s, 3H), 2.86 (s, 6H). LCMS m / z 547.2 [M+H] + , t ret = 1.28 minutes [TFA].
[0614] Step 4
[0615] A suspension of 4-(2-(1-(4-methoxybenzyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)imidazo[1,2-a]pyridin-3-yl)-N,N-dimethyl-1H-imidazol-1-sulfonamide (700 mg, 1.281 mmol) in TFA (20 mL) was added to a microwave-safe flask equipped with a stir bar. The flask was sealed with an aluminum cap and heated at 72 °C for 3 days with stirring. The reaction mixture was cooled to room temperature and evaporated under reduced pressure to an oil, which was then evaporated twice from DCM. The resulting residue was purified by reversed-phase HPLC (MDAP method B). The target fractions were combined, neutralized with ammonium hydroxide, and evaporated under reduced pressure to give 3-(1H-imidazol-4-yl)-2-(3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)imidazo[1,2-a]pyridine (150 mg, 35.6%), a white solid. 1 H NMR (400 MHz, DMSO- d 6 ) δ ppm 15.73-15.33 (br s, 1H), 12.85-12.47 (br s, 1H), 9.64 (d, J = 6.3 Hz, 1H), 8.39 (s, 1H), 8.01 (d, J = 1.3 Hz, 1H), 7.71 (d, J = 9.1 Hz, 1H), 7.45 (ddd, J = 9.1, 6.6, 1.3 Hz, 1H), 7.09 (td, J = 6.8, 1.3 Hz, 1H). LCMS m / z 320.1 [M+H] + , t ret = 0.49 minutes [formic acid].
[0616] Example 14
[0617] 8-Fluoro-3-(1H-imidazol-4-yl)-7-methyl-2-(3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)imidazo[1,2-a]pyridine trifluoroacetate
[0618] Step 1
[0619] Sodium bicarbonate (263 mg, 3.13 mmol) was added to a mixture of 3-fluoro-4-methylpyridin-2-amine (431 mg, 3.42 mmol) and 2-chloro-1-(1-(4-methoxybenzyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)ethyl-1-one (intermediate 3) (950 mg, 2.85 mmol) in 1-butanol (10 mL). The reaction mixture was heated at 85 °C for 18 hours with stirring. The resulting suspension was cooled and filtered, and the collected solids were washed with a mixture of MeOH and water (1:1 v / v). The solid was ground with MeOH / EtOAc (8:1 v / v) to give 8-fluoro-2-(1-(4-methoxybenzyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)-7-methylimidazo[1,2-a]pyridine (270 mg, 22.2%), which was a white solid. 1 HNMR (400 MHz, DMSO- d 6 ) δ ppm 8.75 (d, J = 2.8 Hz, 1H), 8.41 (d, J = 6.8 Hz, 1H), 7.38 (d, J = 8.9 Hz, 2H), 6.99 (t, J = 6.6 Hz, 1H), 6.91 (d, J = 8.9 Hz, 2H), 6.12 (s, 2H), 3.71 (s, 3H), 2.35 (d, J = 2.3 Hz, 3H). LCMS m / z 406.2 [M+H] + , t ret = 1.28 minutes [TFA].
[0620] Step 2
[0621] N-iodosuccinimide (225 mg, 0.999 mmol) was added to a solution of 8-fluoro-2-(1-(4-methoxybenzyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)-7-methylimidazo[1,2-a]pyridine (270 mg, 0.666 mmol) in DCM (10 mL). The reaction mixture was heated at 30 °C for 18 hours with stirring. The solvent was removed by evaporation, and the resulting yellow residue was ground with MeOH / water (1:1 v / v) to give 8-fluoro-3-iodo-2-(1-(4-methoxybenzyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)-7-methylimidazo[1,2-a]pyridine (300 mg, 81%), which is a white solid. 1 HNMR (400 MHz, DMSO- d 6 ) δ ppm 8.33 (d, J = 6.8 Hz, 1H), 7.39 – 7.32 (m, 2H), 7.14(t, J = 6.7 Hz, 1H), 6.92 – 6.88 (m, 2H), 5.99 (s, 2H), 3.71 (s, 3H), 2.39 (d, J = 2.3Hz, 3H). LCMS m / z 532.3 [M+H] + , t ret = 1.38 minutes [TFA].
[0622] Step 3
[0623] To a solution of 8-fluoro-3-iodo-2-(1-(4-methoxybenzyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)-7-methylimidazo[1,2-a]pyridine (580 mg, 1.092 mmol) and N,N-dimethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborhecyclopentan-2-yl)-1H-imidazol-1-sulfonamide (intermediate 2) (395 mg, 1.310 mmol) in DME (20 mL), Pd(dppf)Cl2-CH2Cl2 adduct (89 mg, 0.109 mmol) and CsF (332 mg, 2.184 mmol) were added. The reaction mixture was heated at 110 °C for 45 minutes, then cooled and filtered. The solid was washed with MeOH and dried to give 4-(8-fluoro-2-(1-(4-methoxybenzyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)-7-methylimidazo[1,2-a]pyridin-3-yl)-N,N-dimethyl-1H-imidazo-1-sulfonamide (313 mg), which was a white solid and was used without purification. 1 H NMR (400 MHz, DMSO- d 6 ) δ ppm 8.98 (br. d, J = 7.1 Hz, 1H), 8.52 (s, 1H), 8.38 (s, 1H), 7.43 (br. d, J = 8.6 Hz, 2H), 7.09 (br. t, J = 6.7 Hz, 1H), 6.91(br. d, J = 8.1 Hz, 2H), 5.93 (s, 2H), 3.72 (s, 3H), 2.86 (s, 6H), 2.40 (br s, 3H). LCMSm / z 579.3 [M+H] + , t ret = 1.40 minutes [TFA].
[0624] Step 4
[0625] A solution of 4-(8-fluoro-2-(1-(4-methoxybenzyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)-7-methylimidazo[1,2-a]pyridin-3-yl)-N,N-dimethyl-1H-imidazo-1-sulfonamide (313 mg, 0.541 mmol) in TFA (5 mL) was heated at 70 °C for 18 hours. The reaction was evaporated under reduced pressure to the residue, which was purified by reversed-phase HPLC (MDAP method E). The target fractions were combined and concentrated under reduced pressure to give 8-fluoro-3-(1H-imidazo-4-yl)-7-methyl-2-(3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)imidazo[1,2-a]pyridine trifluoroacetate (30 mg, 11.3%), a white solid. 1 H NMR (400 MHz, DMSO- d 6 ) δ ppm 15.89 (br s, 1H), 12.66 (br s, 1H), 9.42 (br d, J = 7.1 Hz, 1H), 8.42 (s, 1H), 8.01 (d, J = 1.3 Hz, 1H), 7.41 – 7.22 (m, 1H), 6.99 (t, J = 7.0 Hz, 1H), 2.37 (d, J = 2.3 Hz, 3H). LCMS m / z 352.0 [M+H] + , t ret =0.59 minutes [formic acid].
[0626] Example 15
[0627] 3-(1H-imidazol-5-yl)-2-(3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)imidazo[1,2-a]pyridine-8-carboxynitrile
[0628] Step 1
[0629] A solution of 3-(trifluoromethyl)-1H-1,2,4-triazol-5-amine (100 g, 658 mmol) in acetic acid (320 mL) was stirred at 5 °C and then treated with hydrochloric acid (80 mL, 960 mmol). A solution of sodium nitrite (54.4 g, 789 mmol) in water (320 mL) was added dropwise, and the reaction mixture was stirred for 20 minutes. The resulting diazonium salt solution was added dropwise to a stirred solution of copper(II) bromide (294 g, 1315 mmol) in water (1.0 L) cooled to 0 °C, maintaining an internal temperature below 5 °C. The reaction mixture was then allowed to warm to room temperature over 2 hours with stirring. The reaction mixture was diluted with water and extracted with ethyl acetate (3 times). The organic extract was washed twice with water and brine, dried over Mg2SO4, and evaporated to a wet oil, which was then azeotropically reacted with ethanol to give crude oil 5-bromo-3-(trifluoromethyl)-1H-1,2,4-triazole (118.5 g, 83%). LCMS m / z 215.9, 217.9 [M+H] + , t ret = 0.68 minutes [TFA].
[0630] Step 2
[0631] A suspension of potassium carbonate (151 g, 1093 mmol) and 5-bromo-3-(trifluoromethyl)-1H-1,2,4-triazole (118 g, 546 mmol) in 2-butanone (500 mL) was added over 10 minutes with vigorous stirring at 55 °C. The reaction mixture was stirred at the same temperature for 1 hour, then cooled, filtered, and evaporated under reduced pressure to give crude 5-bromo-1-(methoxymethyl)-3-(trifluoromethyl)-1H-1,2,4-triazole (95 g, 66.9%) as a clear oil. This mixture of isomers was used without purification. 1 H NMR (400 MHz, CDCl3) δppm 3.47 - 3.54 (m, 3H) 5.52 - 5.63 (m, 2H). LCMS m / z 260.1, 262.1 [M+H] + , t ret =0.86 minutes [TFA].
[0632] Step 3
[0633] Under nitrogen atmosphere, a THF solution (1.3 M, 800 mL, 1040 mmol) of isopropyl magnesium chloride-lithium chloride complex was added dropwise over 30 minutes to a stirred solution of 5-bromo-1-(methoxymethyl)-3-(trifluoromethyl)-1H-1,2,4-triazole (208 g, 800 mmol) in 2-methyltetrahydrofuran (1600 mL) at -10 °C. The dark mixture was stirred at -10 °C for 30 minutes and then treated with a solution of 2-chloro-N-methoxy-N-methylacetamide (143 g, 1040 mmol) in 2-methyltetrahydrofuran (800 mL), maintaining an internal temperature below -5 °C. The reaction mixture was allowed to warm to ambient temperature over 30 minutes and then quenched with a dilute ammonium chloride solution (1000 mL). The mixture was separated, and the aqueous solution was extracted twice with EtOAc. The combined organic extracts were washed with water and brine, dried over Mg2SO4, and concentrated under vacuum. Purification was performed by silica gel rapid chromatography (10% EtOAc in heptane solution) to give 2-chloro-1-(1-(methoxymethyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)ethyl-1-one (92.2 g, 44.7%). 1 H NMR (400 MHz, CDCl3) δ ppm 5.93 (s, 2H), 4.99 (s, 2H), 3.50 (s, 3H). LCMS m / z 515.4, 517.2 [2M+H] + , t ret = 0.82 minutes [NH4HCO3].
[0634] Step 4
[0635] A suspension of 3-bromopyridin-2-amine (15 g, 87 mmol), sodium bicarbonate (5 g, 59.5 mmol), and 2-chloro-1-(1-(methoxymethyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)ethyl-1-one (20.0 g, 78 mmol) in 1-butanol (200 mL) was stirred at 90 °C for 1 h, followed by stirring at 60 °C for 18 h. The reaction mixture was filtered while hot to remove sodium bicarbonate solids and concentrated. The residue was absorbed with dichloromethane and adsorbed onto silica gel. Purification by rapid silica gel chromatography (0-15% EtOAc in DCM solution) yielded 8-bromo-2-(1-(methoxymethyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)imidazo[1,2-a]pyridine (11.0 g, 37.7%). 1 H NMR (400 MHz, CDCl3) δppm 8.44 (s, 1H), 8.21 (dd,J = 6.6, 1.0 Hz, 1H), 7.60 (dd, J = 7.4, 1.0 Hz, 1H), 6.84(t, J = 6.9 Hz, 1H), 6.37 (s, 2H), 3.58 (s, 3H). LCMS m / z 376.0, 378.0 [M+H] + , t ret =1.04 minutes [formic acid].
[0636] Step 5
[0637] A mixture of 8-bromo-2-(1-(methoxymethyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)imidazo[1,2-a]pyridine (10.6 g, 28.2 mmol) and N-iodosuccinimide (7.61 g, 33.8 mmol) in chloroform (200 mL) was stirred at 75 °C for 24 hours. The reaction was not yet complete, so additional N-iodosuccinimide was added and the reaction was heated to completion. The reaction mixture was cooled, diluted with chloroform, and washed with water. The two phases were separated, and the aqueous phase was extracted with chloroform. The combined organic phases were washed with a 15% sodium thiosulfate aqueous solution, dried (Mg2SO4), and evaporated under reduced pressure. The resulting solid was slurried with diethyl ether, collected, washed with diethyl ether and hexane, and dried to give 8-bromo-3-iodo-2-(1-(methoxymethyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)imidazo[1,2-a]pyridine (12.0 g, 85%). 1 H NMR (400 MHz, CDCl3) δ ppm 8.35 (dd, J = 6.8, 1.0 Hz, 1H), 7.69 (dd, J = 7.4, 1.0 Hz, 1H), 6.98 (t, J = 7.1 Hz, 1H), 6.33 (s, 2H), 3.55 (s, 3H). LCMS m / z 501.9, 504.0 [M+H] + , t ret = 1.21 minutes [formic acid].
[0638] Step 6
[0639] A mixture of 8-bromo-3-iodo-2-(1-(methoxymethyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)imidazo[1,2-a]pyridine (12 g, 23.9 mmol), N,N-dimethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborhecyclopentan-2-yl)-1H-imidazol-1-sulfonamide (intermediate 2) (12.48 g, 41.4 mmol), potassium phosphate (7.44 g, 35.1 mmol), and Pd(dppf)Cl2 (1.399 g, 1.912 mmol) in 1,4-dioxane (200 mL) was purged with nitrogen and heated at 120 °C for 24 hours. The reaction mixture was cooled, filtered, and evaporated to a residue, which was purified by rapid silica gel chromatography (15-45% ethyl acetate in heptane) to give 4-(8-bromo-2-(1-(methoxymethyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)imidazo[1,2-a]pyridin-3-yl)-N,N-dimethyl-1H-imidazol-1-sulfonamide (7.1 g, 54.1%). 1 H NMR (400 MHz, CDCl3) δ ppm 9.34 (dd, J = 7.1, 1.0 Hz, 1H), 8.61(d, J = 1.3 Hz, 1H), 8.10 (d, J = 1.3 Hz, 1H), 7.67 (dd, J = 7.4, 1.0 Hz, 1H), 6.88 (t, J = 7.1 Hz, 1H), 6.38 (s, 2H), 3.56 (s, 3H), 3.03 (s, 6H). LCMS m / z 549.2, 551.2 [M+H] + , t ret = 1.25 minutes [TFA].
[0640] Step 7
[0641] A mixture of 4-(8-bromo-2-(1-(methoxymethyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)imidazo[1,2-a]pyridin-3-yl)-N,N-dimethyl-1H-imidazol-1-sulfonamide (820 mg, 1.493 mmol), tris(dibenzylacetone)dipalladium(0) (137 mg, 0.149 mmol), 1,1'-bis(diphenylphosphino)ferrocene (83 mg, 0.149 mmol) and zinc cyanide (175 mg, 1.493 mmol) in DMF (12 mL) was purged with nitrogen and heated at 120 °C for 24 hours. The reaction mixture was cooled, diluted with water, and extracted with DCM. The organic extract was filtered through a Celite filter and evaporated to the residue, which was then purified by rapid silica gel chromatography (40 g column, using a heptane solution of 0-50% ethyl acetate as the eluent) to give 4-(8-cyano-2-(1-(methoxymethyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)imidazo[1,2-a]pyridin-3-yl)-N,N-dimethyl-1H-imidazo-1-sulfonamide (356 mg, 48.1%) as a yellow solid. 1 H NMR (400 MHz, DMSO- d 6 ) δ ppm 9.47 (dd, J = 7.2, 1.1 Hz, 1H), 8.56 (d, J = 1.3 Hz, 1H), 8.49 (d, J = 1.3 Hz, 1H), 8.27 (dd, J = 7.1, 1.0 Hz, 1H), 7.32 (t, J = 7.1 Hz, 1H), 6.13 (s, 2H), 3.42 (s, 3H), 2.89 (s, 6H). LCMS m / z 496.1 [M+H] + , t ret = 1.14 minutes [formic acid].
[0642] Step 8
[0643] A mixture of 4-(8-cyano-2-(1-(methoxymethyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)imidazo[1,2-a]pyridin-3-yl)-N,N-dimethyl-1H-imidazo-1-sulfonamide (45 mg, 0.091 mmol) and 3M HCl in CPME (5.0 mL, 15.00 mmol) was stirred at 60 °C for 18 h. The reaction mixture was evaporated under reduced pressure and the resulting residue was purified by reversed-phase HPLC (0-99% aqueous solution of acetonitrile containing 0.1% formic acid) to give 3-(1H-imidazo-5-yl)-2-(3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)imidazo[1,2-a]pyridin-8-carboxynitrile (8 mg, 25.3%). 1 HNMR (400 MHz, DMSO- d 6 ) δ ppm 15.61 (br s, 1H), 12.78 (br s, 1H), 9.93 (br d, J =7.4 Hz, 1H), 8.42 (s, 1H), 8.18 (dd, J = 7.1, 1.0 Hz, 1H), 8.04 (d, J = 1.0 Hz, 1H), 7.25 (t, J = 7.2 Hz, 1H). LCMS m / z 345.1 [M+H] + , t ret = 0.54 minutes [formic acid].
[0644] Example 16
[0645] 6,7-Difluoro-3-(1H-imidazol-4-yl)-2-(3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)imidazo[1,2-a]pyridine
[0646] Step 1
[0647] A mixture of 4,5-difluoropyridin-2-amine (300 mg, 2.306 mmol) and 2-chloro-1-(1-(4-methoxybenzyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)ethyl-1-one (intermediate 3) (923 mg, 2.77 mmol) in propionitrile (3 mL) was added to a microwave-safe reaction flask equipped with a stir bar. The reaction mixture was sealed with an aluminum pressure cap and then microwave-treated at 175 °C for 2 hours. The reaction mixture was diluted with EtOAc, washed with a saturated aqueous solution of NaHCO3 and brine, and then evaporated under reduced pressure. The residue was purified by silica gel rapid chromatography (0-40% ethyl acetate in heptane solution) to give 6,7-difluoro-2-(1-(4-methoxybenzyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)imidazo[1,2-a]pyridine (555 mg, 58.8%). 1 H NMR (400 MHz, CDCl3) δ ppm 8.30 – 8.25 (m, 1H), 8.25 – 8.21 (m, 1H), 7.49 – 7.46 (m, 1H), 7.45 – 7.39 (m, 2H), 6.86 (d, J = 7.7 Hz, 2H), 6.12 (s, 2H), 3.79 (s, 3H). LCMS m / z 410.1 [M+H] + , t ret = 1.20 minutes [TFA].
[0648] Step 2
[0649] A mixture of 6,7-difluoro-2-(1-(4-methoxybenzyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)imidazo[1,2-a]pyridine (547 mg, 1.336 mmol) and N-iodosuccinimide (361 mg, 1.604 mmol) in chloroform (10 mL) was stirred at 50 °C for 18 hours. The reaction mixture was washed with an aqueous solution of sodium thiosulfate, and the aqueous phase was then extracted with chloroform. The combined organic extracts were evaporated to the residue, which was purified by rapid silica gel chromatography (0-60% ethyl acetate in heptane) to give 6,7-difluoro-3-iodo-2-(1-(4-methoxybenzyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)imidazo[1,2-a]pyridine (421 mg, 58.9%). 1 H NMR (400 MHz, CDCl3) δ ppm 8.40 (dd, J= 7.1, 5.1 Hz, 1H), 7.51 (dd, J = 9.5, 7.1 Hz, 1H), 7.38 – 7.34 (m, 2H), 6.86 – 6.82 (m, 2H), 6.03 (s, 2H), 3.79 (s, 3H). LCMS m / z 536.1 [M+H] + , t ret = 1.33 minutes [TFA].
[0650] Step 3
[0651] A suspension of 6,7-difluoro-3-iodo-2-(1-(4-methoxybenzyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)imidazo[1,2-a]pyridine (410 mg, 0.766 mmol), N,N-dimethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborhecyclopentan-2-yl)-1H-imidazol-1-sulfonamide (intermediate 2) (346 mg, 1.149 mmol), cesium fluoride (233 mg, 1.532 mmol), and Pd(dppf)Cl2 (84 mg, 0.115 mmol) in DME (10 mL) was added to a microwave reaction flask equipped with a stir bar. The container was sealed with an aluminum pressure cap and then microwaved at 120 °C for 2 hours. The reaction mixture was filtered through diatomaceous earth and then evaporated to the residue, which was purified by rapid silica gel chromatography (0-50% ethyl acetate in heptane) to give 4-(6,7-difluoro-2-(1-(4-methoxybenzyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)imidazo[1,2-a]pyridin-3-yl)-N,N-dimethyl-1H-imidazol-1-sulfonamide (140 mg, 31.4%). 1 H NMR (400 MHz, CDCl3) δ ppm 9.61 (dd, J = 7.2, 6.0 Hz, 1H), 8.58 (d, J = 1.5 Hz, 1H), 8.07 (d, J = 1.5 Hz, 1H), 7.48 (dd, J = 9.5, 7.6 Hz, 1H), 7.39 – 7.34 (m, 2H), 6.83 (d, J = 7.7 Hz, 2H), 6.08 (s, 2H), 3.78 (s, 3H), 2.98 (s, 6H). LCMS m / z583.1 [M+H] + , t ret = 1.39 minutes [TFA].
[0652] Step 4
[0653] A mixture of 4-(6,7-difluoro-2-(1-(4-methoxybenzyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)imidazo[1,2-a]pyridin-3-yl)-N,N-dimethyl-1H-imidazo-1-sulfonamide (135 mg, 0.232 mmol) in TFA (5 mL) was heated at 70 °C for 4 hours. The reaction was evaporated to the residue, which was purified by reversed-phase HPLC (5-75% acetonitrile-water / 0.1% TFA). The target fractions were combined, neutralized with dilute ammonium hydroxide, and evaporated under reduced pressure to give 6,7-difluoro-3-(1H-imidazo-4-yl)-2-(3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)imidazo[1,2-a]pyridine (10 mg, 11.8%). 1 H NMR (400 MHz, DMSO- d 6 ) δ ppm 15.63 (br s, 1H), 13.14 (br s, 1H), 9.84 (brs, 1H), 8.44 (s, 1H), 8.35 (br s, 1H), 7.92 (dd, J = 10.8, 7.3 Hz, 1H). LCMS m / z 356.0 [M+H] + , t ret = 0.56 minutes [formic acid].
[0654] Example 17
[0655] 3-(1H-imidazol-5-yl)-2-(3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)-6,7-dihydro-5H,9H-imidazo[2,1-c][1,4]oxazolidinyl heptacycline, 2,7-trifluoroacetate
[0656] Step 1
[0657] A solution of 3-aminoprop-1-ol (20 g, 266 mmol) and K₂CO₃ (110 g, 799 mmol) in tetrahydrofuran (THF) (150 mL) and water (30.0 mL) was cooled to 0 °C. 2-chloroacetyl chloride (23.30 mL, 293 mmol) was added dropwise, and the mixture was gradually heated to room temperature overnight with stirring. LCMS analysis showed the formation of the desired product. The reaction mixture was slightly concentrated to remove the organic solvent. The crude mixture was extracted with a solution of 10 / 1 DCM / MeOH (6 × 15 mL), the combined organic phases were washed with brine (15 mL), dried over Na₂SO₄, filtered, and concentrated to give a colorless oil, 2-chloro-N-(3-hydroxypropyl)acetamide (20 g, 124 mmol, 46.6% yield). 1 ¹H NMR (400 MHz, CDCl₃) δ ppm 7.28 – 7.16 (m, 1H), 4.05 (s, 2H), 3.68 (t, J = 5.6 Hz, 2H), 3.46 (q, J = 6.2 Hz, 2H), 1.81 – 1.69 (m, 2H), no ¹H signal observed. LCMS m / z 152.0, 154.0 [M+H] + , t ret = 0.27 minutes [TFA].
[0658] Step 2
[0659] A mixture of KOtBu (44.4 g, 396 mmol) in HOBut (20.00 mL) was added to a solution of 2-chloro-N-(3-hydroxypropyl)acetamide (20 g, 132 mmol) in tetrahydrofuran (THF) (40 mL). The reaction was stirred at room temperature for 6 hours; LCMS analysis showed formation of the desired product. The mixture was concentrated to dryness. The residue was adsorbed onto silica gel (~25 g) and purified by rapid column chromatography (100 g column) using 10 / 1 DCM / MeOH as eluent. The target fractions were combined and concentrated to give 1,4-oxazetane-hepta-3-one (20 g, 113 mmol, 86% yield). LCMS m / z 116.3 [M+H] + , t ret =0.31 minutes [NH4HCO3].
[0660] Step 3
[0661] To a 500 mL flask, add 1,4-oxazacycloheptan-3-one (3 g, 26.1 mmol), P2S5 (8.69 g, 39.1 mmol), and toluene (100 mL). Stir the reaction mixture at 90 °C for 5 h; LCMS analysis showed formation of the desired product. Quench the reaction mixture with 100 mL of NaHCO3 aqueous solution, filter, and wash the filter cake with DCM (3 × 100 mL). Separate the two-phase filtrates, wash the organic phase with brine (100 mL), dry to Na2SO4, filter, and concentrate. Adsorb the residue onto silica gel (~6 g), then purify by rapid column chromatography (80 g) using 20:1 DCM:MeOH as the eluent. Combine the desired fractions and concentrate to give impure 1,4-oxazacycloheptan-3-thione (700 mg, 2.170 mmol), a yellow solid. LCMS m / z 132.1 [M+H] + , t ret = 0.56 minutes [formic acid, 3-minute run time].
[0662] Step 4
[0663] 1,4-oxazacycloheptan-3-thione (800 mg, 6.10 mmol) and ammonia (17.4 mL, 122 mmol, 7N in MeOH) were added to a 20 mL flask, and the reaction mixture was stirred at 25 °C for 17 h. LCMS analysis showed the formation of the desired product. The mixture was concentrated under vacuum. The residue was suspended in MeOH (10 mL), the solid was filtered off, and the filtrate was purified by reversed-phase HPLC (C10). 18 Column, 0-5% MeCN / water). Combine the desired fractions and concentrate to give an impure yellow oil, 2,5,6,7-tetrahydro-1,4-oxazacycloheptatrien-3-amine (190 mg).
[0664] Step 5
[0665] 2,5,6,7-Tetrahydro-1,4-oxazacycloheptatrien-3-amine (100 mg, 0.876 mmol), 2-chloro-1-(1-(4-methoxybenzyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)ethyl-1-one (intermediate 3) (292 mg, 0.876 mmol), TEA (0.122 mL, 0.876 mmol), and acetonitrile (4 mL) were added to a 10 mL microwave-safe reaction flask. The reaction mixture was stirred in a microwave reactor at 130 °C for 1 hour. LC-MS analysis showed the formation of the desired product. The reaction mixture was concentrated under vacuum, and the residue was purified by preparative TLC (1:1 PE:EA) to give impure 2-(1-(4-methoxybenzyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)-6,7-dihydro-5H,9H-imidazo[2,1-c][1,4]oxazolidinyl heptacycline (40 mg), a brown solid. LCMS m / z 394.1 [M+H] + , t ret = 1.59 minutes [formic acid, 3-minute run time].
[0666] Step 6
[0667] Add 2-(1-(4-methoxybenzyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)-6,7-dihydro-5H,9H-imidazo[2,1-c][1,4]oxazolidinyl heptacycline (20 mg, 0.051 mmol), acetic acid (1 mL), and NIS (11.4 mg, 1.0 eq) to a 5 mL flask. The reaction mixture was stirred at 30 °C for 1 hour. LCMS analysis showed that most of the starting material remained. Additional NIS (11.4 mg, 1.0 eq) was added, and the mixture was stirred for 17 hours. LCMS analysis still showed some unreacted starting material. Additional NIS (11.4 mg, 1.0 eq) was added, and the mixture was stirred for 1 hour. LCMS analysis showed that the starting material was consumed and the desired product was formed. The reaction mixture was concentrated under vacuum. The residue was purified by preparative TLC (1:1 PE:EA) to give impure 3-iodo-2-(1-(4-methoxybenzyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)-6,7-dihydro-5H,9H-imidazo[2,1-c][1,4]oxazolidinyl heptacycline (10 mg), which was a yellow oil. LCMS m / z 520.1 [M+H] + , t ret= 0.83 minutes [TFA, 1.8 minutes runtime].
[0668] Step 7
[0669] Add 3-iodo-2-(1-(4-methoxybenzyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)-6,7-dihydro-5H,9H-imidazo[2,1-c][1,4]oxazolidinyl heptatriene (20 mg, 0.039 mmol), N,N-dimethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborhexacyclopentan-2-yl)-1H-imidazo-1-sulfonamide (intermediate 2) (13.92 mg, 0.046 mmol), cesium fluoride (11.70 mg, 0.077 mmol), and Pd(dppf)Cl2.DCM (6.29 mg, 7.70 µmol) to a 10 mL microwave reaction flask. Add 1.0 mL of DME, purge the reaction mixture with nitrogen, and then heat in a microwave reactor at 100 °C for 15 min. LCMS analysis showed the formation of the desired product. The reaction mixture was concentrated under vacuum. The residue was dissolved in 1 mL of MeOH and purified by preparative TLC (20:1 DCM:MeOH) to give impure 4-(2-(1-(4-methoxybenzyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)-6,7-dihydro-5H,9H-imidazo[2,1-c][1,4]oxazolidinyl-3-yl)-N,N-dimethyl-1H-imidazo-1-sulfonamide (10 mg), which was a yellow oil. LCMS m / z 567.1 [M+H] + , t ret = 1.05 minutes [formic acid, 2-minute run time].
[0670] Step 8
[0671] Add 4-(2-(1-(4-methoxybenzyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)-6,7-dihydro-5H,9H-imidazo[2,1-c][1,4]oxazolidinyl-heptatrien-3-yl)-N,N-dimethyl-1Himidazo-1-sulfonamide (10 mg, 0.018 mmol) and trifluoroacetic acid (TFA) (1 mL) to an 8 mL flask. Stir the reaction mixture at 80 °C for 2 hours. LCMS analysis showed the formation of the desired product. Concentrate the reaction mixture under vacuum. Dissolve the residue in DMF (1 mL) and purify by reversed-phase HPLC (XBridge Shield RP18 OBD column, eluent: 5%–40% ACN aqueous solution containing 0.05% TFA). The fractions were combined and concentrated to give 3-(1H-imidazol-5-yl)-2-(3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)-6,7-dihydro-5H,9H-imidazo[2,1-c][1,4]oxazolidinyl heptadiene, 2,7-trifluoroacetate (1.4 mg), which is a white solid. 1 H NMR (300 MHz, DMSO- d 6 δ ppm 8.50 (s, 1H), 7.90 (s, 1H), 4.76 (s, 2H), 4.35 (m, 2H), 4.01 (m, 2H), 1.90 (m, 2H), no 2H signal observed. LCMS m / z 340.1 [M+H] + , t ret = 0.67 minutes [TFA, 3-minute run time].
[0672] Example 18
[0673] 3-(1H-imidazol-4-yl)-2-(3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)imidazo[1,2-a]pyrazine
[0674] Step 1
[0675] Pyrazin-2-amine (200 mg, 2.103 mmol) and 2-chloro-1-(1-(4-methoxybenzyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)ethyl-1-one (intermediate 3) (842 mg, 2.52 mmol) were mixed in MeTHF (10 mL). The reaction mixture was stirred at 100 °C for 16 hours. The reaction was repeated once on the same scale. The combined reaction mixture was partitioned between a saturated aqueous solution of NaHCO3 and DCM. The organic layer was washed with brine, dried over MgSO4, and concentrated to give a brown residue. The residue was purified by Isco Combiflash (40 g RediSep column, eluent 5%–50% (3:1 EtOAc / EtOH, containing 1% NEt3) / hexane). The fractions containing the product were combined and concentrated to give impure 2-(1-(4-methoxybenzyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)imidazo[1,2-a]pyrazine as a brown solid (340 mg). LCMS m / z 375.2 [M+H] + , t ret = 1.13 minutes [TFA].
[0676] Step 2
[0677] 2-(1-(4-methoxybenzyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)imidazo[1,2-a]pyrazine (340 mg, 0.908 mmol) was dissolved in DCE (10 mL), followed by NBS (323 mg, 1.816 mmol), and then 3 drops of TFA were added. The reaction mixture was stirred at room temperature for 3 hours. The reaction mixture was partitioned between a 1:1 saturated aqueous solution of Na₂S₂O₃ / NaHCO₃ and DCM. The organic layer was washed with brine, dried over MgSO₄, and concentrated to give a brown residue. The residue was purified by Isco Combiflash (40 g RediSep column, eluent 10%–50% (3:1 EtOAc / EtOH) / hexane). The fractions containing the product were combined and concentrated to give impure 3-bromo-2-(1-(4-methoxybenzyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)imidazo[1,2-a]pyrazine as an orange solid (250 mg). LCMS m / z 453.1 / 455.0 [M+H] + , t ret = 1.00 minutes [TFA].
[0678] Step 3
[0679] 3-Bromo-2-(1-(4-methoxybenzyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)imidazo[1,2-a]pyrazine (120 mg, 0.265 mmol), N,N-dimethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborhecyclopentan-2-yl)-1H-imidazol-1-sulfonamide (intermediate 2) (159 mg, 0.530 mmol), PdCl2(dppf)-CH2Cl2 adduct (21.62 mg, 0.026 mmol), and cesium fluoride (80 mg, 0.530 mmol) were mixed in DME (10 mL). The reaction flask was sealed and heated in a Biotage microwave reactor at 110 °C for 30 min. The reaction mixture was cooled to room temperature and filtered. The filtrate was concentrated, and the residue was purified by Isco Combiflash (40 g RediSep column, eluent 10%-80% (3:1 EtOAc / EtOH, containing 1% NET3) / hexane). Fractions containing the product were combined and concentrated to give impure 4-(2-(1-(4-methoxybenzyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)imidazo[1,2-a]pyrazin-3-yl)-N,N-dimethyl-1H-imidazol-1-sulfonamide, a yellow solid (134 mg). LCMS m / z 548.3 [M+H] + , t ret = 1.19 minutes [TFA].
[0680] Step 4
[0681] 4-(2-(1-(4-methoxybenzyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)imidazo[1,2-a]pyrazin-3-yl)-N,N-dimethyl-1H-imidazo-1-sulfonamide (133.8 mg, 0.244 mmol) was dissolved in 2 mL of TFA. The reaction mixture was stirred at 90 °C for 2 h. The reaction mixture was concentrated, and the brown residue was purified by reversed-phase HPLC (MDAP method D). The clean fractions were combined and concentrated to give 3-(1H-imidazo-4-yl)-2-(3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)imidazo[1,2-a]pyrazine as a yellow solid (70 mg, 89% yield). 1¹H NMR (400 MHz, CD3OD) δ ppm 9.23 (d, J=4.82 Hz, 1H), 9.15 (d, J=1.52 Hz, 1H), 8.38 (d, J=1.01 Hz, 1H), 8.09 (s, 1H), 8.00 (d, J=4.82 Hz, 1H), no 2H signal observed. LCMS m / z 321.2 [M+H] + , t ret = 0.39 minutes [TFA].
[0682] Example 19
[0683] 3-(1H-imidazol-4-yl)-2-(3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)imidazo[1,2-b]pyridazine
[0684] Step 1
[0685] A mixture of 2-chloro-1-(1-(4-methoxybenzyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)ethyl-1-one (intermediate 3) (2 g, 5.99 mmol), pyridazine-3-amine (1.140 g, 11.99 mmol), and TEA (1.671 mL, 11.99 mmol) was stirred in acetonitrile (200 mL) at 80 °C for 16 hours. The reaction mixture was cooled to room temperature and concentrated onto diatomaceous earth. The diatomaceous earth sample was dry-loaded and purified by silica gel chromatography (0%–40% DCM solution of 3:1 EtOAc / EtOH). The target fractions were combined and concentrated under vacuum. The final material was dried under high vacuum to obtain 2-(1-(4-methoxybenzyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)imidazo[1,2-b]pyridazine (334 mg, 14% yield), which is an orange oil. 1 H NMR (400 MHz, DMSO- d 6 ) δ ppm 9.03 (s, 1H), 8.69 (dd, 1H, J=1.5, 4.4Hz), 8.3-8.4 (m, 1H), 7.4-7.5 (m, 1H), 7.3-7.4 (m, 2H), 6.9-6.9 (m, 2H), 6.14 (s, 2H), 3.72 (s, 3H). LCMS m / z 375.1 [M+H] + , t ret= 1.10 minutes [TFA].
[0686] Step 2
[0687] A mixture of 2-(1-(4-methoxybenzyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)imidazo[1,2-b]pyridazine (293 mg, 0.783 mmol) and NBS (142 mg, 0.798 mmol) in acetonitrile (16 mL) was stirred at room temperature for 16 hours. The reaction solvent was removed, and the contents were concentrated onto diatomaceous earth and purified by silica gel chromatography (0%–20% DCM solution of 3:1 EtOAc / EtOH). The target fractions were combined and concentrated. The impure fractions were combined and concentrated onto 4:1 diatomaceous earth:silica gel and purified again (0–50% heptane solution of 3:1 EtOAc:EtOH). The target fractions from the two runs were combined and concentrated to give impure 3-bromo-2-(1-(4-methoxybenzyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)imidazo[1,2-b]pyridazine (450 mg), which was a powdery white solid. 1 H NMR (400 MHz, DMSO- d 6 ) δ ppm 8.8-8.8 (m, 1H), 8.38 (dd, 1H, J=1.5, 9.3 Hz), 7.51 (dd, 1H, J=4.4, 9.3 Hz), 7.3-7.4 (m, 2H), 6.9-6.9 (m, 2H), 6.0-6.0 (m, 2H), 3.71 (s, 3H). LCMS m / z 453.0, 455.0 [M+H] + , t ret = 1.16 minutes [TFA].
[0688] Step 3
[0689] A mixture of 3-bromo-2-(1-(4-methoxybenzyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)imidazo[1,2-b]pyridazine (450 mg, 0.993 mmol), N,N-dimethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborhecyclopentan-2-yl)-1H-imidazol-1-sulfonamide (intermediate 2) (314 mg, 1.043 mmol), potassium phosphate (632 mg, 2.98 mmol), and PdCl2(dppf)-CH2Cl2 adduct (81 mg, 0.099 mmol) was bubbled under argon for 5 minutes in 1,4-dioxane (12 mL) and water (4.80 mL). The reaction mixture was kept under argon and heated to 101 °C with stirring for 16 hours. The reaction mixture was partitioned between DCM (100 mL) and water (10 mL). The organic layer was separated and concentrated onto diatomaceous earth, and purified by rapid column chromatography (0%–60% in a (3:1 EtOAc / EtOH) DCM solution). The target fractions were combined and concentrated to give 4-(2-(1-(4-methoxybenzyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)imidazo[1,2-b]pyridazin-3-yl)-N,N-dimethyl-1H-imidazol-1-sulfonamide (324 mg, 57% yield), which is a brown foam. 1 H NMR (400 MHz, CD2Cl2) δ ppm 8.61 (dd, 1H, J=1.5, 4.4 Hz), 8.27 (d, 1H, J=1.0 Hz), 8.1-8.2 (m, 1H), 7.99 (d, 1H, J=1.5 Hz), 7.2-7.3 (m, 3H), 6.8-6.8 (m, 2H), 5.68 (s, 2H), 3.78 (s, 3H), 2.96 (s, 6H). LCMS m / z 548.1 [M+H] + , t ret = 1.11 minutes [TFA].
[0690] Step 4
[0691] 4-(2-(1-(4-methoxybenzyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)imidazo[1,2-b]pyridazin-3-yl)-N,N-dimethyl-1H-imidazol-1-sulfonamide (324 mg, 0.592 mmol) was dissolved in trifluoroacetic acid (TFA) (12 mL) and stirred at 80 °C for 16 h. The reaction solvent was removed under vacuum, and the residue was adsorbed onto diatomaceous earth for purification by column chromatography (C18Aq 100 g column, eluent 5%–100% CH3CN / water, containing 1% NH4OH). The target fractions were combined and concentrated. The material was dried under high vacuum to obtain 3-(1H-imidazol-4-yl)-2-(3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)imidazo[1,2-b]pyridazine (150 mg, 76% yield), which is a granular yellow powder. 1 H NMR (400 MHz, DMSO- d 6 δ ppm 8.79 (br dd, 1H, J=1.7, 4.2 Hz), 8.35 (s, 1H), 8.2-8.3 (m, 2H), 7.40 (dd, 1H, J=4.4, 8.8 Hz), no 2H signal observed. LCMS m / z 321.1 [M+H] + , t ret = 0.51 minutes [TFA].
[0692] Example 20
[0693] 7-Chloro-3-(1H-imidazol-4-yl)-2-(3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)imidazo[1,2-c]pyrimidine
[0694] Step 1
[0695] 2-Chloro-1-(1-(4-methoxybenzyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)ethyl-1-one (intermediate 3) (500 mg, 1.498 mmol) and 6-bromopyrimidine-4-amine (521 mg, 3.00 mmol) were mixed in 10 mL of CH3CN. The reaction flask was sealed and heated at 150 °C for 1 hour in a Biotage microwave reactor. The reaction was repeated once at a scale of 500 mg, and the two reactions were combined. The black reaction mixture was concentrated, and the residue was partitioned between a saturated aqueous solution of NaHCO3 and DCM. The organic layer was washed with brine, dried over MgSO4, and concentrated to give a brown residue. The residue was purified by IscoCombiflash (40 g RediSep column, eluent 20%–80% (3:1 EtOAc / EtOH) / hexane). The fractions containing the product were combined and concentrated to give a mixture of 7-chloro-2-(1-(4-methoxybenzyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)imidazo[1,2-c]pyrimidine and 7-bromo-2-(1-(4-methoxybenzyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)imidazo[1,2-c]pyrimidine as a brown solid (466 mg). LCMS m / z 409.1, 411.1 [M+H] + , t ret = 1.26 minutes [formic acid].
[0696] Step 2
[0697] 7-Chloro-2-(1-(4-methoxybenzyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)imidazo[1,2-c]pyrimidine (230 mg, 0.563 mmol) was dissolved in DCM (20 mL), and NBS (150 mg, 0.844 mmol) was added. The reaction mixture was stirred at room temperature for 4 hours. The reaction mixture was partitioned between a 1:1 saturated aqueous solution of Na₂S₂O₃ / NaHCO₃ and DCM. The organic layer was washed with brine, dried over MgSO₄, and concentrated to give a yellow residue. The residue was purified by IscoCombiflash (40 g RediSep column, eluent 20%–50% (3:1 EtOAc / EtOH) / hexane). The fractions containing the product were combined and concentrated to give a mixture of 3-bromo-7-chloro-2-(1-(4-methoxybenzyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)imidazo[1,2-c]pyrimidine and the corresponding dibromide, as a yellow solid (143 mg). LCMS m / z487.2, 489.1 [M+H] + , t ret = 1.26 minutes [TFA].
[0698] Step 3
[0699] 3-Bromo-7-chloro-2-(1-(4-methoxybenzyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)imidazo[1,2-c]pyrimidine (143.1 mg, 0.293 mmol), N,N-dimethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborhecyclopentan-2-yl)-1H-imidazol-1-sulfonamide (intermediate 2) (133 mg, 0.440 mmol), PdCl2(dppf)-CH2Cl2 adduct (23.96 mg, 0.029 mmol), and cesium fluoride (89 mg, 0.587 mmol) were mixed in DME (10 mL). The reaction flask was sealed and heated in a Biotage microwave reactor at 100 °C for 10 min. The reaction mixture was cooled to room temperature and filtered. The filtrate was concentrated, and the residue was purified by Isco Combiflash (40 g RediSep column, eluent 10%-80% (3:1 EtOAc / EtOH, containing 1% NEt3) / hexane). Fractions containing the product were combined and concentrated to give impure 4-(7-chloro-2-(1-(4-methoxybenzyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)imidazo[1,2-c]pyrimidin-3-yl)-N,N-dimethyl-1H-imidazol-1-sulfonamide, a yellow solid (25 mg). LCMS m / z 582.3, 584.1 [M+H] + , t ret = 1.37 minutes [TFA].
[0700] Step 4
[0701] 4-(7-chloro-2-(1-(4-methoxybenzyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)imidazo[1,2-c]pyrimidin-3-yl)-N,N-dimethyl-1H-imidazo-1-sulfonamide (25 mg, 0.042 mmol) was dissolved in 2 mL of LTA. The reaction mixture was stirred at 90 °C for 5 hours. The mixture was concentrated, and the residue was purified by reversed-phase HPLC (MDAP method D) to give 7-chloro-3-(1H-imidazo-4-yl)-2-(3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)imidazo[1,2-c]pyrimidin (11 mg, 74% yield). 1 ¹H NMR (400 MHz, CD3OD) δ ppm 9.13 (s, 1H), 8.15 (s, 1H), 8.00 (d, J = 1.3 Hz, 1H), 7.75 (d, J = 1.0 Hz, 1H), no 2H signal observed. LCMS m / z 355.2[M+H] + , t ret = 0.44 minutes [TFA].
[0702] Example 21
[0703] 3-(1H-imidazol-4-yl)-6-methoxy-2-(3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)imidazo[1,2-a]pyrazine
[0704] The title product was prepared by following the method of Example 18, but using a different pyrazine starting material (5-methoxypyrazine-2-amine), and was a yellow solid. 1 H NMR (400 MHz, DMSO- d 6 δ ppm 9.32 (br s, 1H), 9.03 (d, J=1.22 Hz, 1H), 8.56 (s, 1H), 8.07 (d, J=1.22 Hz, 1H), 3.95 (s, 3H), no 2H signal observed. LCMS m / z 351.1 [M+H] + , t ret = 0.46 minutes [TFA].
[0705] Example 22
[0706] 2-(3-(difluoromethyl)-1H-1,2,4-triazol-5-yl)-3-(1H-imidazol-4-yl)imidazo[1,2-a]pyrazine, trifluoroacetate
[0707] The title product was prepared by following the method of Example 18, but using (2-chloro-1-(3-(difluoromethyl)-1-(4-methoxybenzyl)-1H-1,2,4-triazol-5-yl)ethyl-1-one) (intermediate 4), and was a yellow solid. 1 ¹H NMR (400 MHz, CD3OD) δ ppm 9.27 (d, J=1.22 Hz, 1H), 9.15 (d, J=0.98 Hz, 1H), 8.67 (dd, J=4.77, 1.35 Hz, 1H), 8.31 (d, J=1.22 Hz, 1H), 8.13 (d, J=4.65 Hz, 1H), 6.75–7.16 (m, 1H), no 2H signal observed. LCMS m / z 303.2 [M+H] + , t ret = 0.33 minutes [NH4HCO3].
[0708] Example 23
[0709] 6-Ethyl-3-(1H-imidazol-4-yl)-2-(3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)imidazo[1,2-a]pyrazine
[0710] The title product was prepared by following the method of Example 18, but using a different pyrazine starting material (5-ethylpyrazine-2-amine), and was a white solid. 1 ¹H NMR (400 MHz, CD3OD) δ ppm 9.08 (d, J=1.47 Hz, 1H), 9.01 (s, 1H), 8.33 (s, 1H), 8.03 (d, J=0.98 Hz, 1H), 2.88 (q, J=7.58 Hz, 2H), 1.39 (t, J=7.58 Hz, 3H), no 2H signal observed. LCMS m / z 349.0 [M+H] + , t ret = 0.74 minutes [TFA].
[0711] Example 24
[0712] 3-(1H-imidazol-4-yl)-2-(3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)imidazo[1,2-a]pyrazine-6-carboxylic acid methyl ester
[0713] The title product was prepared by following the method of Example 18, but using a different pyrazine starting material (methyl 5-aminopyrazine-2-carboxylate), and was a yellow solid. 1 ¹H NMR (400 MHz, CD3OD) δ ppm 10.57 (s, 1H), 9.23 (d, J=1.22 Hz, 1H), 8.69 (s, 1H), 8.11 (d, J=0.98 Hz, 1H), 3.94 (s, 3H), no 2H signal observed. LCMS m / z 379.1 [M+H] + , t ret = 0.54 minutes [formic acid].
[0714] Example 25
[0715] 3-(1H-imidazol-4-yl)-2-(3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)imidazo[1,2-a]pyridine-7-ol
[0716] Step 1
[0717] 4-(benzyloxy)pyridine-2-amine (720 mg, 3.60 mmol) and 2-chloro-1-(1-(4-methoxybenzyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)ethyl-1-one (intermediate 3) (800 mg, 2.397 mmol) were mixed in CH3CN (10 mL). The reaction mixture was stirred at 100 °C for 16 hours. The reaction mixture was cooled to room temperature and concentrated to the residue. The residue was partitioned between a saturated aqueous solution of NaHCO3 and DCM. The organic layer was washed with brine, dried over MgSO4, and concentrated to give impure 7-(benzyloxy)-2-(1-(4-methoxybenzyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)imidazo[1,2-a]pyridine (1.15 g), a white solid. LCMS m / z 480.3 [M+H] + , t ret = 1.35 minutes [formic acid].
[0718] Step 2
[0719] 7-(benzyloxy)-2-(1-(4-methoxybenzyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)imidazo[1,2-a]pyridine (1.15 g, 2.396 mmol) was dissolved in DCM (0.5 mL), and then NBS (640 mg, 3.59 mmol) was added. The reaction mixture was stirred at room temperature for 4 hours. The reaction mixture was partitioned between a 1:1 aqueous solution of saturated Na2S2O3 / saturated NaHCO3 and DCM. The organic layer was washed with brine, dried over MgSO4, and concentrated to give a brown residue. The residue was purified by Isco Combiflash (40 g RediSep column, eluent 5%–50% (3:1 EtOAc / EtOH) / hexane). The fractions containing the product were combined and concentrated to give 7-(benzyloxy)-3-bromo-2-(1-(4-methoxybenzyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)imidazo[1,2-a]pyridine as a yellow solid (555 mg, 41% yield). 1 H NMR (400MHz, CDCl3) δ ppm 8.09 (d, J=7.58 Hz, 1H), 7.37 - 7.55 (m, 7H), 7.03 (d, J=2.20 Hz, 1H), 6.79 - 6.90 (m, 3H), 6.09 (s, 2H), 5.19 (s, 2H), 3.79 (s, 3H). LCMS m / z 557.8, 559.8 [M+H] + , t ret = 1.45 minutes [TFA].
[0720] Step 3
[0721] 7-(benzyloxy)-3-bromo-2-(1-(4-methoxybenzyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)imidazo[1,2-a]pyridine (250 mg, 0.448 mmol), N,N-dimethyl-4-(4,4,5,5-tetramethyl1,3,2-dioxaborhecyclopentan-2-yl)-1H-imidazol-1-sulfonamide (intermediate 2) (270 mg, 0.895 mmol), cesium fluoride (204 mg, 1.343 mmol), and PdCl2 (dppf) (32.8 mg, 0.045 mmol) were mixed in DME (10 mL). The reaction flask was sealed and heated in a Biotage microwave reactor at 110 °C for 30 min. The reaction mixture was cooled to room temperature and then filtered. The filtrate was concentrated to give a brown residue. The residue was purified by Isco Combiflash (40 g RediSep column, eluent 20%–80% EtOAc / hexane). Fractions containing the product were combined and concentrated to give 4-(7-(benzyloxy)-2-(1-(4-methoxybenzyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)imidazo[1,2-a]pyridin-3-yl)-N,N-dimethyl-1H-imidazol-1-sulfonamide, as a white solid (213.3 mg, 73% yield). 1 H NMR (400 MHz, CDCl3) dppm 9.17 (d, J=7.83 Hz, 1H), 8.49 (d, J=1.22 Hz, 1H), 8.07 (d, J=1.22 Hz, 1H), 7.35 -7.56 (m, 7H), 7.06 (d, J=2.45 Hz, 1H), 6.84 - 6.87 (m, 2H), 6.78 (dd, J=7.82, 2.45 Hz, 1H), 6.14 (s, 2H), 5.21 (s, 2H), 3.79 (s, 3H), 2.98 (s, 6H). LCMS m / z 653.0 [M+H] + , t ret = 1.36 minutes [TFA].
[0722] Step 4
[0723] 4-(7-(benzyloxy)-2-(1-(4-methoxybenzyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)imidazo[1,2-a]pyridin-3-yl)-N,N-dimethyl-1H-imidazo-1-sulfonamide (213.3 mg, 0.327 mmol) was dissolved in trifluoroacetic acid (2 mL, 26.0 mmol). The reaction mixture was stirred at 90 °C for 3 h. The reaction mixture was concentrated, and the brown residue was purified by reversed-phase HPLC (MDAP method F). The clean fractions from HPLC were combined and concentrated to give 3-(1H-imidazo-4-yl)-2-(3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)imidazo[1,2-a]pyridin-7-ol as a white solid (37 mg, 34% yield). 1 H NMR (400 MHz, DMSO- d 6 ) d ppm 15.67 – 14.58 (m, 1H), 13.55 – 12.31 (m, 1H), 11.00 – 10.23 (m, 1H), 9.38 (br d, J = 7.8 Hz, 1H), 8.33 (d, J = 1.0Hz, 1H), 8.06 (s, 1H), 6.81 (d, J = 2.0 Hz, 1H), 6.75 (dd, J = 7.8, 2.4 Hz, 1H). LCMS m / z 336.0 [M+H] + , t ret = 0.38 minutes [TFA].
[0724] Example 26
[0725] 3-(1H-imidazol-4-yl)-2-(3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)imidazo[1,2-a]pyridine-7-carboxylic acid methyl ester
[0726] Step 1
[0727] A mixture of methyl 2-aminoisononin (16.0 g, 105 mmol), sodium bicarbonate (7.83 g, 93 mmol), and 2-chloro-1-(1-(methoxymethyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)ethyl-1-one (24.0 g, 93 mmol) in 1-butanol (250 mL) was stirred at 90 °C for 4 hours. The reaction mixture was cooled to room temperature, and the precipitate was collected by filtration. The solid was then washed successively with ethanol, water, ethanol, and hexane. The mother liquor was evaporated and purified by rapid column chromatography (0%–30% EtOAc / hexane). Fractions containing the product were combined and concentrated to give methyl 2-(1-(methoxymethyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)imidazo[1,2-a]pyridine-7-carboxylate (18.3 g, 55% yield). 1 H NMR (400 MHz, CDCl3) δ ppm 8.53 – 8.42 (m, 2H), 8.26 (dd, J = 7.1, 1.0 Hz, 1H), 7.55 (dd, J = 7.1, 1.5 Hz, 1H), 6.30 (s, 2H), 4.03 (s, 3H), 3.56 (s, 3H). LCMS m / z 356.1 [M+H] + , t ret =1.01 minutes [TFA].
[0728] Step 2
[0729] 2-(1-(methoxymethyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)imidazo[1,2-a]pyridine-7-carboxylate (29.6 g, 83 mmol) and NIS (22.49 g, 100 mmol) were stirred in chloroform (800 mL) at 50 °C for 24 hours. Another portion of NIS (3.2 g) was added, and the reaction mixture was stirred at 75 °C for 16 hours. The reaction mixture was evaporated, and the residue was purified twice by rapid column chromatography (using a 330 g RediSep column and a 220 g RediSep column, respectively, with 0%–60% EtOAc / heptane as the eluent). The fractions containing the product were combined and concentrated to give methyl 3-iodo-2-(1-(methoxymethyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)imidazo[1,2-a]pyridine-7-carboxylate (33.5 g, 84% yield). 1 H NMR (400 MHz, DMSO- d 6) δ ppm 8.64 (dd, J = 7.4, 0.8 Hz, 1H), 8.29 (d, J =1.0 Hz, 1H), 7.57 (dd, J = 7.2, 1.6 Hz, 1H), 6.16 (s, 2H), 3.94 (s, 3H), 2.57 (s, 3H). LCMS m / z 482.1 [M+H] + , t ret = 1.17 minutes [TFA].
[0730] Step 3
[0731] Add to a 1 L round-bottom flask a solution of methyl 3-iodo-2-(1-(methoxymethyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)imidazo[1,2-a]pyridine-7-carboxylate (10.0 g, 20.78 mmol), N,N-dimethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborhecyclopentan-2-yl)-1H-imidazol-1-sulfonamide (intermediate 2) (18.78 g, 62.3 mmol), potassium phosphate (6.62 g, 31.2 mmol), and PdCl2(dppf) (2.281 g, 3.12 mmol) in 300 mL of 1,4-dioxane. Purge the flask thoroughly with nitrogen and reflux with stirring under a dry nitrogen atmosphere (bath temperature 120 °C) for 16 hours. The mixture was cooled to room temperature and evaporated. Ethyl acetate was added to give a thick precipitate, which was collected by filtration. The solid was washed with ethyl acetate and hexane. The crude product was purified by rapid column chromatography (330 g RediSep column, eluent 0%-10% EtOAc / dichloromethane). Fractions containing the product were combined and concentrated to give methyl 3-(1-(N,N-dimethylaminosulfonyl)-1H-imidazol-4-yl)-2-(1-(methoxymethyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)imidazo[1,2-a]pyridine-7-carboxylate (10 g, 91% yield). 1 H NMR (400 MHz, DMSO- d 6) δ ppm 9.30 (dd, J = 7.4, 1.0Hz, 1H), 8.56 (d, J = 1.3 Hz, 1H), 8.48 (d, J = 1.3 Hz, 1H), 8.36 (dd, J = 1.6, 0.9 Hz, 1H), 7.57 (dd, J = 7.4, 1.8 Hz, 1H), 6.13 (s, 2H), 3.95 (s, 3H), 3.37 (s, 3H), 2.89 (s, 6H). LCMS m / z 529.3 [M+H] + , t ret = 1.18 minutes [TFA].
[0732] Step 4
[0733] Methyl 3-(1-(N,N-dimethylaminosulfonyl)-1H-imidazol-4-yl)-2-(1-(methoxymethyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)imidazo[1,2-a]pyridine-7-carboxylate (9.2 g, 17.41 mmol) in a 1 L Erlenmeyer flask was dissolved in chloroform (100 mL) and then treated with a 4 M HCl solution in dioxane (60 mL, 240 mmol). The mixture was stirred at 40 °C for 3 h. Methanol was added during the reaction to improve solubility and achieve better deprotection. The mixture was evaporated, and the residue was absorbed with water. The aqueous solution was extracted twice with diethyl ether, followed by extraction with ethyl acetate. The combined organic solutions were washed twice with 1 M HCl aqueous solution. The combined aqueous solutions were carefully alkalized with solid NaHCO3 and adjusted to pH 6.0 with 0.2 M ammonium citrate buffer. The precipitate was collected by filtration, washed with water, acetonitrile and hexane and dried to give methyl 3-(1H-imidazol-4-yl)-2-(3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)imidazo[1,2-a]pyridine-7-carboxylate (4.5 g, 68% yield). 1 H NMR (400 MHz, DMSO- d 6 ) δ ppm 15.72 (br s, 1H), 12.72 (br s, 1H), 9.86 – 9.65 (m, 1H), 8.47 (br s, 1H), 8.29 – 8.19 (m, 1H), 8.05 (s, 1H), 7.51 (dd, J = 7.4, 1.8 Hz, 1H), 3.94 (s, 3H). LCMS m / z 378.1 [M+H] + , t ret= 0.57 minutes [TFA].
[0734] Example 27
[0735] 2-(3-(1H-imidazol-4-yl)-2-(3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)imidazo[1,2-a]pyridin-6-yl)-2,2-difluoro-N-methylethyl-1-amine
[0736] Step 1
[0737] Boc-anhydride (25.5 mL, 110 mmol) was added to a solution of 5-iodopyridine-2-amine (20.10 g, 91 mmol) in dichloromethane (DCM) (500 mL) at 0 °C, followed by the addition of DMAP (1.116 g, 9.14 mmol). The reaction mixture was warmed to room temperature and stirred for 18 h. The reaction mixture was concentrated, and the residue was purified by rapid column chromatography (330 g RediSep column, eluent: 0 to 30% EtOAc in hexane). Broad peaks of both single-Boc and double-Boc products were obtained. MeOH (200 mL) and K₂CO₃ (5 g) were added to the concentrated mixture. The mixture was then stirred at 65 °C for 1 h. The reaction mixture was cooled to room temperature, and the solids were separated by filtration and washed with water to obtain the first batch of target products. The filtrate was concentrated, diluted with water, and extracted with EtOAc (2 × 50 mL). The organic extracts were combined, washed with brine, dried over MgSO4, filtered, and concentrated under reduced pressure to obtain a solid. This solid was washed with 1:1 DCM:hexane to give a second batch of the target product. The two batches of solids were then combined to give tert-butyl (5-iodopyridin-2-yl)carbamate (22.83 g, 71.3 mmol, 78% yield), a white solid. 1 H NMR (400 MHz, DMSO- d 6 ): δ ppm 9.93 (s, 1H), 8.44 (dd, J=2.45, 0.73 Hz, 1H), 8.04 (dd, J=8.80, 2.45 Hz, 1H), 7.68 (dd, J=8.80, 0.73 Hz, 1H), 1.47 (s, 9H). LCMS m / z 321.0 [M+H] + , t ret = 1.04 minutes [TFA].
[0738] Step 2
[0739] Add tert-butyl (5-iodopyridin-2-yl)carbamate (1.00 g, 3.12 mmol), ethyl 2-bromo-2,2-difluoroacetate (0.561 mL, 4.37 mmol), copper powder (0.993 g, 15.6 mmol), and dimethyl sulfoxide (DMSO) (15 mL) to a 20 mL microwave-safe reaction flask. Then cap the mixture and heat it in a microwave reactor at 85 °C for 3.5 hours. Repeat the above conditions 13 times. After all 14 reactions are complete, combine them and dilute with 200 mL of water and 300 mL of EtOAc. Filter the mixture through filter paper, and extract the filtrate with EtOAc (2 × 100 mL). Combine the organic extracts, wash with brine, dry over MgSO4, filter, and concentrate under reduced pressure. The residue was purified by rapid column chromatography (330 g RediSep column, eluent: 0-20% EtOAc in hexane) to separate the starting material (5-iodopyridin-2-yl) tert-butyl carbamate (1.67 g, 5.22 mmol, 11.93% yield) and the desired product ethyl 2-(6-((tert-butoxycarbonyl)amino)pyridin-3-yl)-2,2-difluoroacetate (7.50 g, 23.71 mmol, 54.2% yield). LCMS m / z 317.1 [M+H] + , t ret = 1.10 minutes [TFA].
[0740] Step 3
[0741] Sodium borohydride (1.166 g, 30.8 mmol) was added to a solution of ethyl 2-(6-((tert-butoxycarbonyl)amino)pyridin-3-yl)-2,2-difluoroacetate (7.50 g, 23.71 mmol) in methanol (200 mL). The reaction mixture slowly became clear and bubbly. After 1 hour, LCMS analysis showed the presence of only the product. The reaction mixture was then partially concentrated and diluted with water (200 mL). A solid precipitate formed, which was separated by filtration and left to stand under vacuum overnight to give tert-butyl (5-(1,1-difluoro-2-hydroxyethyl)pyridin-2-yl)carbamate (5.48 g, 19.98 mmol, 84% yield) as a white solid. 1 HNMR (400 MHz, DMSO- d 6) δ ppm 10.04 (s, 1H), 8.36-8.41 (m, 1H), 7.85-7.92 (m, 2H), 5.62-5.67 (m, 1H), 3.87 (td, J=13.82, 6.11 Hz, 2H), 1.45-1.52 (m, 9H). LCMS m / z 275.1 [M+H] + , t ret = 0.69 minutes [TFA].
[0742] Step 4
[0743] TFA (12.31 mL, 160 mmol) was added to a solution of (5-(1,1-difluoro-2-hydroxyethyl)pyridin-2-yl)carbamate (5.48 g, 19.98 mmol) in dichloromethane (DCM) (50 mL), and the reaction mixture was stirred for 3 hours. LCMS analysis showed no residual starting material. The reaction mixture was concentrated to a clear oil. The oil was dissolved in DCM (150 mL), and then imidazole (6.80 g, 100 mmol) and TBDMS-Cl (3.91 g, 26.0 mmol) were added. A precipitate formed. After 1 hour, LCMS analysis showed only the target product was present. The reaction mixture was diluted with water (150 mL) and extracted with EtOAc (3 × 50 mL). The organic extracts were combined, washed with brine, dried over MgSO4, filtered, and concentrated under reduced pressure. The residue was purified by rapid column chromatography (220 g RediSep column, eluent: 0 to 40% EtOAc in hexane) to give 5-(2-((tert-butyldimethylsilyl)oxy)-1,1-difluoroethyl)pyridine-2-amine (4.10 g, 14.22 mmol, 71.1% yield) as a clear oil. 1 H NMR (400 MHz, DMSO- d 6 ) δ ppm 8.03 (dd, J=2.45, 0.98 Hz, 1H), 7.45 (dd, J=8.80, 2.45 Hz, 1H), 6.47 (d, J=8.80 Hz, 1H), 6.31 (s, 2H), 3.99 (t, J=13.20 Hz, 2H), 0.82 (s, 9H), 0.01 (s, 6H). LCMS m / z 289.2 [M+H] + , t ret = 0.84 minutes [TFA].
[0744] Step 5
[0745] To a solution of 5-(2-((tert-butyldimethylsilyl)oxy)-1,1-difluoroethyl)pyridin-2-amine (4.10 g, 14.22 mmol, 1.00 equivalent) in acetonitrile (150 mL), 2-chloro-1-(1-(4-methoxybenzyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)ethyl-1-one (intermediate 3) (6.17 g, 18.48 mmol) and sodium bicarbonate (1.672 g, 19.90 mmol) were added. The reaction mixture was heated at 85 °C for 4 hours. LCMS analysis showed that some starting material remained. Add 0.2 equivalents of 2-chloro-1-(1-(4-methoxybenzyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)ethyl-1-one (intermediate 3), and stir the reaction mixture at 85°C for another 4 hours. LCMS analysis showed that only a small amount of aniline starting material remained. Dilute the reaction mixture with water (100 mL) and extract with EtOAc (3 × 100 mL). Combine the organic extracts, wash with brine, dry over MgSO4, filter, and concentrate under reduced pressure. The residue was purified by rapid column chromatography (330 g RediSep column, eluent: 0 to 15% EtOAc in hexane) to give 6-(2-((tert-butyldimethylsilyl)oxy)-1,1-difluoroethyl)-2-(1-(4-methoxybenzyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)imidazo[1,2-a]pyridine (6.52 g, 11.49 mmol, 81% yield), as a pale yellow oil that solidified upon standing. 1 H NMR (400MHz, DMSO-) d 6 ) δ ppm 8.97 (s, 1H), 8.80 (s, 1H), 7.89 (d, J=9.29 Hz, 1H), 7.53 (dd, J=9.54, 1.71 Hz, 1H), 7.32-7.38 (m, 2H), 6.86-6.93 (m, 2H), 6.14 (s, 2H), 4.18 (t, J=13.20 Hz, 2H), 3.71 (s, 3H), 0.80 (s, 9H), 0.02 (s, 6H). LCMS m / z 568.4 [M+H] + , t ret =1.58 minutes [TFA].
[0746] Step 6
[0747] NBS (2.147 g, 12.06 mmol) was added fractionally to a solution of 6-(2-((tert-butyldimethylsilyl)oxy)-1,1-difluoroethyl)-2-(1-(4-methoxybenzyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)imidazo[1,2-a]pyridine (6.52 g, 11.49 mmol) in acetonitrile (150 mL), and the reaction mixture was stirred for 0.5 h. LCMS analysis showed the presence of only the product. The reaction mixture was diluted with water (100 mL) and extracted with EtOAc (3 × 100 mL). The organic extracts were combined, washed with brine, dried over MgSO4, filtered, and concentrated under reduced pressure. The residue was purified by rapid column chromatography (220 g RediSep column, eluent: 0 to 15% EtOAc in hexane) to give 3-bromo-6-(2-((tert-butyldimethylsilyl)oxy)-1,1-difluoroethyl)-2-(1-(4-methoxybenzyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)imidazo[1,2-a]pyridine (6.55 g, 10.13 mmol, 88% yield) as a white solid. 1 H NMR (400 MHz, DMSO- d 6 ) δ ppm 8.54 (s, 1H), 8.00 (d, J=9.78 Hz, 1H), 7.64-7.69 (m, 1H), 7.30-7.38 (m, 2H), 6.87-6.93 (m, 2H), 6.05 (s, 2H), 4.24 (t, J=12.96 Hz, 2H), 3.72 (s, 3H), 0.81 (s, 9H), 0.03 (s, 6H). LCMS m / z 648.1 [M+H] + , t ret = 1.73 minutes [TFA].
[0748] Step 7
[0749] To a solution of 3-bromo-6-(2-((tert-butyldimethylsilyl)oxy)-1,1-difluoroethyl)-2-(1-(4-methoxybenzyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)imidazo[1,2-a]pyridine (498 mg, 0.770 mmol) in 1,4-dioxane (6 mL), N,N-dimethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborhecyclopentan-2-yl)-1H-imidazol-1-sulfonamide (intermediate 2) (278 mg, 0.924 mmol), tripotassium phosphate (490 mg, 2.311 mmol), PdCl2(dppf)-CH2Cl2 adduct (62.9 mg, 0.077 mmol) and water (3.00 mL) were added sequentially. The reaction mixture was then capped and heated at 80°C. After 1 minute, all substances were dissolved. The reaction was heated overnight. LCMS analysis showed no remaining starting material, the presence of the target product, and approximately 20% deprotected product. The reaction mixture was diluted with water (15 mL) and extracted with EtOAc (3 × 10 mL). The organic extracts were combined, washed with brine, dried over MgSO4, filtered, and concentrated under reduced pressure. Tetrahydrofuran (THF) (3 mL) and a THF solution of 1 M TBAF (0.770 mL, 0.770 mmol) were added, and the reaction was stirred at room temperature for 1 hour. LCMS analysis showed only the deprotected product. The reaction mixture was diluted with water (5 mL) and extracted with EtOAc (4 × 5 mL). The organic extracts were combined, washed with brine, dried over MgSO4, filtered, and concentrated under reduced pressure. The residue was purified by rapid column chromatography (24 g RediSep column, eluted with 0 to 60% EtOAc in hexane) to give 4-(6-(1,1-difluoro-2-hydroxyethyl)-2-(1-(4-methoxybenzyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)imidazo[1,2-a]pyridin-3-yl)-N,N-dimethyl-1H-imidazo-1-sulfonamide (399 mg, 0.637 mmol, 83% yield), a pale yellow oil that foams into a solid under high vacuum. 1 H NMR (400MHz, DMSO-) d 6 ) δ ppm 9.52 (s, 1H), 8.57 (d, J=1.47 Hz, 1H), 8.43 (d, J= 1.47 Hz, 1H), 7.94-7.99 (m, 1H), 7.61-7.66 (m, 1H), 7.36-7.40 (m, 2H), 6.88-6.94 (m, 2H), 5.97 (s, 2H), 5.73-5.79 (m, 1H), 3.92-4.02 (m, 2H), 3.72 (s, 3H), 2.87 (s, 6H). LCMS m / z 627.1[M+H] + , t ret = 0.77 minutes [TFA].
[0750] Step 8
[0751] To a solution of 4-(6-(1,1-difluoro-2-hydroxyethyl)-2-(1-(4-methoxybenzyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)imidazo[1,2-a]pyridin-3-yl)-N,N-dimethyl-1H-imidazol-1-sulfonamide (257 mg, 0.410 mmol) in dichloromethane (DCM) (3 mL), pyridine (0.166 mL, 2.051 mmol) and trifluoromethanesulfonic anhydride (0.076 mL, 0.451 mmol) were added sequentially. The reaction mixture was stirred at room temperature for 15 minutes. LCMS analysis showed that only the target intermediate was present. The reaction mixture was concentrated, diluted with tetrahydrofuran (THF) (3.00 mL) and methylamine (2.051 mL of 2M THF solution, 4.10 mmol), and then transferred to a 20 mL microwave-safe flask and heated at 85 °C for 1 hour. LCMS analysis showed only the desired product. The reaction mixture was concentrated under reduced pressure, and the residue was purified by reversed-phase HPLC (MDAP method H). Fractions containing the target product were combined and lyophilized to give 4-(6-(1,1-difluoro-2-(methylamino)ethyl)-2-(1-(4-methoxybenzyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)imidazo[1,2-a]pyridin-3-yl)-N,N-dimethyl-1H-imidazol-1-sulfonamide, trifluoroacetate (217 mg, 0.288 mmol, 70.2% yield), as a white solid. LCMS m / z 640.4 [M+H] + , t ret = 0.93 minutes [TFA].
[0752] Step 9
[0753] TFA (4 mL, 51.9 mmol) was added to 217 mg (0.339 mmol) of 4-(6-(1,1-difluoro-2-(methylamino)ethyl)-2-(1-(4-methoxybenzyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)imidazo[1,2-a]pyridin-3-yl)-N,N-dimethyl-1H-imidazol-1-sulfonamide (5 mL) in a 5 mL microwave-safe reaction flask. The flask was capped and heated at 80 °C for 0.5 h. LCMS analysis showed the presence of only the product. The reaction mixture was then concentrated under reduced pressure, diluted with DMSO (1 mL), and purified by reversed-phase HPLC (MDAP method K). The fractions containing the desired product were combined and lyophilized overnight to give 2-(3-(1H-imidazol-4-yl)-2-(3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)imidazo[1,2-a]pyridin-6-yl)-2,2-difluoro-N-methylethyl-1-amine (60.0 mg, 0.146 mmol, 42.9% yield), as a white solid. 1 H NMR (400 MHz, DMSO- d 6 δ ppm 10.02 (br s, 1H), 8.47 (s, 1H), 8.05 (d, J=1.0 Hz, 1H), 7.79 (d, J=8.8 Hz, 1H), 7.54 (dd, J=9.5, 1.7 Hz, 1H), 3.22–3.30 (m, 2H), 2.32 (s, 3H), 3H signal not observed. LCMS m / z 413.0 [M+H] + , t ret = 0.39 minutes [TFA].
[0754] Example 28
[0755] 3-(1H-pyrazol-4-yl)-2-(5-(trifluoromethyl)-1H-1,2,4-triazol-3-yl)-5,6-dihydroimidazo[1,2-a]pyrazine-7(8H)-formate ethyl ester
[0756] Step 1
[0757] Pyrazine-2-amine (0.855 g, 8.99 mmol) and 2-chloro-1-(1-(4-methoxybenzyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)ethyl-1-one (intermediate 3) (1.5 g, 4.50 mmol) were mixed in CH3CN (100 mL) and the mixture was stirred at 90 °C for 16 hours. The reaction mixture was then cooled to room temperature and the solvent was removed by rotary evaporation. The brown residue was purified by Isco Combiflash (120 g RediSep column, eluent 10%–50% (3:1 EtOAc / EtOH) / hexane). The fractions containing the product were combined and concentrated to give 2-(1-(4-methoxybenzyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)imidazo[1,2-a]pyrazine as a yellow solid (267 mg, 16% yield). 1 H NMR (400 MHz, DMSO- d 6 ) δ ppm 9.30 (d, J=0.76 Hz, 1H), 8.87 (s, 1H), 8.68 (dd, J=4.69, 1.65 Hz, 1H), 8.06 (d, J=4.56 Hz, 1H), 7.37 (d, J=8.87 Hz, 2H), 6.91 (d, J=8.87 Hz, 2H), 6.14 (s, 2H), 3.72 (s, 3H). LCMS m / z 375.1 [M+H] + , t ret = 1.07 minutes [TFA].
[0758] Step 2
[0759] 2-(1-(4-methoxybenzyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)imidazo[1,2-a]pyrazine (200 mg, 0.534 mmol) was dissolved in 5 mL of MeOH. Pd-C (10 wt%, 56.9 mg, 0.053 mmol) was added to the reaction mixture under a nitrogen stream. A hydrogen balloon was placed on top of the reaction flask. The reaction mixture was stirred at room temperature for 1 hour. The reaction mixture was filtered, and the filtrate was concentrated to give crude 2-(1-(4-methoxybenzyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyrazine as a brown oil (233 mg, 97% yield). LCMS m / z 379.2 [M+H] + , t ret= 0.72 minutes [TFA].
[0760] Step 3
[0761] 2-(1-(4-methoxybenzyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyrazine (233 mg, 0.616 mmol) was dissolved in DCM (5 mL), followed by the addition of ethyl chloroformate (0.089 mL, 0.924 mmol). The reaction mixture was stirred at room temperature for 1 hour, and LCMS analysis showed that the reaction proceeded to approximately 80%. The reaction mixture was stirred for another 5 hours; LCMS showed no further progress. Triethylamine (0.258 mL, 1.847 mmol) and additional ethyl chloroformate (0.089 mL, 0.924 mmol) were added, and the reaction mixture was stirred at room temperature for 16 hours, but no further conversion occurred. The reaction mixture was partitioned between saturated aqueous NaHCO3 solution and DCM. The organic layer was washed with brine, dried over MgSO4, and concentrated to give a brown residue. The residue was purified by Isco Combiflash (40 g RediSep column, eluent 20%–80% EtOAc / hexane). Fractions containing the product were combined and concentrated to give ethyl 2-(1-(4-methoxybenzyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)-5,6-dihydroimidazo[1,2-a]pyrazine-7(8H)-carboxylate as a colorless oil (164 mg, 59% yield). 1 H NMR (400 MHz, CDCl3) δ ppm 7.62 (s, 1H), 7.37 (d, J=8.62 Hz, 2H), 6.84 (d, J=8.62 Hz, 2H), 5.97 (s, 2H), 4.82 (s, 2H), 4.25 (q, J=7.10 Hz, 2H), 4.08 (d, J=5.32 Hz, 2H), 3.96 (d, J=4.82 Hz, 2H), 3.78 (s, 3H), 1.34 (t, J=7.10 Hz, 3H). LCMS m / z 451.1 [M+H] + , t ret = 1.15 minutes [TFA].
[0762] Step 4
[0763] Ethyl 2-(1-(4-methoxybenzyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)-5,6-dihydroimidazo[1,2-a]pyrazine-7(8H)-carboxylate (164 mg, 0.364 mmol) was dissolved in DMF (5 mL), and then NIS (246 mg, 1.092 mmol) was added. The reaction mixture was stirred at 90 °C for 16 hours. The brown reaction mixture was concentrated, and the residue was purified by Isco Combiflash (40 g RediSep column, eluent 20%–80% EtOAc / hexane). The fractions containing the product were combined and concentrated to give ethyl 3-iodo-2-(1-(4-methoxybenzyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)-5,6-dihydroimidazo[1,2-a]pyrazine-7(8H)-carboxylate, which was a colorless oil (146 mg, 70% yield). 1 HNMR (400 MHz, CDCl3) δ ppm 7.32 (d, J=8.62 Hz, 2H), 6.85 (d, J=8.62 Hz, 2H), 5.88 (s, 2H), 4.84 (s, 2H), 4.26 (q, J=7.10 Hz, 2H), 4.00 (s, 4H), 3.79 (s, 3H), 1.35 (t, J=7.10 Hz, 3H). LCMS m / z 577.1 [M+H] + , t ret = 1.25 minutes [TFA].
[0764] Step 5
[0765] Ethyl 3-iodo-2-(1-(4-methoxybenzyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)-5,6-dihydroimidazo[1,2-a]pyrazine-7(8H)-carboxylate (146 mg, 0.253 mmol), 1-(tetrahydro-2H-pyran-2-yl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborhecyclopentan-2-yl)-1H-pyrazole (78 mg, 0.279 mmol), and K3PO4 (108 mg, 0.507 mmol) were mixed in 1,4-dioxane (6.00 mL) and water (2 mL). Nitrogen gas was bubbled into the reaction mixture for 5 minutes, and then PdCl2dppf (20.69 mg, 0.025 mmol) was added. The reaction flask was sealed and heated in a Biotage microwave reactor at 100°C for 15 minutes. The reaction mixture was cooled to room temperature and partitioned between H₂O and DCM. The organic layer was washed with brine, dried over MgSO₄, and concentrated to give a brown residue. The residue was purified by Isco Combiflash (40 g RediSep column, eluent 10%–80% (3:1 EtOAc / EtOH) / hexane). Fractions containing the product were combined and concentrated to give ethyl 2-(1-(4-methoxybenzyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)-3-(1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-4-yl)-5,6-dihydroimidazo[1,2-a]pyrazine-7(8H)-carboxylate as a light brown solid (91 mg, 60% yield). LCMS m / z 601.3 [M+H] + , t ret = 1.21 minutes [TFA].
[0766] Step 6
[0767] Ethyl 2-(1-(4-methoxybenzyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)-3-(1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-4-yl)-5,6-dihydroimidazo[1,2-a]pyrazine-7(8H)-carboxylate (30 mg, 0.050 mmol) was dissolved in TFA (2 mL). The reaction mixture was stirred at 65 °C for 16 h. The black reaction mixture was concentrated, and the black residue was purified by reversed-phase HPLC (XSELECT CSH C18 column, eluent 30%–85% CH3CN / H2O, containing 0.1% formic acid). The clean fractions from the combined HPLC fractions were concentrated to give ethyl 3-(1H-pyrazol-4-yl)-2-(5-(trifluoromethyl)-1H-1,2,4-triazol-3-yl)-5,6-dihydroimidazo[1,2-a]pyrazine-7(8H)-carboxylate as a white solid (13 mg, 65% yield). 1 H NMR (400 MHz, DMSO- d 6 ) δ ppm 15.13 – 14.72 (m, 1H), 13.39 – 13.03 (m, 1H), 8.29 (s, 1H), 7.97 (d, J = 1.5 Hz, 1H), 4.73 (br s, 2H), 4.16 – 4.11 (m, 2H), 4.06 (brt, J = 5.3 Hz, 2H), 3.86 (br d, J = 4.8 Hz, 2H), 1.25 (t, J = 7.1 Hz, 3H). LCMS m / z 397.2 [M+H] + , t ret = 0.67 minutes [TFA].
[0768] Example 29
[0769] 3-(1H-imidazol-4-yl)-7-(trifluoromethyl)-2-(3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)imidazo[1,2-b]pyridazine
[0770] Steps 1-3
[0771] 2-chloro-1-(1-(4-methoxybenzyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)ethyl-1-one (intermediate 3) (767 mg, 2.30 mmol) was added to a solution of 5-(trifluoromethyl)pyridazine-3-amine (250 mg, 1.53 mmol) in acetonitrile (16 mL). The reaction mixture was heated in a microwave reactor at 175 °C for 4 hours. The reaction mixture was concentrated, and the residue was purified by silica gel chromatography, eluting with a heptane solution of 0-100% ethyl acetate to give 2-(1-(4-methoxybenzyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)-7-(trifluoromethyl)imidazo[1,2-b]pyridazine (440 mg). This material was dissolved in acetonitrile (10 mL), and NBS (266 mg, 1.49 mmol) was added. The reaction mixture was heated at 70°C for 3 hours. The reaction mixture was concentrated. The residue was absorbed with ethyl acetate, the organic phase was washed with water (×4), dried over Na2SO4, and concentrated. The residue was absorbed with DCM, and insoluble matter was removed by filtration. The filtrate was directly purified by silica gel chromatography, eluting with a heptane solution of 0-50% ethyl acetate to give 3-bromo-2-(1-(4-methoxybenzyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)-7-(trifluoromethyl)imidazo[1,2-b]pyridazine (440 mg). The material (410 mg of the isolated 440 mg) was dissolved in 1,4-dioxane (16 mL) with N,N-dimethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborhexacyclopentan-2-yl)-1H-imidazol-1-sulfonamide (intermediate 2) (421 mg, 1.40 mmol). K3PO4 (342 mg, 1.61 mmol), PdCl2(dppf)-CH2Cl2 (128 mg, 0.157 mmol), and water (4 mL) were added. Nitrogen gas was bubbled into the mixture. The reaction mixture was heated in a microwave reactor at 115 °C for 1.75 h. Volatile substances were removed. The residue was absorbed with ethyl acetate and filtered through a Celite filter. The filtrate was washed with water and dried over Na2SO4. The crude product was purified by silica gel chromatography, eluting with a heptane solution of 0-100% ethyl acetate. The separated material (300 mg) was dissolved in TFA (4 mL) and heated overnight at 75 °C in a sealed container. The reaction mixture was concentrated. The residue was absorbed with methanol and the pH was adjusted with a methanol solution of 7N ammonia. Volatile substances were removed. The residue was absorbed with DMSO, filtered, and purified by reversed-phase chromatography (MDAP method I) to give 3-(1H-imidazol-4-yl)-7-(trifluoromethyl)-2-(3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)imidazo[1,2-b]pyridazine (8.3 mg). 1H NMR (400 MHz, DMSO- d 6 ) δ ppm 9.20 (d, J = 2.4 Hz, 1H), 8.96 (s, 1H), 8.42 (s, 1H), 8.37 (s, 1H), no 2H signal observed. LCMS m / z 389.3 [M+H] + , t ret = 0.63 minutes [TFA].
[0772] The following examples also employ a similar method to that described above and are prepared according to general methods.
[0773]
[0774]
[0775]
[0776]
[0777]
[0778]
[0779]
[0780]
[0781]
[0782]
[0783]
[0784]
[0785]
[0786]
[0787]
[0788]
[0789]
[0790]
[0791]
[0792]
[0793]
[0794]
[0795] Biological data
[0796] Production of recombinant human CGAS.
[0797] In lysis buffer (20 mM HEPES, pH 7.5, 400 mM NaCl, 10% glycerol, 30 mM imidazole, 1 mM MMSF, 1 mM TCEP, 100 mM arginine, 100 mM glutamate and protease inhibitor (Roche completely EDTA-free)), Ni-IDA affinity chromatography was used to extract E. coli (BL21(DE3)) expressing an N-terminal His-MBP-tev tag. Human cGAS (157-522) was purified in [a specific solution] and eluted stepwise with 50 and 500 mM imidazole in wash buffer (20 mM HEPES, pH 7.5, 400 mM NaCl, 10% glycerol, 1 mM TCMSP). The eluted protein was further purified by size exclusion chromatography using Superdex 75 equilibrated in 20 mM HEPES, pH 7.5, 400 mM NaCl, 1 mM TCMSP, 1 mM MMSF.
[0798] Determination by RapidFire 300 mass spectrometry (RF-MS 300).
[0799] The compound was resuspended in 10 mM stock concentration using DMSO and its IC50 value for human CGAS (157-522) was determined using RapidFire mass spectrometry. The compound was serially diluted 2, 3, or 4 times in pure DMSO to generate an 11-point dose-response profile, and then 250 nL of the compound or DMSO solution was transferred to a Greiner 384-well V-bottom plate (catalog #781280) using an Echo acoustic dispenser (Labcyte). Using a Combi liquid processor (ThermoFisher), a solution of 150 μM ATP, 150 μM GTP, 20 μM pppGpA (GTP-2'5'-AMP, custom-synthesized from ChemGenes), and 10 μg / mL cleaved salmon sperm DNA (Sigma, catalog #D1626) in assay buffer (20 mM Trizma, pH 7.5, 10 mM magnesium chloride, 0.3 mM CHAPS, and 0.01% (w / v) bovine serum albumin) was added at 12.5 μL / well to columns 1-17 and 19-24 of the plate. A low control solution containing 150 μM ATP, 150 μM GTP, and 20 μM pppGpA in assay buffer was added at 12.5 μL / well to column 18 using Combi. Then, using Combi, 12.5 μL / well of a 10–100 nM human CGAS (157–522) solution in assay buffer was added to all wells of the plate. The plate was centrifuged to mix the solutions and then incubated at room temperature for 1–2 hours. The reaction was quenched by adding 50 μL / well of 0.5% (v / v) trifluoroacetic acid (TFA) in mass spectrometry-grade deionized water containing 5 μM cyclic di-UMP (ci-di-UMP; Invivogen catalog #tlrl-cdu) (as internal standard (IS)). The plate was centrifuged for 1 min, and the quenched reaction was analyzed using an RF-MS300 system running in multiple reaction monitoring (MRM) detection mode.
[0800] The sample (10 μL injection volume) was passed through silica C 18The analyte (2'3'-cyclic guanosine monophosphate adenosine monophosphate (2'3'-cGAMP), a product of a biochemical reaction) was adsorbed onto a C-type solid-phase extraction (SPE) column using pppGpA / c-di-UMP IS. The adsorbed sample was desalted for 3000 ms using 100% water eluent A / desalting solution. Subsequently, the desalted sample was directly eluted onto a Sciex 4000, 5000, or 5500 triple quadrupole mass spectrometer (QQQ-MS) using 0.5% TFA in 20% / 80% acetonitrile / water eluent B / elution solution for MRM analyte / IS detection. The QQQ-MS detection conditions are as follows: Scan type: MRM; Curtain gas (CUR): 30 psi; Nebulizer gas (GS1): 50 psi; Dry gas (GS2): 60 psi; Collision-activated dissociation (CAD) gas: 12 relative settings; Precursor ion (Q1) mass: 2'3'-cGAMP: m / z 675.1 Da / pppGpA: m / z 853.0 Da / c-di-UMP: m / z 613.1 Da; Fragment ion (Q3) mass: 2'3'-cGAMP: m / z 524.1 Da / pppGpA: m / z 702.0 Da / c-di-UMP: 307.1 Da; Declustering Potential (DP): 2'3'-cGAMP: +81 V / pppGpA: +85 V / c-di-UMP: +85 V; Inlet Potential: +10 V (all analytes); Collision Energy (CE): 2'3'-cGAMP: +33 V / pppGpA: +36 V / c-di-UMP: +35 V; Collision Cell Outlet Potential (CXP): +10 V (all analytes); Interfacial Heater (Sciex 4000 / 5000 only): On; Q1 Resolution: Units (all analytes); Q3 Resolution: Units (all analytes). The area under the curve (AUC) for all analytes was obtained using the RapidFire Integrator software application to calculate the AUC-2'3'-cGAMP / AUC-c-di-UMP intensity ratio. Product formation % was calculated by comparing the response to column 6 (high control) / column 18 (low control). Product inhibition % was calculated as follows: % Inhibition = 100 x [(Sample - Average Low Control) / (Average High Control - Average Low Control)] Use the following equation for curve fitting: , Where A is the minimum response, B is the maximum response, and C is log10. XC50, D is the slope factor, and x is the log10 concentration of the compound [M] in ABASEXE.
[0801] CGAS Complete Blood Cytokine Release Assay
[0802] Blood collection: Collect blood into a tube containing 10% heparin sodium (5ml / 45ml final blood volume).
[0803] Protocol for CGAS Whole Blood Cytokine Release Assay: The compound, serially diluted 1:3, is provided at 150 nL per well in a 384-well polypropylene microplate (catalog 781280; GreinerBio-One, Frickenhausen, Germany). 5 μL of PBS / 20% NullBacMam is allocated to all wells except column 18 on a Multidrop Combi (Thermo Scientific, Waltham, MA). 5 μL of PBS is allocated to column 18. 45 μL of donor-derived blood is transferred to the compound plate using a Bravo (Agilent, Santa Clara, CA). The Bravo protocol involves mixing the blood and compound / PBS five times. The plate is incubated at 37°C with 5% CO2 for 6 hours. At the 6-hour mark, the plate is removed and centrifuged at 3000 RPM for 10 minutes. 3 μL of the supernatant is transferred from the plate to a 384-well NBS microplate (catalog 4513; CorningLife Sciences, Corning, NY). These plates were sealed with adhesive foil and stored in a -80°C freezer until they were ready for analysis.
[0804] For cytokine assays, human IP-10 BD flow cytometry bead arrays (CBA) (BD Biosciences, Franklin Lakes, NJ) were used. The capture bead solution was prepared by diluting the IP-10 capture bead stock solution 1:50 in BD diluent for serum / plasma (catalog 51-9003991 BD Biosciences, Franklin Lakes, NJ). 2 μL of this solution was added to each well of an assay microplate, which was then sealed with adhesive foil and incubated in the dark at room temperature for 2 h. Assay reagents were further prepared by diluting the assay reagent stock solution 1:50. 2 μL of the assay reagent was added to each well, and the microplate was sealed with adhesive foil and incubated in the dark at room temperature for 1 h. After 1 h incubation, 3 μL of BD CBA wash buffer was added to each well of the microplate. Data were obtained using an iQue Screener flow cytometer. The inhibition of IP-10 in the sample wells was quantified using f...
Claims
1. A compound of formula (I) or a tautomer thereof, or a pharmaceutically acceptable salt thereof, (I) in R 1 is hydrogen or a prodrug moiety; R 2 selected from hydrogen, halogen, cyano, nitro, C 1-3 alkyl, halo(C 1-3 )alkyl, halo(C 1-3 )alkoxy, -S(O)R 7 , -SO2R 7 , -C(O)NR 7 R 8 , -NR 7 C(O)R 8 , and -CO2R 7 , wherein C 1-3 alkyl, halo(C 1-3 )alkyl, and halo(C 1-3 )alkoxy are optionally substituted with hydroxy, -NR 7 R 8 , or C 3-4 cycloalkyl; R 3 C is an optional replacement. 1-3 Alkyl, -C(O)R 8 Or a 5- or 6-membered heteroaryl group in the prodrug portion; Ring A is a 5- or 6-membered heteroaryl or a 5- to 7-membered heterocyclic alkyl ring, wherein the heteroaryl or heterocyclic alkyl ring contains 1, 2 or 3 heteroatoms independently selected from N, O and S; p is 0, 1, 2 or 3; Each X is independently selected from oxidized and LY; Each L is independently selected from the key, -(CR) a R b ) n -、-O-、-(CR a R b ) n O-、-O(CR a R b ) n -、-(CR a R b ) n O(CR a R b ) m -, -SO2-, -SO2(CR) a R b ) n -, -C(O)O-, -OC(O)-, -C(O)O(CR a R b ) n -、-(CR a R b ) n C(O)O-、-C(O)NH(CR a R b ) n -、-NR a C(O)(CR a R b ) n -or-NH(CR) a R b ) n - where each n or m is independently selected from 1, 2 or 3; Each R a and R b Independently selected from hydrogen, halogen, or C 1-4 alkyl; Each Y group is independently selected from hydrogen, halogen, hydroxyl, cyano, C 1-4 Alkyl, C 1-4 Alkoxy, C 3-7 cycloalkyl, C 5-7 Cycloalkenyl, C 2-4 alkenyl, C 2-6 alkynyl, thioyl (C 1-4 )alkyl, hydroxyl (C 1-6 )alkyl, cyano (C 1-4 )alkyl, halogenated (C 1-4 )alkyl, halogenated (C 2-4 alkenyl, hydroxyl (C) 2-6 ) ynyl group, -NR 9 R 10 -C(O)NR 9 R 10 -C(O)SR 10 -CO2R 10 -C(O)R 10 -CHCHC(O)OR 10 -OSO2R 10 -S(O)R 10 -N(R) 10 SO2R 10 -P(O)(Ph)OR 10 -P(O)(OR) 10 )2、-P(S)(Ph)OR 10 phenyl, 5- or 6-membered heteroaryl, and 3- to 7-membered heterocyclic alkyl rings, wherein the heteroaryl or heterocyclic alkyl ring comprises 1, 2, or 3 heteroatoms independently selected from N, O, and S, wherein the C 3-7 cycloalkyl, C 5-7 The cycloalkenyl, phenyl, heteroaryl, and heterocyclic alkyl groups may be optionally substituted with one, two, or three independent substituents selected from the following: halogen, amino, hydroxyl, -C(O)R 10 Oxygen, C 1-4 Alkyl, C 1-4 Alkoxy, halogenated (C 1-4 )alkyl and hydroxyl (C 1-4 alkyl; or Two X substituents, together with the carbon atoms they are attached to, form a ring selected from the following: phenyl, C... 5-8 cycloalkyl, C 5-8 Cycloalkenyl, 5- to 8-membered heteroaryl, or 5- to 8-membered heterocyclic alkyl ring, wherein the heteroaryl or heterocyclic alkyl ring comprises one or two heteroatoms independently selected from N, O, and S, wherein the phenyl, C 5-8 cycloalkyl, C 5-8 The cycloalkenyl, 5- to 8-membered heteroaryl, or 5- to 8-membered heterocyclic alkyl ring is optionally substituted by one, two, or three independent substituents selected from the following: halogen, C 1-4 Alkyl, oxo, -C(O)R 10 -SO2R 10 -C 1-3 Alkylene-NR 9 R 10 and -C 1-3 Alkylene-OR 10 ; R 7 and R 8 Independently selected from hydrogen and C 1-3 alkyl; R 9 Independently selected from hydrogen, hydroxyl, C 1-4 Alkyl, -C(O)C 1-4 Alkyl and halogenated (C 1-4 )alkyl; and R 10 Independently selected from hydrogen and C 1-6 Alkyl; or Where R 9 and R 10 Together with the nitrogen atoms attached to them, they form a 5- to 8-membered heterocyclic alkyl ring comprising one or two heteroatoms independently selected from N, O, and S, wherein the heterocyclic alkyl ring is optionally substituted by one, two, or three substituents independently selected from: halogen, amino, hydroxyl, -C(O)R 10 Oxygen, C 1-4 Alkyl, C 1-4 Alkoxy, halogenated (C 1-4 )alkyl and hydroxyl (C 1-4 )alkyl; The condition is that the compound of formula (I) is not a compound of formula (II). (II) Where R 1 R 2 R 3 X and p are as defined by equation (I).
2. The compound or its tautomer according to claim 1, or a pharmaceutically acceptable salt of said compound or its tautomer, wherein ring A is selected from... , Each ring A is substituted with -X p As defined in any of the preceding claims.
3. The compound of claim 1 or claim 2, or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or tautomer thereof, wherein the compound of formula (I) is a compound of formula (ID). (ID) 。 4. A compound or tautomer thereof according to any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein each R a and R b It is independently selected from hydrogen and fluorine.
5. The compound or its tautomer according to any one of the preceding claims, or a pharmaceutically acceptable salt of said compound or its tautomer, wherein each prodrug moiety is independently selected from -CH(R) c )OP(O)(OR d (OR) e ), -CH(R c )OC(O)-C 1-6 Alkylene-OP(O)(OR) d (OR) e ), -CH(R c )OC(O)-C 1-6 Alkylene-P(O)(OR) d (OR) e ), -CH(R c )OC(O)-C 1-6 Alkylene -CO2H, -CH(R) c )OC(O)R d -CH(R) c )OC(O)OR d -CH(R) c )OC(O)OC 1-6 Alkylene -CO2H, -CH(R) c )OC(O)-C 1-6 Alkylene-NR d R e -CH(R) c )OC(O)OC 1-6 Alkylene-NR d R e -C(O)R d -CH(R) c )OC(O)-C 1-6 alkylene-heterocyclic alkyl, -CH(R) c )OC(O)-C 1-6 alkylene-heterocyclic alkyl and -CR d R e -O-(C(O)-NR d -heteroaryl-CH2O-C(O)-CH2-NR d R e ; Where R c Independently selected from hydrogen and methyl; R d and R e Each is independently hydrogen or C 1-6 alkyl; Each heterocyclic alkyl group is 4- to 6-membered and contains one or two heteroatoms independently selected from N, O, and S; and Each heteroaryl group is 5- or 6-membered and contains one or two heteroatoms independently selected from N, O and S.
6. The compound or tautomer of any of the preceding claims, or a pharmaceutically acceptable salt of the compound or tautomer of the preceding claims, wherein each prodrug moiety is independently selected from... 。 7. The compound or its tautomer according to any one of the preceding claims, or a pharmaceutically acceptable salt of the compound or its tautomer, wherein each prodrug moiety is 。 8. The compound or its tautomer according to any one of the preceding claims, or a pharmaceutically acceptable salt of said compound or its tautomer, wherein R 3 It is a 5-membered heteroaryl group.
9. A compound or tautomer thereof according to any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein R 3 It is a 5-membered nitrogen-containing heteroaryl group.
10. A compound or tautomer thereof according to any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein R 3 It is an imidazole group or a pyrazole group.
11. The compound or its tautomer according to any one of the preceding claims, or a pharmaceutically acceptable salt of said compound or its tautomer, wherein R 1 It is the prodrug portion and R 3 It is an imidazole group.
12. The compound or its tautomer according to any one of claims 1 or 2, or a pharmaceutically acceptable salt of said compound or its tautomer, wherein R 1 It is hydrogen and R 3 It is an imidazole group.
13. The compound or its tautomer according to any one of the preceding claims, or a pharmaceutically acceptable salt of said compound or its tautomer, wherein R 2 Selected from hydrogen, bromine, cyano, -C(O)NH2, -CF2CH2NH2, -CF2CH2CH2NH2, -CHFCH2NH2, -CF2CH2NHCH3, -CF2CH2OH, -CH2F, -CHF2, -CF3, -CF2CF3, -CF2CH3, -CF2CH(OH)CH3, -CF2CH(NH2)CH3, -CF2CHF2, -OCHF2, -S(O)CH3, -C(O)OCH2CH3, -CClF2, -CH3 and -CF2-cyclopropyl.
14. The compound or its tautomer according to any one of the preceding claims, or a pharmaceutically acceptable salt of said compound or its tautomer, wherein R 2 Selected from Br, -CHF2 and -CF3.
15. A compound or tautomer thereof according to any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein R 2 It is -CF3.
16. A compound or tautomer thereof according to any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein each L is a bond, -(CR) a R b ) n -、-O-、-(CR a R b ) n O、-O(CR a R b ) n -、-(CR a R b ) n O(CR a R b ) m -, -SO2-, -SO2CH2-, -C(O)O-, -OC(O)-, -C(O)O(CR a R b ) n -、-C(O)NH(CR a R b ) n -or-NH(CR) a R b ) n - and each Y is independently selected from hydrogen, halogen, hydroxyl, cyano, C 1-4 Alkyl, C 1-4 Alkoxy, C 3-7 cycloalkyl, C 5-7 Cycloalkenyl, C 2-4 alkenyl, C 2-6 alkynyl, hydroxyl (C 1-6 )alkyl, halogenated (C 1-4 )alkyl, hydroxyl (C 2-6 ) ynyl group, -NR 9 R 10 -C(O)NR 9 R 10 -CO2R 10 -COR 10 -OSO2R 10 phenyl, 5- or 6-membered heteroaryl, and 4- to 6-membered heterocyclic alkyl rings, wherein the heteroaryl or heterocyclic alkyl ring comprises 1, 2, or 3 heteroatoms independently selected from N, O, and S, wherein the C 3-7 cycloalkyl, C 5-7 The cycloalkenyl, heteroaryl, and heterocyclic alkyl groups may be optionally substituted by one, two, or three independent substituents selected from the following: halogen, amino, C 1-4 Alkyl, C 1-4 Alkoxy and hydroxyl (C 1-4 )alkyl.
17. The compound or tautomer thereof according to any one of the preceding claims, or a pharmaceutically acceptable salt of the compound or tautomer thereof, wherein each L is a bond.
18. The compound of claim 17 or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or a tautomer thereof, wherein each Y is independently selected from hydrogen, halogen, hydroxyl, cyano, C 1-4 Alkyl, C 1-4 Alkoxy, C 3-6 cycloalkyl, cyclohexenyl, C 2-4 alkenyl, C 2-6 alkynyl, hydroxyl (C 1-6 )alkyl, halogenated (C 1-4 )alkyl, hydroxyl (C 2-6 ) ynyl group, -NR 9 R 10 -C(O)NR 9 R 10 -CO2R 10 -C(O)R 10 -SO2R 10 -OSO2R 10 -SO2NR 9 R 10 phenyl, 5- or 6-membered heteroaryl, and 4- to 6-membered heterocyclic alkyl ring, wherein the 5- or 6-membered heteroaryl or 4- to 6-membered heterocyclic alkyl ring comprises 1, 2, or 3 heteroatoms independently selected from N, O, and S, wherein the C 3-6 Cycloalkyl, cyclohexenyl, heteroaryl, and heterocycloalkyl groups are optionally separated by one C 1-3 Alkyl substitution.
19. The compound or tautomer thereof according to any one of the preceding claims, or a pharmaceutically acceptable salt of the compound or tautomer thereof, wherein X is independently selected from oxo and LY.
20. A compound or tautomer thereof according to any one of the preceding claims, or a pharmaceutically acceptable salt of said compound or tautomer thereof, wherein each Y is independently selected from hydrogen, halogen, hydroxyl, cyano, C 1-3 Alkyl, -CO2R 10 -COR 10 Halogenated (C 1-3 )alkyl, C 1-3 Alkyl and phenyl.
21. The compound or its tautomer according to any one of the preceding claims, or a pharmaceutically acceptable salt of the compound or its tautomer, wherein Y is independently selected from hydrogen, fluorine, cyano, methyl and -CO2Me.
22. The compound or its tautomer according to any one of the preceding claims, or a pharmaceutically acceptable salt of the compound or its tautomer, wherein p is 1.
23. A compound or its tautomer, or a pharmaceutically acceptable salt thereof, selected from: 1-(3-(1 H -imidazol-4-yl)-2-(3-(trifluoromethyl)-1 H -1,2,4-triazol-5-yl)imidazo[1,2-a]pyridin-6-yl)ethyl-1-one, 5-(1 H -imidazol-5-yl)-2-methyl-6-(3-(trifluoromethyl)-1 H -1,2,4-triazol-5-yl)imidazo[2,1-b]oxazol, 7-(1 H -imidazol-5-yl)-6-(3-(trifluoromethyl)-1 H -1,2,4-triazol-5-yl)imidazo[1,2- b [1,2,4]triazine, 3-(1 H -imidazol-5-yl)-2-(3-(trifluoromethyl)-1 H -1,2,4-triazol-5-yl)-5,6-dihydro-8 H -imidazo[2,1- c [1,4]Oxazine, 5-(1 H -imidazol-5-yl)-6-(3-(trifluoromethyl)-1 H -1,2,4-triazol-5-yl)-1 H -imidazo[1,2-a]imidazo, 3-(1 H -imidazol-5-yl)-2-(3-(trifluoromethyl)-1 H -1,2,4-triazol-5-yl)-6,7-dihydro-5 H -pyrrolo[1,2- a Imidazole-6-ol, 6-Fluoro-3-(1 H -imidazol-5-yl)-2-(3-(trifluoromethyl)-1 H -1,2,4-triazol-5-yl)imidazo[1,2-a]pyridine, 2-(3-bromo-1- H -1,2,4-triazol-5-yl)-6,8-difluoro-3-(1 H -imidazol-5-yl)imidazo[1,2- a ]Pyridine, (5-(8-fluoro-3-(1) H -imidazol-5-yl)-7-methylimidazo[1,2-] a ]pyridin-2-yl)-3-(trifluoromethyl)-1 H -1,2,4-triazol-1-yl)methylphosphodihydrogen ester, 6-Bromo-3-(1 H -imidazol-5-yl)-7-methyl-2-(3-(trifluoromethyl)-1 H -1,2,4-triazol-5-yl)imidazo[1,2- a ]Pyridine, 3-(1 H -imidazol-5-yl)-5,7-dimethyl-6-phenyl-2-(3-(trifluoromethyl)-1 H -1,2,4-triazol-5-yl)imidazo[1,2- a ]Pyridine, 7-Bromo-3-(1 H -pyrazole-4-yl)-2-(3-(trifluoromethyl)-1 H -1,2,4-triazol-5-yl)imidazo[1,2-a]pyridine, 3-(1 H -imidazol-4-yl)-2-(3-(trifluoromethyl)-1 H -1,2,4-triazol-5-yl)imidazo[1,2- a ]Pyridine; 8-Fluoro-3-(1 H -imidazol-4-yl)-7-methyl-2-(3-(trifluoromethyl)-1 H -1,2,4-triazol-5-yl)imidazo[1,2- a ]Pyridine, 3-(1 H -imidazol-5-yl)-2-(3-(trifluoromethyl)-1 H -1,2,4-triazol-5-yl)imidazo[1,2-a]pyridine-8-carboxynitrile, 6,7-Difluoro-3-(1 H -imidazol-4-yl)-2-(3-(trifluoromethyl)-1 H -1,2,4-triazol-5-yl)imidazo[1,2- a ]Pyridine, 3-(1 H -imidazol-5-yl)-2-(3-(trifluoromethyl)-1 H -1,2,4-triazol-5-yl)-6,7-dihydro-5 H 9 H -imidazo[2,1- c [1,4]oxazine-heptacyclic hepttriene, 3-(1 H -imidazol-4-yl)-2-(3-(trifluoromethyl)-1 H -1,2,4-triazol-5-yl)imidazo[1,2- a Pyrazine, 3-(1 H -imidazol-4-yl)-2-(3-(trifluoromethyl)-1 H -1,2,4-triazol-5-yl)imidazo[1,2-b]pyridazine, 7-Chloro-3-(1 H -imidazol-4-yl)-2-(3-(trifluoromethyl)-1 H -1,2,4-triazol-5-yl)imidazo[1,2-c]pyrimidine, 3-(1 H -imidazol-4-yl)-6-methoxy-2-(3-(trifluoromethyl)-1 H -1,2,4-triazol-5-yl)imidazo[1,2- a Pyrazine, 2-(3-(difluoromethyl)-1 H -1,2,4-triazol-5-yl)-3-(1 H -imidazol-4-yl)imidazo[1,2- a Pyrazine, 6-Ethyl-3-(1 H -imidazol-4-yl)-2-(3-(trifluoromethyl)-1 H -1,2,4-triazol-5-yl)imidazo[1,2-a]pyrazine, 3-(1 H -imidazol-4-yl)-2-(3-(trifluoromethyl)-1 H Methyl 1,2,4-triazol-5-yl)imidazo[1,2-a]pyrazine-6-carboxylate, 3-(1 H -imidazol-4-yl)-2-(3-(trifluoromethyl)-1 H -1,2,4-triazol-5-yl)imidazo[1,2- a ]Pyridine-7-ol, 3-(1 H -imidazol-4-yl)-2-(3-(trifluoromethyl)-1 H -1,2,4-triazol-5-yl)imidazo[1,2- a Methyl pyridine-7-carboxylate, 2-(3-(1 H -imidazol-4-yl)-2-(3-(trifluoromethyl)-1 H -1,2,4-triazol-5-yl)imidazo[1,2-a]pyridin-6-yl)-2,2-difluoro-N-methylethyl-1-amine, 3-(1 H -pyrazole-4-yl)-2-(5-(trifluoromethyl)-1 H -1,2,4-triazol-3-yl)-5,6-dihydroimidazo[1,2- a ]Pyrazine-7(8 H ethyl formate, and 3-(1 H -imidazol-4-yl)-7-(trifluoromethyl)-2-(3-(trifluoromethyl)-1 H -1,2,4-triazol-5-yl)imidazo[1,2- b ]pyridazine, Or its tautomers, or pharmaceutically acceptable salts of the compound or its tautomers.
24. The compound according to claim 1, which is , , , or Or its tautomers, or pharmaceutically acceptable salts of the compound or its tautomers.
25. The compound according to any one of claims 1 to 24.
26. A pharmaceutical composition comprising (a) a compound or tautomer thereof as defined in any one of claims 1 to 25, or a pharmaceutically acceptable salt of said compound or tautomer thereof; and (b) a pharmaceutically acceptable excipient.
27. A method of treating an autoimmune disease, an autoinflammatory disease, or an immune-mediated disease in a person in need, comprising administering to the person a therapeutically effective amount of a compound or a tautomer thereof as defined in any one of claims 1 to 25, or a pharmaceutically acceptable salt thereof.
28. A compound or tautomer thereof as defined in any one of claims 1 to 25, or a pharmaceutically acceptable salt thereof, for therapeutic purposes.
29. A compound or tautomer thereof as defined in any one of claims 1 to 25, or a pharmaceutically acceptable salt thereof, for the treatment of autoimmune diseases, autoinflammatory diseases, or immune-mediated diseases.
30. Use of a compound or a tautomer thereof as defined in any one of claims 1 to 25, or a pharmaceutically acceptable salt thereof, in the preparation of a medicament for treating an autoimmune disease, an autoinflammatory disease, or an immune-mediated disease.
31. The treatment method, compound, or use according to any one of claims 27, 29, or 30, wherein the condition is selected from systemic lupus erythematosus (SLE), cutaneous lupus erythematosus (CLE), lupus nephritis, Sjögren's syndrome, dermatomyositis, scleroderma, amyotrophic lateral sclerosis (ALS), Parkinson's disease (PD), and Alzheimer's disease (AD), acute kidney injury, chronic kidney disease, diabetic kidney injury, myocardial infarction, stroke, cardiac hypertrophy / heart failure, non-alcoholic steatohepatitis (NASH), and non-alcoholic fatty liver disease (NAFLD).
32. The method, compound, or use according to claim 31, wherein the condition is systemic lupus erythematosus or lupus nephritis.
33. A combination comprising (i) a compound or tautomer thereof as defined in any one of claims 1 to 25, or a pharmaceutically acceptable salt thereof; and (ii) an immunomodulator.
